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There! is!now!extensive!published! research! that! suggests!early! treatment!with!disease!
modifying!drugs!can!retard!joint!damage!and!improve!outcome.!In!a!proportion,!drugW!
free! remission! is! possible.! However,! there! remain! both! individuals! with! persistently!
active! disease! despite! standard! drug! treatments! and! those!with! longstanding! disease!
not!exposed!to!effective!early!treatment!that!remain!relatively!unresponsive!to!therapy.!!
!
There! is! a! growing! literature! that! epigenetic! modifications!may! underpin,! or! at! least!
accelerate!the!development!of!many!autoimmune!disorders.!These! include!alterations!
in! DNA! methylation! patterns,! histone! tail! modifications,! postWtranslational! mRNA!
regulation! by! microRNA! and! combinations! therein.! Having! established! the! human!





In! order! to! explore! the! hypothesis! that! specific! epigenetic! changes! may! underpin!
differences!in!response!to!therapy,!I!first!examined!the!characteristics!of!a!cohort!of!50!
RA! patients! with! longstanding! and! active! disease! (DAS28! >3.2)! despite! receipt! of!
standard! therapies! (disease! modifying! drugs! (DMARD)! and! biologic! therapies).! This!
included!a!detailed!examination!of!clinical!characteristics,!immune!profile,!inflammatory!
markers! and! burden! of! coWmorbid! complications! such! as! vascular! disease! and!








biologic! resistance.! An! analysis! of! the! serum! cytokine! profile! of! the! biologic! resistant!
and!DMARD!resistant!groups!was!also!performed.!Finally,!to!extend!the!analysis!beyond!
conventional!clinical!and!novel!molecular!biomarkers!the!influence!of!additional!patient!








some! improvements! seen! over! the! sixWmonth! assessment! period! reflecting! treatment!









composite! measures! of! disease! activity! and! inflammatory! markers.! An! observed!
reduction!also!paralleled!DAS28!improvements.!
Lastly! coping! strategies! favoured! were! adaptive! and! problem! based.! These! were!
unaffected!by!the!high!prevalence!of!mood!disturbance.!Conversely,! illness!perception!
was!influenced!by!mood!and!both!affected!subjective!disease!assessments.!The!strong!









The! question! of! true! biologic! resistance! remains! open.! Undoubtedly! residual!
inflammation! exists! in! longstanding! RA! but! significant! ‘disease! activity’! may! be!
explained!at!least!in!part!by!subjective!clinical!variables!influenced!by!both!external!and!
internal! factors! (comorbidites).! The! identification! of! a! ‘biologic! resistant’! microRNA!
profile! may! act! both! as! a! biomarker! of! treatment! response! in! longstanding! disease,!
superior! to! the! DAS28! scoring! system! and,! through! target! identification,! better!
understanding!of!the!regulation!of!the!molecular!pathways!of!inflammation!operating!in!
such!patients.!In!this!way!novel!pathways!of!treatment!resistance!may!be!exposed!and!
novel! treatment! targets! revealed.! It! is! also! supportive! of! a! ‘resistant’! RA! patient.!
However,!mood!and!thus!illness!perception!also!contribute!to!resistance!to!therapy!and!
should! be! sought,! characterized,! and! directly! addressed! to! add! to! the! global!














correlation! with! clinical! variables! and! implications! for! practice.! Oral! presentation! to!
Scottish!Society!for!Rheumatology!Spring!meeting,!April!2012.!
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Baxter!RD,!Emerson!SJ,!Porter!D,!McInnes! IB.!Associations!and!predictors!of! fatigue! in!








including! the! epidemiology,! those! underlying! aetiological! factors! important! for!
development! of! disease! and! related! pathophysiology.! Having! described! the! typical!
clinical!features!of!RA,!the!assessment!of!disease!and!treatment!will!then!be!examined!





I!will! then! explore! the! principles! of! epigenetics! as! an! area! of! study.! I!will! relate! how!
these! changes! may! link! to! both! autoimmunity! and! the! area! of! treatmentWresistant!
disease.!I!will!go!on!to!examine!specific!epigenetic!findings!demonstrated!to!date!in!this!
field!and!how!these!may!not!only!explain!the!persistent!state!of!inflammation!observed!
in! RA! but! also! reveal! novel! levels! of! transcriptional! regulation.! ! The! focus!will! be! on!
microRNA!as!the!primary!epigenetic!modification!examined!in!this!thesis.!
!
Both! these! areas! will! highlight! the! limitations! of! current! RA! management! and! those!



















The! presence! of! other! risk! factors,! such! as! smoking! and! family! history,! confers!
additional! multiplicative! and! cumulative! risk.! The! incidence! of! RA! may! however! be!
decreasing!(Doran!et!al.!2002)!related!perhaps!to!changes! in!environmental! influences!
(protective! effect! of! the! oral! contraceptive! pill?),! change! in! exposure! to! an! unknown!
infectious! agent,! reduced! rates! of! smoking! or! better! dental! health.! Additionally,! an!
aging!population!and!access!to!better!healthcare!may!affect!this!prediction.!In!the!same!
way!a! lack! of! access! to!healthcare!makes!accurate!estimation! in!developing! countries!
more!difficult!to!ascertain!and!through!practical!difficulties!collecting!data.!!
!
Worldwide! prevalence! of! RA! varies! with! falling! rates! in! more! southern! continental!







Susceptibility,!pattern!of!onset,! course!and! response! to! therapy!might!be!expected! to!
have! an! underpinning! genetic! influence.! Indeed,! this! is! suggested! in! epidemiological!
studies;!RA!is!more!common!in!firstWdegree!relatives!and!monozygotic!twin!concordance!
is!approximately!15%!falling!to!4%!in!dizygotic!twins!(D.!M.!Lee!&!Weinblatt!2001).!Age!
at! onset! varies! widely! suggesting! other! influences! exist! such! as! environment!












2004).! Allele! types! vary! between! ethnic! populations.! Furthermore,! smoking,! in! the!







PTPN22! (protein! tyrosine! phosphatase,! non! receptor! type! 22)! is! perhaps! the! bestW
described! nonWMHC! susceptibility! locus.! It! codes! for! the! protein! lymphoid! tyrosine!
phosphatase!(Lyp),!a!negative!regulator!of!TWcell!activation,!which!may!act!by!preventing!
TWcell!receptor!signalling!in!animal!models.!It!has!been!implicated!in!a!number!of!other!
human! autoimmune! disorders! including! Graves’! disease! and! systemic! lupus!
erythematosus! (SLE)! and! identified! in! many! ethnic! populations.! A! single! nucleotide!
polymorphism! (SNP)! and! consequent! amino! acid! substitution! in! the! minor! allele! of!
PTPN22! (R620W)! is! associated! with! RA! (Carlton! et! al.! 2005).! This! change! could!
predispose!to!autoimmunity!by!preventing!negative!thymic!selection!of!autoWreactive!TW
cell! populations.! Significant! risk! of! developing! RA! is! associated! with! PTPN22! 1858T!
carriage! and! the! presence! of! anti! citrullinated! protein/peptide! antibodies! (ACPA)! or!




Further! study!with! genome!wide! association! studies! reveal!many! other! ‘nonWHLA’! RA!
susceptibility! loci.!CTLA!4! (cytotoxic!TWlymphocyte!antigen!4)!CT60!polymorphism!may!
confer! a! small! additional! risk! (Rodríguez! et! al.! 2002).! PADI4! (peptidyl! arginine!
deiminase,! type! 4)! identified! in! Asian! (Suzuki! et! al.! 2003)! and! US! cohorts,! is! of! note!
coding! for! an! enzyme! responsible! for! converting! arginine! residues! to! citrullinine! (the!
postulated! target! for! ACPA! antibodies).! Other! risk! loci! include! signal! transducer! and!
activator!of! transcription!4! (STAT4)! (Remmers!et!al.!2007),!CDW40! (Raychaudhuri!et!al.!
2008),!TNF!receptor!associated!factorW1!(TRAFW1)!(Plenge!et!al.!2007)!and!interleukin!2!
receptor! alpha! (IL2WRA)! (D.! Plant! et! al.! 2011)! for! the!Wellcome!Trust! consortium!who!
also! strongly! confirmed! PTPN22).! The! additional! risk! conferred! is! small! compared! to!
those!above.!
!
Karlson!et!al! sought! those!known! risk!alleles!above!with!environmental! risk! factors! in!
those! developing! RA! in! wellWestablished! prospective! cohorts! (Karlson! et! al.! 2010).!
Although!displaying!valid!discriminative!ability,!such!an!application!still!makes!screening!
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of! the! general! population! impractical.! Thus! genetic! advances! have! still! to! be!




The! presence! of! an! environmental! trigger!may! be! the! second!necessary! crucial! event!
before! symptoms! manifest.! Candidates! include! biomechanical! trauma,! infectious!
triggers!and!vascular!dysfunction!allowing!ingress!of!inflammatory!cells!and!exposure!to!
novel! antigens.! Most! evidence! lies! with! smoking.! Both! intensity! and! duration! are!
important!in!the!period!before!symptom!development!and!the!link!strongest!in!men,!RF!
positive,! PTPN22! and! possessing! the! SE! (Costenbader! et! al.! 2006;! Costenbader! et! al.!





A! role! for! dental! disease! has! been! postulated.! Porphyromonas! gingivalis! is! the!main!
cause! of! periodontitis! and! an! observed! increased! prevalence! in! RA! has! been! noted.!
Novel! citrullinated! antigens! generated! by! such! bacteria! provide! a! potential! trigger! of!
systemic!autoimmunity!to!endogenous!peptides!(Wegner!et!al.!2010).!In!general,!there!





al.! 2006)!but! this! finding! is! not! consistent! (Pikwer!et! al.! 2009).! Prolonged! (more! than!
one!year)!breastWfeeding!may!be!protective!against!the!development!of!RA!(Pikwer!et!al.!
2009).! RA! shows! female! preponderance! however! and! remission! often! occurs! in!
pregnancy.!!
Silica!exposure!(from!dusts!such!as!the!building!trade)!may!also!be!associated!not!only!
with! RA! but! other! autoimmune! disorders! (Khuder! et! al.! 2002).! Alcohol! may! be!




in! 1991! (Carstairs! &! R.! Morris! 1991).! The! link! between! increasing! deprivation! and!
mortality! is! well! recognised.! Postcodes! are! assigned! a! score! using! combinations! of!
variables!from!the!Census!data!that!are!considered!detrimental.!Specifically,!social!class!




affluent.! Results! therefore! do! not! take! into! the! account! the! individual! but! their!
population!environment.!
!
The! alternative! Scottish! Index! of! Multiple! Deprivation! (SIMD)! (available! from!




In! RA,! deprivation! has! been! closely! studied! in! Glasgow! owing! to! the! greatest!
concentration! of! deprivation! in! Scotland! found! within! the! Greater! Glasgow! area.!
Deprivation! affects! course! but! not! risk! of! development,! although! smoking! is! more!
common! in! lower! social! classes.!McEntegart! et! al! identified! clear! functional! outcome!
differences!over!five!years! in!a!cohort!with!RA!(McEntegart!et!al.!1997).!Harrison!et!al!
prospectively! followed! over! 400! RA! patients! and!measured! disease! activity,! disability!
and!quality!of! life!over! three!years.!Using! the!Townsend!deprivation! scale! they! found!
that! those! more! deprived! patients! had! higher! baseline! DAS28,! poorer! function! and!
psychological! scores.! The! same! group! did! however! see! the!most! improvements! with!
treatment!(M.!J.!Harrison!et!al.!2005).!
1.5!Pathophysiology!and!Histology!
RA! is!an!autoimmune!disorder! characterised!by!a!highly! coordinated!yet!dysregulated!
inflammatory! network.! The! earliest! event! is! currently! considered! to! be! a! loss! of! selfW
tolerance! at! the! central! (thymic)! and/or! peripheral! level! to! unknown! citrullinated!
proteins! (antigen).! Alternatively,! cell! types! such! as! dendritic! cells,! fibroblasts! and!
macrophages! that! possess! antigenWpresenting! capability! may! process! material! of!
perhaps! bacterial,! viral! or! endogenous! origin! generating! an! autoimmune! response.! A!
long!period!of!immune!dysregulation!follows!characterised!by!epitope!spreading!before!
localisation! to! the! joint! and! onset! of! symptoms.! In! this! asymptomatic! period,! the!
presence!of!antibodies! to!citrullinated!proteins!can!be!demonstrated!often!more!than!
five!years!prior!to!symptom!onset!and!prior!to!any!cytokine!rises!(Rantap!Dahlqvist!et!al.!
2003).! Subsequent! studies! have! validated! these! findings! in! different! populations!
(RantapääWDahlqvist!2009).!Prior!to!symptom!onset!in!this!preWarticular!phase,!the!ACPA!
titre! is! seen! to! rise! but! the! defining! event! prior! to! localisation! within! the! articular!
compartment!is!not!known!(Kokkonen!et!al.!2010).!
!
Following! the! TWcell! interactions! described! above,! BWcells! are! recruited! and! produce!
immunoglobulins! and! further! cytokine! stimulation.! TWcells! activate! and! recruit!








types! such! as! CD4! TWlymphocytes! predominantly! locating! in! the! synovial! subWlining!
layers.! There! is! prominent! plasmablast,! plasma! cell! and! BWcell! ingress! responsible! for!
local! autoantibody! and! cytokine! production.! In! some! these! may! form! lymphoid!
aggregates! resembling! lymphoid! follicles.! To! facilitate! this! ingress! of! cells! there! is!
marked! increases! in! vascular! permeability! and! angiogenesis! mediated! by! vascular!








Joint! destruction! is! caused! by! direct! fibroblast! and! mononuclear! cell! invasion! with!




The!primary!role! for!TWcells! in!RA! is!one!of!antigen!recognition!and!the!presence!of!TW
cells!in!lymphoid!aggregates!supports!this!as!a!central!event!in!disease!pathogenesis.!TW
cells! constitute! up! to! 20%!of! the! cells! in! RA! synovium.! It! is! postulated! naïve! CD4+! TW
helper!cells!(Th!cells)!and!dendritic!cells!(DCs)!interact!in!the!draining!lymph!node!(data!
communicated! via! BTWCure! Consortium! meeting,! Prague! 2013! by! Professor! Danielle!
Gerlag!et!al,!AMC).!MHC!Class!II/peptide!complexes!are!presented!to!the!TWcell!receptor!
with!a!necessary!coWstimulatory!signal.!Naïve!TWcells!(not!previously!exposed!to!antigen)!
may! also! be! activated! through! the! additional! activities! of! the! innate! immune! system!
through! TollWlike! receptor! (TLR)! signalling.! This! ‘initiation’! phase! proceeds! to! a!
‘commitment’! phase! to! produce! activated! effector! TWcells! under! the! influence! of!
cytokines.! Finally,! and! in! the! presence! of! onWgoing! antigen! exposure,! transcription!





of! interferon!(IFN)!gamma!and!tumour!necrosis! factor!alpha!(TNFa)! in!the!presence!of!
interleukins!(IL)W12,!ILW23!and!ILW6.!A!diminished!Th2!response!with!reduced!ILW4!and!ILW
13! is! seen.! The! novel! discovery! of! a! third! subset! of! Th17! regulatory! cells! suggests! at!
least! a! third! important! effector! TWcell! type.! Th17! cells! produce! ILW17A,! which! is! proW
inflammatory!acting!in!a!similar!way!to!Th1!cells!to!facilitate!B!cells,!activate!fibroblasts!













addition! to! direct! cell! lysis! (Szekanecz! &! Koch! 2007).! In! the! peripheral! blood,! as!





inflammatory! mediators! to! induce! further! cell! migration,! granulocyte/macrophage!
colony! stimulating! factor! (GMWCSF)! which! promotes! monocyte! lineage! maturation,!
further! TNFa! secretion! to! prolong! cellular! survival,! matrix! degradation! products! and!
angiogenesis!factors.!Secretion!of!receptor!activator!of!nuclear!factor!kappaWB!ligand!






BWcells,! plasmablasts! and!mature! antibodyWproducing! plasma! cells,! are! responsible! for!
the!production!of!immunoglobulins!(Ig)!including!IgG!rheumatoid!factor!and!ACPA.!They!
are!also!important!antigen!presenting!cells!and!thus!important!for!local!TWcell!activation.!
They! produce! further! proW! and! antiWinflammatory! cytokines! and! have! a! role! in!
immunological! memory.! Clustering! of! plasma! cells! can! occur! within! the! joint! in!
structures!reminiscent!of!ectopic!germinal!centres!in!peripheral!lymphoid!tissue!where!
BWcell!maturation!and!antibody!production!occurs!(Silverman!&!Carson!2003;!Manzo!et!
al.! 2010).! BWcells! may! also! produce! RANKL! thus! mediating! osteoclast! activity! and!
angiogenesis!and!chemokine!factors!enhancing!cellular!recruitment.!
The! importance!of! BWcells! in!RA!pathogenesis! is! confirmed!by! successful! therapy!with!
the!anti!CD20!BWcell!depleting!agent!Rituximab.!It!is!effective!at!treating!the!symptoms!
of!RA!and!preventing!radiological!erosive!damage!(Keystone,!Emery,!et!al.!2009a)!often!
for! over! six! months.! A! reduction! in! synovial! BWcell! and! plasmablast! populations!













They!play!a! key! role!as!both!effector! cells! and! coordinators!of! the!other! immune!cell!
types! above! by! the! nature! of! the! multitude! of! receptors! (TLRs,! cytokine! and!
chemokines)! and! molecules! produced! such! as! proteinases,! vascular! factors! and!
inflammatory!molecules!(MüllerWLadner!et!al.!2007).!!
In! RA! fibroblasts! adopt! an! aggressive! and! destructive! phenotype! contributing! to!
cartilage! damage! (MüllerWLadner! et! al.! 2005;! Pap! 2005).! The! trigger! is! unknown! but!
TNFa! facilitates! a! change! in! state! to! of! proliferation,! typically! more! resistant! to!
apoptosis! (MüllerWLadner! et! al.! 2005)! and! ability! to! migrate! and! induce! disease! in!
hitherto!unaffected!areas;!at! least!when!tested!in!mouse!models!(Lefèvre!et!al.!2009).!





Osteoclasts! are! large! multinucleated! cells! that! participate! in! bone! turnover! through!
bone! breakdown! and! remodelling.! They! are! strongly! influenced! to! differentiate! from!
macrophage! precursors! to! mature! osteoclasts! by! ILW1! and! TNFa,! both! directly! and!
mediated!by!RANK/RANKL!binding!secreted!by!fibroblasts!and!Th1!cells,! leading!locally!





through! the! production! of! angiogenic! factors! and! expression! of! vascular! adhesion!
factors!by!endothelial!cells.!This!is!an!important!early!event!needed!for!the!recruitment!
and!retention!of!leucocytes.!The!central!angiogenic!factor!is!VEGF,!which!is!upWregulated!
by! ILW1!and!TNFa! (Veale!2006).!Therapeutic! targeting!of!VEGF!has!been!undertaken! in!
cancer!therapy!and!antiWangiogenesis!in!some!part!explains!the!action!of!some!biologic!
therapies! (Szekanecz! et! al.! 2009)! as! treatment! with! TNFa! blocking! therapies! reduces!
VEGF! (Marrelli! et! al.! 2011).!VEGF!correlates!with!CWreactive!protein! (CRP)!and!disease!
activity! linking! with! power! Doppler! ultrasound! (US)! and!magnetic! resonance! imaging!
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Conceptually,! ligandWreceptor!binding! leads! to!activation!of! a! series!of! small!molecule!
cascades! that! will! ultimately! change!mRNA! transcription.! A! variety! of! cell!membrane!
receptor! systems! have! been! proposed! to! have! an! influence! on! the! RA! pathogenetic!
state.!!
The! TollWlike! receptors! (TLRs)! are! an! important! member! of! the! family! of! pattern!
recognition! receptor! surface! receptors! involved! in! the! recognition! of! self! (in! this!
instance! joint!breakdown!products!may!be! relevant)! and! foreign!proteins,!particularly!
highly!evolutionarily! conserved!bacterial!wall! components! and!viral! envelope!proteins!
(Andreakos!et!al.!2005).!TLRs!are!present!on!the!surface!of!most!cells!involved!in!antigen!
recognition!and!are!a!key!component!of! the! innate! immune!system.!As! such! they!are!
nonWspecific! yet! able! to! respond! to! broad! patterns! of! molecular! structure,! especially!
those!with!repeating!structures!–!this!allows!for!a!rapid!recognition!of! foreign!or! local!
tissue!damage!associated!moieties!prior! to! the!elaboration!of!a!peptide! specific!TWcell!
adaptive! response.! The! observation! that! various! members! of! the! TLR! family! are! upW
regulated! in! RA! has! been! reproduced! on! many! occasions! (McCormack! et! al.! 2009;!
Brentano!et!al.!2005).!This!may!lend!weight!to!the!bacterial!antigen!driven!hypothesis!of!
RA,! although! equally! one! can! propose! them! as! an! amplificatory! pathway! working! in!
parallel!to!autoantigen!driven!events.!The!TLRs!serve!to!activate!downstream!signalling.!
For! example,! following! TLR4! ligand! activation,! nuclear! factor! kappa! beta! (NFkB)!
signalling!occurs!via!recruitment!of!myeloid!differentiation!primary!response!gene!(88) 
(MyD88)! family! of! adaptor! proteins! (with! TRAF6! and! IRAK1! and! TRIF/IRF! 3! leading! to!
type! 1! interferon! (IFN)! expression.! NFkB! is! a! central! pleiotropic! regulator! of! gene!
transcription! key! in! the! inflammatory! response.! For! example,! TNFa! and! ILW6!




generation! of! (immune)! response.! Following! cytokine! binding,! downstream! triggering!
subsequently! occurs! via! cascades! of! small!molecules! involving! the! phosphorylation! of!
kinases.!One!such!mechanism!is!the!binding!of!cytokines!to!tethered!janus!kinase!signal!
transducers.!This!provides!a!binding!site!for!the!signal!transducer!and!activation!(STAT)!
family! of! transcription! factors! which! can! influence! DNA! binding! and! thus! gene!
expression.!Negative!regulation!of!the!STAT!signal!occurs!via!the!suppressor!of!cytokine!








Targeting! small! molecules! of! such! signalling! cascades! shows! therapeutic! promise.!







phenotypes,! disease! onset! and! spectrum! of! severity! associated! with! distinct!
autoantibody!expression!is!commensurate!with!this!observation.!
1.8.1!ACPA!antibodies!
The! antiWcitrullinated! protein! antibodies! are! directed! toward! citrullinated! peptides!
including!vimentin,!fibrinogen,!alpha!enolase,!type!II!collagen,!keratin!and!filaggrin.!They!
are!present!in!approximately!two!thirds!of!patients!with!RA!but!are!restricted!to!RA!with!
>95%! specificity! (Nishimura! et! al.! 2007).! They! are! formed! by! postWtranslational!
deamination! of! arginine! to! citrulline,! mediated! by! the! family! of! peptidylarginine!
deiminases.! The! humoral! response! mounted! in! bone! marrow,! and! ultimately! within!
synovium!that!is!characteristic!of!RA,!is!toward!these!citrullinated!epitopes.!!
There! is! evidence! that! citrullination!may!occur! in! the! lungs!as!evidenced!on!bronchoW
alveolar!lavage!and!demonstration!of!citrullinated!molecules!in!the!joint!(Klareskog!et!al.!
2005;!Demoruelle!et!al.!2012).!This!process!is!enhanced!by!smoking!and!in!keeping!with!
the! greatly! increased! risk! smoking! and! ACPA! positivity! presents.! It! is! proposed! that!
immune!complexes!may!trigger!downstream!inflammatory!cascades.!!




Rheumatoid! factor!has!been! in!use! for!over!50!years! since! the!original!description!by!
Waaler.!Rheumatoid!factor!is!a!polyclonal!autoantibodies!directed!toward!the!constant!
regions! (Fc! fragment)! of! IgG.! They!may! be! of! any! immunoglobulin! type! but! enzymeW
linked! immunosorbent! assay! (ELISA)! conventionally! measures! RF! IgM.! Production! by!
plasma! cells! occurs! in! the! joint! where! IgMWcontaining! immune! complexes! can! be!
identified.!Around!two!thirds!of!patients!with!RA!will!have!RF!and!there!is!evidence!that!
the! titre! may! vary! with! time! and! disease! stage! (like! ACPAs,! RF! may! also! be!
demonstrated! in! the! preWarticular! phase! of! RA).! Correlation! exists! between! RF! and!
radiological!progression,!disease!severity!and!presence!of!extraWarticular!manifestations.!
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There! are! a! number! of! conditions! where! RF! may! be! demonstrated! including! other!
connective! tissue! disorders,! chronic! infections,! neoplasms! and! increasing! age.! RF! is!




and! severity!models.! ACPA! assays! are! significantly!more! expensive.! In!models! where!
preWtest! probability! is! low! then! neither! test! helps.! If!moderate! probability! then!ACPA!
performs! better! than! RF.! If! high! probability! then! either! test! is! simply! confirming! the!





some! point! there! is! an! as! yet! unknown! insult! that! triggers! symptomatic! disease! and!
localisation!to!the!articular!component.!Several!studies!however,!for!example!the!BeST!
study! (GoekoopWRuiterman! et! al.! 2007),! would! suggest! that! progression! to! chronic!
arthritis! is! not! inevitable.! Either! a!proportion! spontaneously! remits!or! treatment!with!







et! al.! 1988)! classify! and! define! individuals! with! established! RA.! In! such! a! way,! most!





The! 2010! ACR/EULAR! (Aletaha! et! al.! 2010)! criteria! capture! those! features! of! early!
undifferentiated! arthritis;! an! important! population! where! early! treatment! results! in!
most!gains.!A!score!of!six!or!higher!diagnoses!RA!in!the!presence!of!at!least!one!swollen!
joint! and! no! alternative! explanation.! The! new! criteria! recognise! the! sensitivity! and!
specificity!of!the!autoimmune!profile!and!the!insensitivity!of!plain!radiographs!in!early!
disease.! ! Finally,! the! recognition!of! subtypes!of! RA!has! gained!prominence! in! view!of!








































The! hand! and! wrist! are! the! most! frequently! involved! joints.! Feet,! ankles,! proximal!
interphalangeal! joints,! elbows! and! shoulders! are! commonly! affected.! Symmetrical!
involvement! is! characteristic.! SacroWiliac,! axial! and! distal! interphalangeal! joint!






Constitutional! features,! including! fatigue,! are! some! of! the! most! significant! extraW
articular!manifestations!to!patients.!When!severe,!weight!loss!and!a!catabolic!state!are!
termed! ‘rheumatoid! cachexia’.! Respiratory! involvement! includes! pleural! effusion,!
pulmonary! nodules! and! interstitial! lung! disease.! Cardiac! involvement! can! include!
pericardial!inflammation!and!myocarditis.!Eye!involvement!ranges!from!sicca!syndrome!
(secondary! Sjogrens)! to! episcleritis,! conjunctivitis! to! potentially! sight! threatening!
scleritis.! Vasculitis! may! cause! skin! and! nerve! involvement.! Peripheral! nerves! may! be!
involved! both! by! compression! (eg! carpal! tunnel)! or! mononeuritis! multiplex.! Cervical!
myelopathy!is!an!important!consideration!with!longstanding!neck!disease.!Rheumatoid!
nodules! typically! occur! over! areas! of! pressure! including! extensor! surfaces! and! occur!
only!in!those!seropositive!for!rheumatoid!factor.!Haematological!abnormalities!are!not!
uncommon! including! lymphopaenia! and! thrombocytopaenia! (Felty’s! syndrome).!
Lymphoma!is!more!common!in!RA!patients!and!is!associated!with!high!disease!activity,!
especially!that!which!remains!over!time.!





polymyalgicWonset! RA! (indistinguishable! initially! from! Polymyalgia! Rheumatica),!





























Confers! risk! of! development! (Padyukov! et! al.! 2004),! is!





et! al.! 2009)!until! later! in! life!when! females! fare!worse.!
Female:male=3:1!
Subsequent!risk!of!persistent!disease!of!68%!in!early!RA!!


































Regulates! threshold! for!TWcell! activation! (van!der!HelmW
van!Mil!et!al.!2005;!Begovich!et!al.!2004).!Overall!effect!
if! present! is! reduced! TWcell! receptor! signalling! so! less!
thymic!negative!selection.!
!




















!In! order! that! treatment! can! be! administered! most! appropriately! and! judiciously,!
attempts!have!been!made!to!predict!disease!course!and!outcome!on!the!basis!of!clinical!
factors,! biomarkers! and! genetic! profiling.! Severity! and! course! reflect! those! factors! in!
Table!1W2!from!genetic,!epigenetic,!environmental!to!psychosocial!factors.!
!
Clinical! and! laboratory! factors! are! not! accurate! when! predicting! outcome! in! early!
arthritis.! The! Norfolk! early! arthritis! registry! examined! clinical! factors! and! basic!
immunological! data! to! seek! a! responder! pattern! to!Methotrexate! (Hider! et! al.! 2008).!








not!predict! response.! Smoking! impairs! response! to! Infliximab! (IFX)!and! longer!disease!
duration!and!more!severe!degree!of!disability!at!baseline!predict!less!response.!!Further!
discussion! of! genetic! aspects! of! treatment! response! and! resistance! are! performed! in!
1.14.!!
1.11!Related!coDmorbidity!
When! compared! to! ageWmatched! healthy! individuals,! RA! patients! have! significantly!
more!comorbidity,!sometimes!referred!to!as!‘multiWmorbidity’.!Such!conditions!may!be!a!
primary! disease! manifestation! or! independent,! but! coWexist! more! frequently! in! RA!
patients.!These!are!important!in!relation!to!reducing!quality!of!life!or!premature!death.!
Poor! disease! control! and! longer! disease! duration! correlates! with! increased! risk!
suggesting!the!cumulative!exposure!to! inflammatory!mediators! is! important.!This!may!
manifest!as!accelerated!vascular!disease! (premature! cardiovascular!disease!and!death!
and!incidence!of!stroke),!depression,!fatigue!and!weight! loss.!Of!these!I!have!focussed!









around! a! third! of! the! deaths! in! longWterm! follow! up! of! the! British! Society! for!
Rheumatology!biologics!registry!cohort!were!related!to!cardiovascular!deaths.!Mortality!
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is! increased! with! standardised! mortality! ratio! of! x1.7! (Sokka! et! al.! 2008).! Subclinical!
early!atherosclerosis!can!be!identified,!by!examining!carotid!intimal!thickness!or!arterial!
stiffness! as! a! surrogate! with! ultrasound,! and! is! responsive! to! tumour! necrosis! factor!








to! reduced!ability! to!undertake!physical! exercise.!Other! risk! factors! include! increasing!
age,!ethnicity,!gender,!smoking!status!and!emotional!stress.!These!can!then!be!further!
divided! into! modifiable! and! nonWmodifiable! risk! factors! for! the! purposes! of! targeted!
intervention.!There! is!a!close! link!with!other!diseases!such!as!diabetes,!chronic!kidney!
disease,! obstructive! sleep! apnoea! and! related! systemic! inflammatory! (autoimmune)!
disorders!such!as!systemic!lupus,!psoriasis!and!RA.!
!
Lipid! profiling! in! RA! is! of! interest,! as! it! appears! to! bear! relation! to! systemic!
inflammation.! The! ‘total! cholesterol:HDL! (high! density! lipoprotein)! cholesterol! ratio’!
(TC:HDL! Chol! ratio)! falls! in! the! presence! of! inflammation! (Kitas! &! Gabriel! 2010).!











score! in!RA.!RA!patients! lose! skeletal!muscle!due! to!deconditioning!and! inflammation!
and! replace! this! with! adipose! tissue! (Kitas! &! Gabriel! 2010).! In! this! way! effective!
measured!weight!would!be!unchanged.!In!the!case!of!preferential!adipose!deposition!in!
the!abdominal!area,!most!cardiovascular!risk!is!observed.!“Adipocytokines’!may!explain!




as! the! ‘metabolic! syndrome’! (MetS).! There! are! a! number! of! definitions! and! typical!















with! ‘longWstanding’! RA! studied! by! Chung! et! al! met! the! NCEP! and! the!World! Health!








Waist! >102cm! Waist! >94cm!
! >88cm! ! >88cm!
Dyslipidaemia! TG!>150mg/dl! Dyslipidaemia! TG!>150mg/dl!
! HDL!<40mg/dl!M! ! HDL!<35mg/dl!M!
! HDL!<50mg/dl!F! ! HDL!<40mg/dl!M!
BP! >/=!130/95! BP! >/=!140/90!






The! presence! of! the! MetS! is! associated! with! increased! atherosclerosis! (Chung! et! al.!
2008).!However,!even!allowing!for! ‘traditional’!risk!factors,!excess!CV!risk!remains!(del!




One! hypothesis! that!may! explain! increased! CV! risk! is! that! of! the! presence! of! similar!
pathology!existing!in!the!atherosclerotic!plaque!and!joint.!Endothelial!injury!by!reactive!
oxygen! species! (Cai! &! D.! G.! Harrison! 2000)! and! influx! of! inflammatory! cells! such! as!
macrophages!and!TWcells! (Frostegård!2011)!has!been!observed!and!may!represent! the!
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earliest! stages! of! atherosclerosis.! Tumour! necrosis! factor! alpha! (TNFa)! may! be!
responsible!for!driving!this!action!and!the!recruitment!of!effector! leucocytes.!Systemic!
action! upon! adipocytes! may! be! responsible! for! abnormal! lipid! profiles.! Additional!
reasons!why!patients!may!experience!more!events! include!use!of!steroids,!adverse!fat!
distribution! (with! a! preponderance! of! central! obesity)! and! use! of! nonWsteroidal! anti!




quantified.! !However! the! thresholds! to! treat! are!more!uncertain.!NICE! guidelines! and!
those!below!would!generally!suggest!treatment!and!lifestyle!advice!should!be!offered!if!
the!10Wyear!risk!score!is!>20%.!This!is!the!suggested!threshold!for!statin!therapy.!
Of! the! scoring! systems! available,! each! weights! CV! risk! factors! differently! and! is!
dependent! on! the! source! cohort! studied! in! order! to! determine! risk.! The! original! and!
bestWknown! worldwide! is! the! Framingham! score.! The! Joint! British! Societies! Coronary!
Risk! Prediction! (JBSCRP)! is! based! on! this! cohort! and! most! familiar! to! physicians! as!
accessible!in!the!British!National!Formulary.!It!may!underestimate!risk!by!not!accounting!
for!strong!family!history,!elevated!triglycerides!and!impaired!glucose!tolerance.!!
The! ASSIGN! score! (ASSessing! CV! risk! using! SIGN! guidelines! to! ASSIGN! preventative!
treatment)!has!become!more!widely!adopted!in!Scotland!by!nature!of!taking!account!of!
the! effect! of! social! deprivation! and! family! history.! It! also! allows! for! the! number! of!
cigarettes!smoked.!!
Within! Europe,! the! SCORE! (Systemic! Coronary! Risk! Evaluation)! risk! calculator! is!
suggested,! although! also! acknowledged! as! imperfect.! It! has! been! derived! combining!
large! mixed! European! cohort! studies.! ! Population! differences! are! thus! factored! in!
through!application!of!‘lower’!and!‘higher’!risk!country!of!study.!
!
The! significance! of! addressing! cardiovascular! risk! is! recognised! in! the! 2010! EULAR!
guidelines! (Peters!et!al.!2010).!The! taskforce!set!out!guidance! for! the!management!of!
cardiovascular! risk!management.!The!goal! is! firstly! the! recognition!of!excess!mortality!
and!education!in!this!area.!Secondly,!the!creation!of!a!framework!of!guidelines!for!the!
management!of!this!excess!risk;!an!annual!assessment! is!suggested! irrespective!of!the!
presence/absence! of! risk! factors.! They! note! that! scoring! models! such! as! the! SCORE!



























Normal! <130! <85! Stage!1! ≥140/90! ≥135/85!
! High!normal! 130W139! 85W89! Stage!2! ≥160/100! ≥150/95!
! Mild!
!(Grade!1)!
140W159! 90W99! Stage!3! ≥180! n/a!
! Moderate!
(Grade!2)!
160W179! 100W109! ! ! !
! Severe!(Grade!
3)!
>180! >110! ! ! !
! Isolated!systolic!hypertension! ! ! !
! Grade!1! 140W159! <90! ! ! !











disease! control! (Dixon! et! al.! 2007;! Askling! &! Dixon! 2011).! Interestingly,! effective!
treatment!with!TNFa! inhibitors!may!result! in! increased!activity!yet!weight!gain!and!an!




RA! is! associated!with! accelerated! bone! loss! (osteopaenia)! and! is! an! independent! risk!
factor!for!osteoporosis.!Bone!loss!is!not!only!local!(disuse!of!an!inflamed!joint)!but!also!
systemic! due! to! osteoclast! activation.! Additionally,! patients! are! more! at! risk! of! falls,!
more! likely! to! be! female,! undertake! less! physical! activity! (known! to! be! protective! of!















only! the!disease! itself!but!also! the! impact!upon!the! individual.!Disease!activity!can!be!















change! and! determines! additional! therapeutic! modifications.! Any! assessment! must!






Joint! swelling! (SJC=swollen! joint! count)! and! tenderness! (TJC=tender! joint! count)! are!
physically!assessed!by!palpation.!Synovial!proliferation!and!thickening!results!in!swelling!
and! pain!may! result! from! both! active! inflammation! and! joint! damage.! SJC!may! be! a!
stronger!predictor!of!structural!damage!than!the!TJC!(Emery!et!al.!2009).!!
The! reporting! of! joint! counts! has! been! standardised! in! the! 28! joint! count:W! ten!
metacarpophalangeal! joints! and!proximal! interphalangeal! joints,!wrists,! elbows,! knees!
and! shoulders! (Prevoo! et! al.! 1995;! Smolen! et! al.! 1995).! Although! the! feet! are! not!




disease! in! one! easily! recorded! and! referenced! index! that! can! be! shared! between!
professionals.! The! weaknesses! of! clinical! joint! exam! include! the! interWobserver!
reproducibility!and! the!potential! impact!on!DAS28!score! (Marhadour!et!al.!2010).!The!
same!authors!observed! that! synovitis,! particularly! low!grade,! is!underestimated!when!
compared!with!ultrasound!findings!in!longerWstanding!arthritis!(JousseWJoulin!et!al.!2010)!!
It! is! important!that!the!same!observer!carries!out!joint!examination!where!possible.!In!
the! longer! term,! clinical! joint! findings! may! not! correlate! well! with! radiographic!
progression!and/or!functional!decline.!!




In! practice,! disease! activity! measures! are! combined! into! composite! scores! to! allow!
standardised!comparison.!These!scores!have!the!advantage!of! familiarity!to!physicians!
and!offer!a!rapid!point!of!reference.!In!the!absence!of!alternatives!such!as!biomarkers!or!







assessment,! erythrocyte! sedimentation! rate! (ESR)! and! 44Wjoint! count.! The! ‘modified!
DAS’!scores!28!joints!and!scoring!requires!a!calculator!owing!to!the!complex!calculation!
that! allows! weighting! of! factors.! It! requires! the! input! of! four! variablesW! the! TJC,! SJC,!
patient! global! assessment! of! disease! activity! and! either! the! ESR! or! CWreactive! protein!
(CRP)! (DASW28!CRP!(Fransen!et!al.!2003).!The! incorporation!of!a!patient!assessment!of!




and! adopted! in! largeWscale! trialling! acts! as! a! fundamental! outcome! measure.!
Furthermore! the! DAS28! then! represents! a! treatment! target! and! benchmark! for!
satisfying!TNFi!prescription!in!the!UK!(Deighton!et!al.!2010).!
!
However,! the! DAS! is! subject! to! influence! by! a! wide! variety! of! factors! including! age,!
gender,! health! and! illness! expectations,! mood! and! coWmorbidity.! This! introduces!
variability,! which!must! be! considered.! The! TJC! and! SJC! contribute! around! half! of! the!
overall!score,!the!TJC!is!slightly!more!weighted.!!As!illustration,!a!patient!global!score!of!
100!may!add!as!much!as!1.0!to!the!DAS!score.!ESR!contributes!fifteen!per!cent!of!the!
DAS28WESR!and! thus,! in!other!states!where! the!ESR! is!not!suppressed,!may!result! in!a!
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DAS28! not! achieving! remission! (where! joints! in! fact! are).! Diffuse! increases! in! gamma!
globulins! and! nonWarticular! comorbidity! often! accompany! longstanding! RA,! both! of!
which!may!increase!the!ESR.!
Patients! with! concurrent! chronic! pain! syndromes! such! as! fibromyalgia! would! be!
expected! to! demonstrate! high!patient! global! assessments! and! TJC!where! the! SJC! and!
inflammatory!markers!may! not! be! elevated.! In! the! same!way! articular! damage,! as! is!
evident! in! longstanding! RA,! may! elevate! the! TJC! where! inflammatory! disease! is! not!
present.!!
An! additional! weakness! of! clinical! joint! exam! is! interWobserver! reproducibility! (it! is!
important!that!the!same!observer!carries!out!joint!examination!where!possible)!and!the!
potential!impact!on!DAS28!score!(Marhadour!et!al.!2010).!!




in! long! term! follow! up! may! not! correlate! well! with! radiographic! progression! and/or!
functional!decline.!
!





Early! standard! CRP! assays! were! sensitive! to! a! value! of! <5mg/l! where! more!
commonplace! high! sensitivity! (hsCRP)! assays! measure! as! low! as! 0.3mg/dl.! There! are!
several!methods!of! detection!of! CRP! including!nephelometry,! ELISA! and! turbidimetry.!
Values!where!more!than!one!assay!is!examined!may!not!be!comparable!(Roberts!et!al.!
2001). Values!>3mg/l!may!associated!with! increased!cardiovascular!risk!and!discussion!








The! American! College! of! Rheumatology! (ACR)! and! European! League! against!







physician! global! score,! patient! disability! assessment! (HAQ)! and! acute! phase! reactant!
(ESR!or!CRP)! (Felson!et!al.!1995).!An! ‘ACR20! response’! is! the!definition!of!a!minimum!
response! observed! between! placebo! and!DMARD.! The!weakness! of! this! composite! is!













The! EULAR! response! criteria! compares! baseline! DAS28! evaluation! with! a! second!






! >1.2! >0.6!to!<1.2! <0.6!!
<3.2! good! moderate! none!
3.2!to!5.1! moderate! moderate! none!




Activity! Index! (CDAI)! (Aletaha! &! Smolen! 2007)! are! also! continuous! measures! being!




disease!activity! (0W10!Likert! scale)!and!CRP! (mg/dl).! It!avoids! the!need! for!a!calculator!
but!as!a!CRP!result!will!not!be!available!until!after!the!consultation,!an!immediate!result!






The! CDAI! uses! the! sum! of! the! TJC! and! SJC,! patient’s! assessment! of! pain! and! global!
disease! score.! There! is! no! need! for! an! acute! phase! reactant.! Remission! is! <2.8,! low!
disease! activity! 2.9W10,!moderate! disease! activity! 11W22! and!high! disease! activity! >22.!




inception! of! this! study)! reviewing! RA! disease! measures! suggests! that! the! use! of! the!
SDAI,! CDAI! and! DAS28! ESR! or! CRP! are! all! valid,! discriminative! measures! of! disease!
activity!(J.!Anderson!et!al.!2012)!.!
!
A! comparison! between! the! different! means! of! assessment! is! shown! below.! Each!
captures!slightly!different!patient!information,!time!to!complete!and!inherent!problems.!
!
! TJC! SJC! PG! PhG! Patient!VAS! HAQ! ESR! CRP!
! ! ! ! ! ! ! ! !
DAS28!
ESR!
✔ ✔! ✔! ! ! ! ✔! !
DAS28!
CRP!
✔! ✔! ✔! ! ! ! ! ✔!
ACR!
response!
✔! ✔! ✔! ✔! ✔! ✔! ! ✔!
CDAI! ✔! ✔! ✔! ✔! ! ! ! ✔!
SDAI! ✔! ✔! ✔! ✔! ! ! ! !







specificity! representing! surrogate!measures!of! the! inflammatory! response.! In! this!way!
they!do!correlate!with!clinical!measures!of!disease!activity!and!may!have!some!value!in!
predicting!radiographic!progression.!For!some!individuals,!the!ESR!and!CRP!may!be,!and!
remain! throughout! disease! course,! resolutely! normal.! ESR! is! subject! to! other!
confounding! variables! including! anaemia,! gender,! age! and! plasma! proteins! such! as!
fibrinogen! and! globulins,! higher! RF! titres! and! immunoglobulins.! Secondary! Sjogren’s!
syndrome!should!be!considered!as!a!cause!of!ESR!elevation.!
!
CRP! correlates! with! interleukinW6! and! TNFa! levels! and! most! notably! increases! with!
infection.!It!is!not!affected!by!those!variables!above!and!in!this!way!the!CRP!may!be!of!
more! value! (Wolfe! 1997).! A! suppressed! CRP! correlates! with! improvements! in! and!
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maintenance! of! function! (Devlin! et! al.! 1997)! ! and! the! CRP! level! correlates! with!
radiological!progression!over!time!(M.!J.!Plant!et!al.!2000).!
1.12.3.2!Immunology!
As! addressed! above,! the! presence! of! rheumatoid! factor! and! ACPA! help! to! inform!




A! normochromic! and! normocytic! anaemia! is! often! observed! in! longstanding! RA.! This!
may! represent! a! state! of! reduced!marrow! production! owing! to! chronic! inflammation!
and!increased!peripheral!turnover.!Concurrent!iron!deficiency!owing!to!gastroWintestinal!
loss!or!failure!of!utilisation!may!be!present.!Hypoalbuminaemia!is!a!nonWspecific!finding!
reflecting! increased! catabolic! protein! turnover! in! the! acute! phase! response.!
Thrombocythaemia,! reflecting! increased! turnover! and! marrow! production! may! be!






The!assessment!of! joint!activity! through!clinical!assessments!and! laboratory!measures!
must! be! considered! alongside! a! subjective! patient! assessment! of! function.! Broadly,!
these! are! short! questionnaires! completed! by! the! patient! as! short! accessible!
questionnaires!completed!in!a!few!minutes!potentially!in!the!clinic!waiting!area.!PROMs!
are! available! for! the! majority! of! common! rheumatological! disorders! capturing! the!








The! HAQ! is! an! instrument! that!measures! physical! functioning.! The! HAQWDI! (disability!
index)!(Kirwan!&!Reeback!1986;!Pincus!et!al.!1983;!Bruce!&!J.!Fries!2005)!is!a!two!page,!
twentyWactivity! modified! version! of! the! original! HAQ! which! asks! the! patient! to! selfW
assess!physical!functioning!over!the!last!week!in!terms!of!ability!or!otherwise!to!perform!
eight!daily!household!tasks!(dressing,!arising,!eating,!walking,!hygiene,!reach,!grip,!and!
common! activities).! These! are! rated! at! four! levels! of! difficulty! from! zero! to! three!





in!this!study).! If!a!category!score!is! less!than!two!it! is! increased!to!a!‘two’! if!help!from!
another!person!or!device!in!that!category!is!needed.!The!summary!score!is!an!average!
of! the! responses! such! that! a! higher! score! represents! poorer! function.! Total!




longstanding! articular! damage! and! active! inflammatory! disease.! In! later! disease,!
whereas! the! DAS! may! be! relatively! constant,! the! HAQ! tends! to! increase! reflecting!
articular!damage!rather!than!inflammatory!disease!(Welsing!et!al.!2001).!Thus!age,!pain!
and! patient! global! assessment! of! disease! correlate! with! the! HAQ.! The! HAQ! is! not!
‘diseaseWspecific’!and!thus!does!not!evaluate!any!psychiatric!or!social!dysfunction.!These!
domains! and! any! other! coWexistent! morbidity! may! of! course! influence! the! HAQ.!
Moreover!the!scoring!system!adopted!for!the!HAQ!does!not!equally!weight!the!different!
components!of!the!score!for!their!true!impact:!for!example!inability!to!walk!may!equate!
in! the! score! to!a! combination!of! less! significant! incremental! reductions! to!upper! limb!
function! but! to! most! observers! the! former! would! constitute! a! more! substantial!
impediment.!
!
The!HAQWDI! is! a! key!outcome! in! therapeutic! drug! studies! and! is! routinely! assessed! in!
daily! UK! clinic! practice! and! is! a! requirement! as! part! of! disease! followWup! to! judge!





can! be! utilised! as! part! of! the! assessment! of! cost! utility! analysis! (QALYs)! behind!
prescribing.!It!comprises!of!both!a!descriptive!system!of!five!questions!to!reflect!health!
state! on! that! day! (namely! mobility,! selfWcare,! usual! activities,! pain! and!




to! a! single! summary! index! using! value! sets! from! reference! populations.! This!
transformation! is! most! useful! when! measuring! change! after! an! intervention! or!
treatment.! !The!20cm!VAS! is!completed!to!reflect!a!general!health!state!from!‘best!to!




The! EuroQol! has! been! validated! and! tested! in! rheumatic! diseases! (Hurst! et! al.! 1997;!
Wolfe!&!Hawley! 1997)! and! tested! in! nonWUK! populations! (Luo! et! al.! 2003)! and! other!




Quality! of! life! in! RA!may! be! assessed! using! the! SFW36.! The! generic! SFW36v2! (www.sfW

























These!values!may!also!be! further!combined! into!a!Physical!Component!Score! (PF,!RP,!
BP,!GH)!and!Mental!Component!Score!(VT,!SF,!RE,!MH),!which!are!often!referred!to!as!
the! ‘representative! summary!outcomes’.! Each!question!may!have! five! response! levels!
and!asks!patients!to!reflect!on!the!last!four!weeks.!It!is!therefore!more!time!consuming!
but!provides! a! comprehensive! snapshot!of! a!number!of!different!health!domains! and!















(HADSWD)! and! anxiety! (HADSWA).! There! are! seven! items! for! each!mood! state! and! four!
possible! responses! scoring! 0W3! reflecting! mood! over! the! preceding! few! days.! Thus!
depression!and!anxiety! scores! range! from!zero! to! twentyWone.! Interpretation!of! these!
values! is! suggested! by! the! authors! whereby! 0W7! represents! no! further! evaluation!




As! part! of! a! series! of! questionnaires! (http://www.facit.org/FACITOrg/Questionnaires)!
originally! developed! to! assess! heath! domains! in! chronic! illnesses! and! in! particular!
Oncology,!the!Functional!Assessment!of!Chronic!Illness!Therapy!Fatigue!Scale!(FACITWF)!
is!a!validated!(Webster!et!al.!2003;!Cella!et!al.!2005;!Chandran!et!al.!2007)!single!page!








Fatigue! remains! one! of! the! most! difficult! elements! of! RA! to! treat.! It! is! a! frequent!
complaint!in!up!to!40%!of!patient!with!RA!(van!Hoogmoed!et!al.!2010)!and!the!symptom!
patients!would!most! like! treated! (Wolfe! &!Michaud! 2004).! Pain! and!mood! are! often!
associated! whereas! neither! van! Hoogmoed! nor! Nikolaus! found! inflammation! to! be!





In!order! to!put! the!FACITWF!values! in! context! (but!not! to!directly! compare),! the!mean!
FACITWF! values!of! recent! selected!but! representative!biologic! therapy! trials! are! shown!
below.! As! fatigue! is! an! important! patient! outcome! it! is! widely! reported! in! clinical!


















In! view! of! the! known! increased! prevalence! of! IHD! and! myocardial! events! in! this!
population,!the!Rose!angina!questionnaire!was!completed!at!interview!at!baseline!only!
(Rose!et!al.!1977).!It!has!since!been!reproduced!and!adapted!in!different!forms!such!as!
the! WHO! angina! questionnaire.! There! are! a! number! of! cohorts! followed! up! several!
decades! after! Rose! questionnaire! administration! that! demonstrate! higher!
cardiovascular! mortality! (Murphy! et! al.! 2006;! GraffWIversen! et! al.! 2008).! The!







no! chest! pain! experienced! (no! further! questions! were! asked)! or! if! chest! pain! was!
present! then! may! be! categorised! as! definite! Rose! angina! (exertional! chest! pain! and!





Patients! are! usually! happy! to! discuss! the! domains! such! questionnaires! address! and!
which!are!arguably!of!greater!importance!to!the!patient.!Furthermore!they!may!provide!
information! to! the! patient! beyond! simple! improvements! in! clinical! and! biochemical!
measures! that! may! inform! compliance! and! establish! physicianWpatent! relations!
(Miedany!et!al.!2011).! In!a!2003!evaluation!of!ACR!members,!despite!63%!considering!
such!evaluation!as!of!benefit,!only!48%!routinely!collected!this!data!(Russak!et!al.!2003).!
61%! considered! the!major! barrier! time! taken! to! complete/score.! A! similar! survey! by!
Wolfe! et! al! confirmed! the! higher! importance! many! Rheumatologists! place! on! these!
evaluations! in! a! trial! setting! rather! than! daily! clinical! care! (Wolfe! et! al.! 2003).!





changes,! uncertainty! how! to! interpret! the! psychological! evaluations! and! the! time!







is! plain! radiographs,! most! often! of! hands! and! feet.! Joint! space! narrowing! reflecting!
cartilage! loss,! and! presence! and! extent! of! characteristic! juxtaWarticular! erosions! are!
assessed! by! a! number! of! standardised! and! reproducible! scoring! systems! such! as! the!
modified! Sharp! and! Larsen! score.! Progressive! erosions! are! an! indicator! of! endWorgan!
damage!and! thus! represent! inadequate! treatment.! Plain!XWrays!may! lack! sensitivity! in!
early!disease,! an!observation! that! is!particularly! in! view!of! current!effective! therapies!
starting! ideally! before! erosions! are! visible.! However! erosions! would! be! expected! to!
develop!in!the!first!few!years!in!poorer!prognosis!disease.!In!later!disease!(and!in!these!
older! cohorts),! the! presence! of! new! erosions! tends! to! plateau! and! sequential!
radiographs!provide!less! information!(Salaffi!&!Ferraccioli!1989).!A!further!weakness! is!
relatively! slow!change!with! time!often! in! the!order!of! six! to! twelve!months.!Although!
they! correlate!with! deformity! they! do! not! correlate!well!with! joint! counts,! predicting!
work!disability!or!functional!outcome!(van!Riel!&!Fransen!2007).!
There! have! been! a! number! of! methods! to! score! radiographic! damage! designed! to!
standardize!outcomes!(Boini!&!Guillemin!2001)!.!The!original!Sharp!method!in!1971!was!
modified! by! van! der! Heijde! in! 1989! and! is! very! much! the! standard! for! reporting! in!





Ultrasound! (US)! permits! rapid,! quantitative! assessment! of! synovitis! with! realWtime!
power!Doppler!use.! It! is!more!sensitive!at!detecting!subclinical! synovitis:W! for!example!
grade! 1W2! synovitis! remains! clinically! undetectable! but! represents! inflammation! that!
may! lead! to! joint!damage.! Tendinopathy,! entheseal! assessment,! quantification!of! and!
guided!injection!of!joint!effusions!are!also!possible.!
1.12.5.3!MRI!(magnetic!resonance!imaging)!










Plain! XWrays! are! an! insensitive! tool! in! early! disease! but! may! help! in! detecting!
progression.! Those! presenting!with! erosions! at! first! clinic! visit! have! poorer! prognosis!
disease! but! often! because! they! present! later! –! established! disease! being! more!
treatment!resistant.!!Choice!of!imaging!is!thus!important.!
!
Imaging! also! presents! the! possibility! of! a! new! paradigm! of! ‘imaging! remission’.!
Radiological!progression!can!progress!despite!low!clinical!indices!of!inflammation.!!Such!





The! assessments! above! may! be! considered! as! both! short! and! longer! term!
measurements.! ShorterWterm! assessments! in! the! order! of! weeks! to! less! than! a! year!
would! be! assessed! by! the! components! of! the! DAS,! employment! status! and!
inflammatory! markers.! LongerWterm! disease! assessment! in! the! order! of! years! is! best!
gauged!by!deformity!and!need! for! joint!surgery,!xWray!scores!and!progression!thereof,!





allied! health! professionals.! Involvement! of! relevant! medical! specialties! such! as!
Respiratory,!Neurology,! Psychiatry/Psychology! and!Orthopaedic! surgical! are! necessary!
to!manage!coWmorbidities.!
1.13.1!Multidisciplinary!Therapies!
Briefly,! the! involvement! of! allied! health! professions! such! as! physiotherapists! (joint!
protection,! mobilisation! and! strengthening,! education! and! treatment! options),!
occupational! therapists! (provision! of! aids! in! the! home! and! workplace! to! overcome!
limitations! of! function),! social! work! involvement! (in! terms! of! access! to! disability!





The! role! of! the! Rheumatology!Nurse! Specialist! is! key! in! terms! of! offering! counselling!













physician.! This! is! further! enhanced!by!expert! recommendations! in! the! form!of!
guidelines)!
• Safety! profile! (evidence! not! only! from! trialling! and! registry! data! but! personal!
experience)!
• Individual!patient!history!ie!including!age!and!coWmorbidities!











The!main!aim!of! treatment!of! inflammatory! joint!disease! is! remission,!or! at! least! low!
disease!activity!as!soon!as!practically!possible.!This!is!defined!as!‘symptomWfree’!through!
the!application!of!a!composite!disease!activity!scores!such!as! the!DAS!scoring!system.!
Treatment! of! inflammatory! disease! is! associated! with! the! prevention! of! radiological!
damage,!the!strongest!predictor!of!disability! (van!der!Heijde!et!al.!2008).!The!strategy!






(DMARDs)! in! stepWup,! stepWdown! and! combination! regimens! (Möttönen! et! al.! 1999;!
Landewé!et!al.!2002).!
!!
These! have! consistently! performed! better! than! sequential! monotherapy! strategies.!












• ‘TreatWtoWtarget’! strategies! aiming! for! remission! in! early! disease! (Schoels! et! al.!
2010;!Smolen!et!al.!2010).!
!
By! achieving! remission! it! has! been! suggested! that! the! inevitable! progression! of! RA! is!








DecisionWmaking! in! established! disease! is! less! evidence! based! but! follows! similar!
principles! to! early! arthritis.! Those! with! more! active! disease! and! features! of! poorer!
prognosis! disease! should! be! treated! with! biologic! therapies! early! rather! than! cycling!
DMARDs.!
1.13.2.2.2!NSAIDs!(nonDsteroidal!anti!inflammatory!drugs)!
NSAIDs! remain! first! line! symptom! relieving! treatments.! Instigation! is! often! early! as! a!
bridge! to! disease! modifying! therapy! and! continued! until! such! time! as! possible! to!
withdraw.! ShortWterm! adverse! effects! include! triggering! asthma! and! bronchospasm.!
LongerWterm!use! has! limitations:W! daily! use!may! result! in! peptic! ulceration! (to! include!
gastric! and! duodenal! irritation),! which! ranges! from! asymptomatic! effect! to! dyspeptic!
symptoms! to! frank! ulceration! with! bleeding.! This! is! mediated! via! inhibition! of!
prostaglandin!necessary!to!maintain!the!gastric!mucosal!barrier.!Owing!to!inhibition!of!
renal!cycloWoxygenase!(COX),!hypertension!and!renal!impairment!may!result.!!




there! may! be! ‘less’! risk! (eg! Naproxen! vs! Diclofenac).! Their! place! is! very! much! as!
symptom!controlling! treatments!and!as!adjuncts! to!DMARD!therapy.! It! is!of!note! that!





Despite! the! heterogeneous! nature! of! RA! autoWantigens! and! cytokine! profiles! outlined!
above,! treatment! for! RA! is! typically! less! individualised.! DMARDs! represent! a! nonW!
selective!approach.!Methotrexate!(MTX)!is!first!choice!of!the!synthetic!DMARDs!in!view!
of! its! low! toxicity! profile! and! efficacy! (Smolen! et! al.! 2010).! Sulphasalazine,!
Hydroxychloroquine,!Leflunomide!and!parenteral!Gold!remain!efficacious!particularly!in!
combination!strategies.!Despite!their!longer!term!drawbacks,!adjunctive!use!of!oral!and!
intraWarticular! steroid! provide! prompt! clinical! benefit! and! have! a! moderate! diseaseW
modifying!role.! In!strategies!of!tight!control!they!are!essential.!They!may!be!used!as!a!
‘bridge’!until!DMARD!effect!is!captured!or!in!daily!low!dose!(7.5mg!or!less).!
Methotrexate! is! the! soWcalled! ‘anchor’! drug! in! RA.! It! has! been! used! since! the! early!








inflammation! is! important! (GoekoopWRuiterman! et! al.! 2007).! Strategies! employing!
additional!steroid! in! this!period!are! important.!The!efficacy! in!suppressing!radiological!
damage! is! also! inferior! to! biologic! agents! alone! (Genovese! et! al.! 2002).! In! terms! of!
efficacy,!MTX! alone! is! similar! when! compared!with! Etanercept! (van! der! Heijde! et! al.!
2006;! Emery,! Breedveld,! et! al.! 2008a)! and! Adalimumab! (Breedveld! et! al.! 2006)! but!
Tocilizumab!may!be!superior!(G.!Jones!et!al.!2010).!
1.13.2.2.4!Biologic!agents!!
The! advent! of! biologic! therapies! has! transformed! the! care! of! RA! for! those! not!




and! represent! a! cytokineWspecific! approach! to! treatment.! These! therapies! are!
efficacious:W!they!reduce!the!signs!and!symptoms!of!RA!and!improve!quality!of!life!and!








of! human! IgG! to! facilitate! delivery.! Approval! for! use! within! the! UK! is! regulated.!




















! Etanercept! TNFa!receptorWFc!fusion!protein! s.c!weekly!




































Owing! to!molecular! differences! (even!within! the! TNFi)! there! are! different! side! effect!
profiles.!In!terms!of!side!effects,!there!is!an!increased!risk!of!infection!with!biologics!(as!
there! is!with! DMARDs),! particularly! in! the! first! few!months! of! usage! (Galloway! et! al.!
2011).!The!risk!of!reactivation!of!latent!tuberculosis!(TB)!exists!but!is!reduced!by!careful!
screening.!Conventional! infections! are! increased,! as! are!more!atypical! infections,! viral!
infections!(such!as!herpes!zoster)!and!of!septic!arthritis! (native!and!replacement).!The!
risk! of! cancer! does! not! seem! to! be! increased! per! se! by! drug.! There! are! a! number! of!
other!more! rare!phenomena! including! autoimmune! (autoantibody!positive)! disorders,!







Major!Surgery! Suspend! treatment! one! week! before! and! after! (local!
practice!may!vary)!
Vaccination! Live!vaccines!are!contraindicated!
Active!infection! Suspend! until! treated.! Presentation!may! be! atypical! and!
organism!opportunistic!






Demyelination! (including! family! history!
of)!or!new!neurological!features!




Generation! of! autoWantibodies! (ANA,!
DNA)!
Evaluate! presence! of! lupusWlike! features! and! suspend! if!
present!and!pathological!
Formation! of! antiWdrug! antibodies!
manifesting!as!loss!of!clinical!effect!












IgG1.! It! may! also! bind! less! membrane! bound! TNFa! and! other! members! of! the! TNF!












Golimumab! and! Certolizumab! are! the! most! recently! approved! TNFi.! Their!
pegylated! form! allows! for! more! infrequent! dosing,! while! remaining! delivered!
subcutaneously,!which!is!an!important!patient!related!consideration.!
!
Rituximab! binds! the! CD20! receptor! expressed! at! certain! stages! of! BWcell!
development! causing! cell! lysis.! Depletion! is! temporary! and! return! of! symptoms!




between!CD28!present!on!naïve! TWcells! and!CD80/86!on! antigen!presenting! cells! thus!
preventing!the!interaction.!This!interaction!is!necessary!for!subsequent!TWcell!activation!






free! forms)! and! is! effective! in! those! who! fail! TNF! therapy! (Emery,! Keystone,! et! al.!
2008b).!The!mode!of!action!additionally!improves!many!of!the!systemic!features!of!RA!







Breedveld,! et! al.! 2008a),! Abatacept! (Genovese! et! al.! 2008)! and! Golimumab! (Emery,!
Fleischmann,! et! al.! 2011a)! were! the! landmark! studies! demonstrating! superiority! to!
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placebo!in!MTX!failures!in!early&arthritis!in!combination!with!MTX.!Disease!duration!was!
longer! than! conventionally! one! would! wait! before! commencing! therapy! in! current!
practice,!which!may!diminish!the!observed!benefits.!!
!
The! use! of! TNFi! in! earlier! stages! of! RA! is! more! controversial.! The! BeST! (GoekoopW
Ruiterman!et!al.!2007)!and!one!year!SWEFOT!trials! (van!Vollenhoven!et!al.!2009)!may!
suggest!that!early!use!of!biologic!therapy!in!combination!with!MTX!induces!remission!in!




The! patient! with! established! disease! differs! from! early! disease! where! erosions! are!
established! and! disability! may! be! less! responsive.! Improvements! in! synovitis! are! still!
possible! but! damage! is! not! albeit! slowing! of! progression!may! thus! be! an! achievable!
satisfactory! target.!Evidence! for! the! first! generation!TNFi! in!RA!comes! from! the! large,!
placebo! controlled! trials! of! infliximab! (ATTRACT! (Lipsky! et! al.! 2000),! Etanercept!
(Weinblatt!et!al.!1999)!and!Adalimumab!(Keystone!et!al.!2004;!Weinblatt!et!al.!2003)!in!
those! in!whom!MTX! has! failed! (biologic! +MTX! in!MTX! refractory! disease).! Rituximab,!







Abatacept! vs! Adalimumab! in! MTX! inadequate! responders! where! outcomes! were!
comparable! (Gabay! et! al.! 2013;! Schiff! et! al.! 2013)! In!metaWanalyses! these! treatments!
may! be! roughly! equally! effective! in! reducing! the! signs! and! symptoms! of! RA! and!
improving!quality!of!life!and!psychological!measures!(Singh!JA!2011).!Large!registry!data!





















The! option! of! switch! to! different! cytokine! target! or! change! in! DMARD! represent! the!
major!considerations!and!a!strategy!backed!by!randomised!trials.!Those!drugs!studied!in!
randomised!trials!include!Rituximab,!Golimumab,!Abatacept!and!Tocilizumab!(Cohen!et!




ACR20! response! rates! may! be! between! oneWtwo! in! every! five! patients.! In! general!















treatment! failure! then! the! chances! of! a! meaningful! response! are! lower! than! if! the!
reason!were! side! effect! (Hyrich! et! al.! 2007).! Indeed! a! switch! to! Rituximab!may! offer!
better! response! (Salliot! et! al.! 2011).! Switching! to! a! third! TNFi! is! least! likely! to!
demonstrate!a!meaningful!response!in!this!instance.!
Best! clinical! response!occurs!with! first! treatment.! In! those! trials! examining!options! in!







defined! target! variables! exist! and! those! that! fail! to! achieve! these! merit! treatment!
!! 61!
escalation! (PolidoWPereira!et! al.! 2011).! There!are! very! few!definitions!of! ‘resistant!RA’!
(Kroot!et!al.!1999)!but!‘severity’!is!a!more!subjective!definition!and!taking!into!account!a!





thereby! an! opportunity! to! identify! and! apply! ‘personalised! medicine’! if! these!
polymorphisms!can!be!isolated!and!tested.!Secondary!resistance!is!less!well!understood!
and!the!molecular!mechanisms!not!known.!Van!der!Heijden!et!al!have!reviewed!some!of!
the!previously! reported!mechanisms!of!drug! resistance! to! specific!DMARDs!and! these!
are! shown! in! Table! 1W12! (van! der! Heijden! et! al.! 2007).! The! bestWstudied!mechanisms!






Impaired!cellular!uptake! Transporter! effect;! reduced! uptake! or! enhanced!
efflux!













more! likely! to! be! female! and! RF! positive.! The! biological! phenomena! underlying! this!
observation!were!not!determined.!
!
The! final! challenge! having! defined! resistance! to! therapy! is! to! then! measure! it! in!
observational! cohorts.! ! The!observed!effect! in!daily! clinical!use! is!often! less! than! that!
observed! in! trials! (Kievit! et! al.! 2007).! This! can!be!explained!by! the! stringent! inclusion!
criteria!in!trialling!that!may!not!be!reflective!of!local!populations.!Surrogate!measures!of!
treatment! failure! include!a! switch! to!an!alternative!biologic,! intensification!of!dose!of!
concurrent! DMARD! or! increase! in! dose! of! biologic! agent! (Sidiropoulos! &! Boumpas!
2006).!Challenges! include!confounders!such!as!disease!duration,!defining! ‘responders’,!







level! this! represents! immune! cells! adopting! a! selfWperpetuating! phenotype.! It! is! not!
presently! possible! to! determine! which! individuals! will! go! on! to! develop! persistent!
disease! but! there! are! factors! that! suggest! disease! course!may!be!more! severe! (Table!
1.2).!
1.14.2!Response!to!Biologic!therapy!
Individual! response! to!biologic! therapy! is!not!predictable.! ‘Resistance’! to!conventional!
therapy! should! be! distinguished! from! those! individuals! displaying! toxicity! or! adverse!
events!during!the!course!of!their!treatments.!Some!individuals!may!‘acquire’!resistance!
to!therapy.!Ultimately!for!the!individual!the!end!result!is!the!same!but!for!the!purposes!








driver! to! disease.! In! the! second! an! important! cause! may! be! formation! of! antiWdrug!
antibodies! as! discussed! below.! Alternatively,! immunological! escape! mechanisms! are!
proposed! as! driven! by! alternative! cell! types! or! pathways.! The! final! situation! remains!
entirely! unpredictable! but! is! usually! overcome! by! switching! to! an! alternative! drug!
targeting!the!same!moiety.!
!
Overall! best! response! occurs! to! first! biologic! therapy! and! when! employed! earlier! in!
disease!course.!Primary!resistance!to! therapy!may!occur! in!up!to!a! third! (Hyrich!et!al.!
2007).!Overall!major!response!rates!of!52W67%!with!biologic!therapies!can!be!expected!
(Papagoras! et! al.! 2010).! Drug! persistence! also! tends! to! tail! with! time! but! overall!
discontinuation!for!Infliximab!or!Etanercept!after!a!year!is!around!1!in!5!(Sidiropoulos!&!
Boumpas!2006).!Most!discontinuation!occurs!within!year!one!and!reaches!a!plateau!by!
year! two! and! thereafter.! There! may! be! differences! between! individual! drugs! and!
duration! of! persistence:W! Etanercept! demonstrates! the! longest! persistence! for!
individuals!and!Infliximab!lowest!of!the!three!firstWgeneration!TNFi.!Either!or!both!ACPA!
and!RF!positive!status!strongly!predicts!Rituximab!response.!In!contrast,!the!same!signal!
is! not! seen! with! Abatacept! in! metaWanalyses,! TNFi! nor! Tocilizumab.! This! has! been!
repeated!in!a!number!of!studies!and!registry!data.!
1.14.3!Methotrexate!pharmacology!and!coDprescription!
Methotrexate! is! the!most! commonly! prescribed! firstWline! DMARD! and! as! such,! when!
examining!mechanisms!of!resistance,!is!most!widely!studied.!!
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The! complex! folate! metabolism! pathways! represent! many! potential! points! of!
pharmacokinetic! interWindividual! variation! from! variable! first! pass! liver! inactivation! to!
the! 7Whydroxymethotrexate! form,! elevated! drug! efflux! transporter! action! such! as! the!
ATP!binding!cassette!transporters!(a!mechanism!highly!studied!in!Oncology)!to!altered!
polyglutamylation! (a! necessary! step! prior! to! downstream!action)! and! variation!within!
folate!absorption!and!metabolism!pathways.!!
Absorption! and! distribution! of! methotrexate! has! been! well! characterised.!
Physiologically,! there! is!a!plateau!of!drug!that!can!be!absorbed!from!the!GI!tract.!This!
may! have! implications! for! those! with! higher! BMI! and! thereby! insufficient! drug!
concentration! in! inflamed! tissue.! Resistance! to! therapy! therefore! may! represent!
inadequate! dosing.! There! is! a! single! clinical! trial! that! suggests! some! benefit! of!





predictive!model! combining! clinical! factors!with!pharmacogenetic! testing.! In! this!way,!
the! authors! used! gender,! baseline! DAS28,! immunological! status,! smoking! and!
genotyping! (polymorphisms! within! the! folate! metabolism! pathways)! to! predict!
likelihood!of!response!to!MTX!(Wessels!et!al.!2007)!.!
!
When! administered! with! MTX,! the! biologic! therapies! represent! the! most! effective!
treatment! available.! ACR! 20/50/70! responses! are! broadly! similar! between! therapies!
however.!Both!the!PREMIER!(Adalimumab)!and!TEMPO!(Etanercept)!study!examined!a!
biologic! monotherapy! arm.! Remission! rates! were! similar! between! the! biologic!
monotherapy!and!MTX!arms!but!almost!doubled!in!the!biologic/MTX!combination!arms.!
This!improvement!in!disease!control!is!reflected!in!prevention!of!erosions!in!addition.!
The! mechanism! is! probably! a! synergistic! combination! of! enhanced! prevention! of!
damage! at! the!molecular! level,! inhibition! of! those! pathways! not! targeted! by! the! anti!
cytokine!drug!and!prevention!of!antiWdrug!antibody!(discussed!below)!









The! presence! of! antiWdrug! antibodies! (acquired! resistance! to! treatment)! can! be!
associated! with! a! loss! of! clinical! response! through! drug! neutralisation! and! enhanced!




drug! antibodies! studied! and! identified! but! no! definitive! link! with! reduced! efficacy!
(Vincent!et!al.!2013).!
Not!all!antiWdrug!antibodies!may!be!functionally!relevant!in!vivo!however.!A!weakness!of!
current! ELISA! (enzyme! linked! immunosorbent! assays)! based! assays! is! the! inability! to!
measure! such! antibodies! in! the! presence! of! drug.! The! presence! of! antibodies! can! be!
measured! against! disease! outcome! measures! but! considered! within! the! overall!




Of! the! earliest! studies!was! by! Padyukov! et! al!who! identified! cytokine! polymorphisms!
associated! with! responders! (favoured! TNFa! production)! and! for! nonWresponders!
(alternative! ILW1! production)! in! those! treated!with! Etanercept! (Padyukov! et! al.! 2003).!






of! antiWdrug! antibody.! The! detection! of! antiWdrug! antibodies! is! particularly! significant!
owing! to! its! dosing! (rapid! serum! peaks)! and! immunogenicity! (largest! relative! portion!
murine).!Wolbink!et! al! identified!nearly!half! of! their! cohort!displayed!drug!antibodies!
and! was! associated! with! reduced! response! (Wolbink! et! al.! 2006).! Sakai! et! al!
prospectively!studied!a!Japanese!cohort!and!found!higher!discontinuation!of!Infliximab!
due!to!adverse!events!if!antiWdrug!antibodies!were!identified!(Sakai!et!al.!2012).!PascualW
Salcedo!et! al! found!antidrug! antibodies! in!one! in! three! and! in! all! the!nonWresponders!
(PascualWSalcedo!et!al.!2011).!This!finding!was!also!associated!with!loss!of!response!and!
of!more! infusion!reactions.!This!effect!may!be!overcome!temporarily!by!dose! increase!
and! DMARD! dose! increases! (Finckh! 2006).! In! keeping,! Infliximab! has! the! lowest!





had! antibodies! predictive! of! less! response.! By! three! years! just! over! a! quarter! had!
antibodies! associated! with! fewer! achieving! low! disease! activity! (Bartelds! et! al.! 2007;!
Bartelds!2011).!The!clinical!utility!of!this!approach!has!also!been!studied!by!(Bartelds!et!
al.! 2010).! In! their! cohort,! when! drug! loss! of! effect! occurred,! then! if! no! antiWIFX!
antibodies!were!found!and!a!switch!to!Adalimumab!made,!then!a!lack!of!response!was!
often! observed.! The! implication! is! nonWTNFa! mediated! disease! was! present! in! these!
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individuals.! Radstake! et! al! made! similar! findings! whereby! clinical! response! closely!
followed! the! serum! drug! levels! as! mediated! by! antiWdrug! antibodies! (Radstake! et! al.!
2009).!
!
In! conclusion,! it! is! possible! that! future! decisionWmaking! after! treatment! failure! with!
biologics! may! be! driven! by! measured! immunogenicity! in! addition! to! patient! related!
factors.!
1.14.4.5!Biologic!Dosing!
It! was! observed! in! the! ATTRACT! trial! (Infliximab)! that! a! proportion! of! the! initial!
improvements! waned! with! time! but! could! be! recaptured! with! dose! increase!
(Sidiropoulos!&!Boumpas!2006).!A!secondary!loss!of!response!can!be!overcome!by!dose!
increase!particularly! in!those!with!antiWdrug!antibody.!Adalimumab!and!Etanercept!are!
not! dose! adjusted! and! there! is! some! suggestion! (unlicensed)! that! increasing! dose! to!





al.! 2012;! Abhishek! et! al.! 2010).! Hyrich! et! al! identified! that! the! Infliximab! response! is!





The!presence!of! the! shared! epitope! confers! increased! susceptibility! but! not! influence!
response! to! TNFi! (Potter! et! al.! 2008).! A! similar! finding! was! observed! with! PTPN22.!
However,!the!presence!of!RF!or!ACPA!is!associated!with!less!response!using!the!DAS28.!





SNP! in! the! TNF!promoter! gene! and! thus!postulated! to! increase! TNFa!messenger!RNA!
(mRNA).! Various! groups! have! examined! the! effect! of! this! polymorphism! and! TNFi!
treatment! (Emery!&! Dörner! 2011;!Wesoly! et! al.! 2006).! Prior! reviews! suggested! the! W
308GG!allele!is!associated!with!a!better!response!to!TNFi!than!W308AA!but!more!recently!
this! may! not! hold! true! as! either! a! class! effect! or! individual! TNFi! (Pavy! et! al.! 2010)!!
(Krintel!et!al.!2012)!using!the!DANBIO!registry).!
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outcome! measures! limit! the! application! of! these! observations.! Genome! wide!
association!microarray!studies!(GWAS)!have!been!used!to!measure!the!gene!output!of!




those! genes! and! pathways! that! differ! in! responders! (Lindberg,! af! Klint,! Catrina,! et! al.!
2006a).!The!aim!was!to!create!a!genetic!profile!of!a! ‘good!responder’.!Higher! levels!of!
TNFa!preWtreatment!were! associated!with! a! better! response.! Synovial! biopsy!of! every!
patient! preWtreatment! is! not! practical! and! study! of! circulating! mononuclear! cells!
preferable.! These! cells! may! not! however! reflect! the! articular! compartment! cytokine!
expression.!Their!observation!of! significant! intraHindividual! gene!expression! is!of!note.!
This! may! underpin! the! heterogeneous! phenotype! observed! and! explanation! of! the!
variable!response!to!treatment!of!a!single!cytokine.!
!
There! are! other! promising! applications! of! a! genetic/biomarker! approach.! Plant! et! al!
examined!GWAS!data!(between!zero!and!six!months)!for!566!TNFi!treated!RA!patients!
within! the!BSR! registry!and! identified!seven!novel! loci! influencing! treatment! response!
(D.! Plant! et! al.! 2011).!Hueber! et! al! also! identified! a! predictive! biomarker! signature! in!
preWtreatment!RA!patients!of!cytokines!and!autoantibodies!(Hueber!et!al.!2009).!Badot!




Studying! the! protein! output! signature! is! biologically! relevant! in! seeking! a! profile! of!
resistance! to! treatment.! Fabre! et! al! have! studied! this! in! both! TNFi! (Etanercept)! and!
Rituximab! treated!patients! (Fabre!et!al.!2008;!Fabre!et!al.!2009).!Whereas! the! former!
study! noted! a! baseline! profile! predictive! of! threeWmonth! response,! the! latter! study!
failed!to!find!a!good!responder!cytokine!profile!from!baseline!(the!threeWmonth!profile!
differed).!Koczan!et!al!measured!global!mRNA!profiles! in!peripheral!mononuclear!cells!
at! baseline! and! after! three!months! of! Etanercept! in! order! to! determine!which! genes!




Biomarker! profiles! of! treatment! response! in! RA! are! subject! to! confounders! such! as!
diurnal!variation,!tissue!variation!(blood!vs!synovial!fluid!vs!synovium),! intra!and!interW





Having! a! higher! DAS28! at! baseline! and! being! more! disabled! (higher! HAQ)! make!




et! al! examined! nearly! 1500! patients! from! previously! published! DMARD! trials! (J.! J.!
Anderson! et! al.! 2000).! They! identified! four! factors! from! their! univariate! analysis!
associated!with!reduced!likelihood!of!response;! longer!disease!duration,!female,!being!
more!disabled!and!prior!DMARD!use.!Mancarella!et!al!examined!over!1200!RA!patients!




activity! pre! treatment,!were!most! likely! to! achieve! EULAR! responses! (Jawaheer! et! al.!
2006).!!
These! are! all! publications! from! largeWscale! registries! and! the! differences! are!
representative! of! the! respective! heterogeneous! populations,! ethnicity! and! treatment!
characteristics.! Whether! or! not! they! represent! indicators! of! poor! prognosis! or!
pathological!factors!is!not!clear.!
1.13.8.3!Compliance!
There! have! been! a! few! attempts! to! quantify! this! question.! It! is! well! known! that!
compliance!with!medication!is!any!chronic!disease!is!not!optimal.!Furthermore!patient!











addition! (Salt! &! Frazier! 2010).! They! highlight! the! falling! drug! ‘persistence’! rates! with!










M.! Gordon! et! al.! 2002).! Knowledge! around! the! rationale! behind! treatment! and!
how/when! it! should! be! taken! is! key! to! achieving! compliance.! Other! authors! have!
reproduced! this! finding! identifying! financial! concerns! (drug! prescription! rates)! in!
addition! to! transport! costs! to! appointments! that! may! relate! outcome! to! social! class!
(Garcia!PopaWLisseanu!et!al.!2005).!























retained! permitting! adaptive! changes! to! persist! in! a! cell! lineage! in! order! to!maintain!
integrity!in!subsequent!generations.!
Epigenetic! processes! offer! an! attractive! dynamic! mechanism! whereby! environmental!
effects! such! as! nutrition,! hormonal! influence! and! drugs! may! interact! and! influence!
genomic!output!(Javierre!et!al.!2011).!For!example,!despite!strong!genetic!concordance!
in!monozygotic!twins!the!phenotypic!picture!in!disease!can!markedly!diverge.!Epigenetic!
marks! demonstrate! variance! and! drift! with! age! that! may! explain! this! phenomenon!
(Lodish!et!al.!2008).!Indeed,!it!is!postulated!that!epigenetic!modifications!may!explain!a!
number! of! the! disease! characteristics! not! currently! explained! merely! by! geneW
environment!interaction!such!as!age!of!onset,!differences!in!gender!distribution,!disease!
severity!and!course.!
Epigenetic! mechanisms! allow! the! cell! and! organism! to! adapt! to! the! environment! by!
rapidly! influencing!gene!expression!and!controlling! transcription! factor!binding.! In! this!
way,!the!precise!degree!to!which!a!gene!is!expressed!is!highly!regulated.!Thus!the!timing!
and! dynamic! integration! of! epigenetic! regulation! of! gene! expression! is! central! to!
adaptive!and!developmental!processes.!
1.15.2!Epigenetic!changes!driving!resistance!to!Oncology!therapies!
In! cancer! therapy! it! is! understood! that! effective! therapy! selects! for! resistant!mutant!
cancer!cells!that!persist!despite!treatment!and!account!for!observed!resistance/relapse!
observed.!For!example,!the!phenomenon!of!transient!resistant!populations!emerging!is!
described! related! to! chromatin! alterations! and! overcome! by! treatment! with! histone!
deacetylase! inhibitors! (HDACs)! (Baylin!2011).! In! this!way,! resistant!clones!are!selected!
for.!While!TNFi! therapy!does!not! induce!cell!death!or!apoptosis,! it! is! conceivable! that!
selection!for!pathways!under!epigenetic!control!could!be!selected!(Sharma!et!al.!2010).!
In! addition! transient! changes! in! chromatin! methylation! was! noted! following!
chemotherapy! that! may! mediate! resistance.! Importantly! these! changes! may! be!
potentially!reversible!and!used!in!combination!with!standard!chemotherapy.!
Conversely,! disruption! of! epigenetic! processes! leads! to! inappropriate! gene! activity! or!
tumour!suppressor!silencing,!a!key!finding!in!many!cancers.!Thus!the!field!of!epigenetics!
has! advanced! most! notably! in! Oncology! (Esteller! 2008)! and! most! specifically!
haematopoietic! cancers! such! as! lymphoma! and! leukaemia! owing! to! the! central!
pathological!role!of!epigenetic!modifications!(Metzler!et!al.!2004).!!
References! pertaining! to! the! role! of! epigenetics! and! metabolic! disorders! (including!
obesity!and!diabetes!(Stöger!2008)!in!addition!to!vascular!and!angiogenic!pathogenesis!
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are! important! as! these! processes! are! not! only! physiological! in! health! but! central! to!
tumour! progression! and! metastasis,! inflammation! (the! provision! of! adequate! blood!




both! detectable! prior! to! imaging! and! accessibility! in! almost! any! bodily! secretion.!




The! incidence! of! autoimmune! disorders! rises! with! age.! One! theory! may! be! the!
accumulation! of! epigenetic! events! and/or! the! influence! of! cumulative! environmental!
exposure!acting!on!epigenetic!processes! that!explains! this!observation.! In!parallel! the!
incidence! of! cancer! rises! with! age! (Goronzy! et! al.! 2010).! Immune! cells! display!




environmental! triggers.! In! RA,! genetic! factors! alone! do! not! explain! the! heritable!
characteristics.! As! epigenetic! mechanisms! regulate! at! fundamental! levels! described!
above,!it!is!little!surprise!that!a!loss!of!regulation!may!form!part!of!the!pathogenesis!of!
disorders!other! than! rheumatoid!arthritis! and!an!area!prime! to!be! studied.! There!are!





To!date!a!myriad!of!epigenetic!processes!have!been! identified!and! the! resultant!gene!
expression!is!the!endWproduct!of!multiple,!dynamic!and!interacting!processes.! !Broadly!
there!are!three!epigenetic!mechanisms!that!I!have!chosen!to!refer!to!and!are!explored!
below! namely! DNA! methylation,! modification! of! histones! and! regulatory! nonWcoding!
RNAs.! Breakdown! of! this! regulation! is! associated! with! autoimmune! diseases.! Of! the!




and! cell! differentiation,! and! within! fundamental! processes! such! as! XWchromosome!
inactivation.! Patterns! of! DNA! methylation! are! not! transferred! vertically! but! are!
maintained!in!subsequent!cell!divisions.!Early!methylation!pattern!is!established!in!utero!
where!the!epigenome! is!most!susceptible!to! factors!such!as!the! influence!of!maternal!
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diet!or!even!behaviour.!These!changes!may!persist!into!adult!life!(Heijmans!et!al.!2008).!
Such! differences! are! being! actively! studied! by! groups! such! Gordon! et! al! who! are!
studying! twin! pairs! and! recording! environmental! influences! (Novakovic! et! al.! 2011;! L.!
Gordon!et! al.! 2012).! Some!authors!have! linked!early! socioWeconomic!deprivation!with!
later!observed!DNA!methylation!patterns!in!adulthood!(McGuinness!et!al.!2012;!Borghol!
et! al.! 2012)! .! Importantly! the! promoters! involved! occur! in! cell! signalling! pathways!
including! ILW6,!MAP! kinases,! cardiovascular! risk! markers! and! cancers.! A! link! between!
epigenetics!and! socioWeconomics! can! thus!be!proposed!and! the! increased! risk!of! such!
diseases!in!part!explained.!
!
One! of! the! most! important! regions! influenced! by! methylation! are! CpGWrich! islands.!
These! comprise! a! cytosine! base! immediately! followed! by! a! guanine! base! in! the! DNA!
sequence! often! immediately! upstream! of! a! gene! promoter! acting! to! regulate!
transcription!(Saxonov!et!al.!2006).!Within!these!islands!they!may!not!be!subject!to!the!
same! methyltransferase! maintenance! and! regulation! catalysed! by! DNA!
methyltransferase! 1! (DNMT1).! In! normal! human! DNA! 3W6%! of! cytosine! residues! are!
methylated! but! the! majority! of! CpG! islands! are! demethylated! (MuleroWNavarro! &!
Esteller!2008).!DNA! in! its!methylated! state! (along!with!histone!conformational! state!
addressed! below)! prevents! physical! access! of! DNA! binding! factors! or! activation! of!
transcriptional!coDrepressors!thus!transcription!does!not!proceed.!The!same!is!true!of!
the! methylation! state! of! the! CpG! islands;! methylation! of! the! island! located! at! the!





Genomic! DNA! hypomethylation! is! dynamic! and! contributes! to! normal! regulation.! It!
occurs! with! aging! but! it! may! be! particularly! relevant! in! those! genes! relating! to! the!
immune!system.!Hypomethylation!is!also!associated!with!insulin!resistance!independent!
of! other! risk! factors.! Smoking! affects!methylation!dynamically! and! reversibly! but!may!
account! for! the! persisting! adverse! risks! after! stopping! (Wan! et! al.! 2012;! Zhao! et! al.!
2012).! It! is! not! clear! if! methylation! patterns! in! peripheral! white! cells! may! act! as!
‘markers’!of!exposure!to!toxin!and!thus!of!risk!for!disease!(Terry!et!al.!2011).!
!
Global! genomic! hypomethylation! is! a! characteristic! finding! in! RA! and! most! likely!
represents! a! further! contributory! factor! to! the! resistant! RA! patient! (Karouzakis! et! al.!
2009).! Indeed,! the! influence! of! treatment! and! methylation! status! in! inflammatory!
arthritis! is! not! a! recent! concept.! Kim! et! al! examined!DNA!methylation! in! albeit! small!
numbers!of!patients!with!inflammatory!arthritis!(RA!and!psoriatic!arthritis!)!treated!with!
methotrexate! (Kim! et! al.! 1996).! They! identified! genomic! hypomethylation! in! patients!












Targeting! methylation! represent! a! challenge! owing! to! a! lack! of! specificity! but! is!
underway! in! cancer! therapy! (X.!Yang!et!al.! 2010).!However!more! focussed!delivery!of!






form!of! chromatin! as!part!of!nuclear!packaging.! In! this!way!DNA! is! closely! associated!
with!core!protein!subunits!known!as!histones,!which!together,!comprise!chromatin.!The!
uncoiling!and!exposure!of!gene!promoter! regions!allow!access! to! transcription! factors!
and! RNA! (ribonucleic! acid)! polymerase! II! initiates! gene! expression.! This! process! of!
unwinding! is!mainly!mediated! through! a! balance! between! the! activities! of! acetylases!
(HATs! (histone! acetyltransferases)! and! HDAC! (histone! deacetylases)).! The! acetylated!
state! of! chromatin! is! associated! with! reduced! affinity! between! DNA! and! the! histone!
component!lysine.!In!such!a!way,!transcription!may!proceed!whereas!the!deacetylated!
state! is! associated! with! gene! silencing.! The! process! demonstrates! further! complexity!
and! degrees! of! epigenetic! regulation! through! acetylation! of! lysine! residues! of! the!
transcription! factors! themselves! (Grabiec! et! al.! 2008).! Further! postWtranscriptional!
modifications! of! histone! tails! include! sumoylation,! phosphorylation,! methylation! and!
ubiquitination!amongst!others.!
1.17.3!MicroRNA!!




partial! complementarity! binding! to! a! sequence! in! the! 3’! UTR! of! linW14! and! thus!
influenced! developmental! timing.! From! this! time! there! has! been! an! explosion! of!
research!and!publications!within!the!microRNA!field.!It!has!become!clear!that!microRNA!
are! fundamental! regulators!of!postWtranslational!gene!regulation.!The!annotation!used!
microRNA! followed! by! a! number,! which! represents! the! order! of! discovery.! A! letter!









Typically! the! pattern! of! microRNA! is! cell! dependent,! with! rapid! fluctuation! but! also!
context!dependent!such!as!a!state!of!cellular!activation!or!resting!state.! It! is!therefore!
little! surprise! that! dysregulation! of! microRNA! at! any! level! is! implicated! in! disease!
pathogenesis.! The! focus! below! is! upon! those!microRNA! involved! in! the! autoimmune!
field.!
1.17.3.1!Biogenesis!
MicroRNA! are! short! (typically! 20W26! nucleotides)! regulatory,! nonWcoding! RNA! strands!
encoded!within! the!host! genome.! Sequences! coding! for!microRNA!are!often! found! in!
clusters!and!coWtranscribed!with!the!mRNA!nearest!where!they!reside!(Rodriguez!et!al.!
2004;!Weber!2005).!Transcription!by!RNA!polymerase!II!occurs!in!the!nucleus!to!create!a!
stemWloop! shaped! primary! or! priWmicroRNA! that! is! cleaved! by! the! enzyme! Drosha! to!
create!a!hairpin!shaped!preWmicroRNA.! !Active!transport! through!nuclear!pores!occurs!
to! the! cytoplasmic! compartment! by! ExportinW5! where! the! action! of! a! second! RNase!
termed!Dicer!acts!to!further!cleave!and!process!the!microRNA!to!its!single!strand!form.!
This!creates!the!guide!strand!to!which!proteins!of!the!Argonaut!family!bind!creating!the!
microRNAWRNAWinduced! silencing! complex! (RISC).! It! is! this! mature! complex! that! will!




The! action! of! microRNA! is! to! act! through! RNA! interference.! They! act! through! both!
translational!repression!of!mRNA!(Guo!et!al.!2010)!but!also!through!mRNA!cleavage!and!
thus!downWregulation!post!transcription.!
Primary! binding! occurs! most! often! between! the! seed! sequence! in! the! microRNA!
(positions!2W7!of!the!3’UTR!end)!and!target!mRNA.!Binding!in!this!area!is!key!but!binding!
may!also!occur! in!nonWseed!sequence!regions.!These! include!binding!of!the!5’UTR!end!




This! is!more! often! the! case! in! plants! and!more! simple! organisms.! Imperfect! binding,!












1.17.6.3! Studying!microRNA;!MicroRNADmRNA! interactions! and! target! prediction! ‘in!
silico’!
One!of! the! key!questions! in!microRNA!discovery! lies! in!predicting!mRNA! targets.! This!





to! varying! extents! in! a! tissue! dependent! context.! For! example,! Lim! et! al! found! that!
transfection!with!a!single!microRNA,!microRNAW124,!downWregulated!at!least!174!genes!
thus!altering!gene!expression!toward!that!of!a!particular!cell!type!(Lim!et!al.!2005).!In!a!
similar! way,! the! different! murine! cell! types! of! the! haematopoietic! system! exhibit!






of! the! mature! microRNA! is! ‘UUAAUGCUAAUCGUGAUAGGGG’! and! that! of! the! seed!
sequence! ‘UAAUGCU’.! Predicted! targets! are! made! based! on! the! knowledge! of! this!
sequence! and! matched! mRNAs! with! conserved! complementary! binding! sequences.!
Database! such! as! TargetScan! (www.targetscan.org)! or! miRbase! (www.mirbase.org)!
provide! such! a! resource.! MicroRNAW155! had! around! 300! predicted! targets! at! the!




experimental! microRNA! transfection! or! antagonism! within! cells! or! through!
computational!approaches!(‘in&silico’).!For!the!researcher,!the!‘in!silico’!approach!is,!to!
some! extent,! addressed! by! the! computational! predictive! databases! and! open! access!
libraries!above!(others!are!outlined!by! (Mishra!&!Bertino!2009).!These!operate!on!the!
principal! of!matching! cognate! sequences! of!microRNA.! The! evolution! of! databases! is!
dependent!on!published!work!and!submissions!made!to!reference! libraries.!The!result!
may!be!many!hundreds!of!predicted!targets!and!experimental!verification!will!always!be!
necessary! to! confirm! a! computationally! predicted! target.! Furthermore,! results! vary!




The!weakness! of! this! approach! is! the! loss! of! cellular! context! and! regulation! that! lies!
therein.!Experimental!approach! is!designed!to! try! to!overcome!the!weaknesses!of! the!
computational!method;!they!work!on!those!algorithms!defined!by!those!findings!already!
published!and!do!not!address!any!novel!interactions!(Ørom!&!Lund!2007).!
In! principal,! microRNA! can! be! studied! in! animal! models! in! gain! ofW! or! loss! ofW!
experiments! in!order! to!biologically! validate! findings.!MicroRNA!can!be! introduced!by!
vectors!(often!adenoWassociated!viruses)!to!enforce!expression!but!also!as!an!‘antiWmiR’!
to! block! action.!An! ‘antagomir’! differs! by!being! conjugated! to! cholesterol! to! facilitate!














mRNA! inhibition! may! be! small! within! balanced! networks! and! thus! more! difficult! to!
predict!‘in!vivo’!phenotypic!effects.!
Inflammatory! networks! require! tight! regulation! to! avoid! excessive! unchecked! and!
damaging!inflammation!through!a!balance!of!proWinflammatory!and!negative!regulatory!
pathways.! For!example,!although! the!primary!action!of!a!microRNAWmRNA! interaction!
may!be!downWregulation!of!target!protein,!the!resultant!phenotypic!cellular!or!organism!




Additionally,! the! field! of! bioinformatics! can! facilitate! the! construction! of! complex!
computational! (yet! entirely! theoretical)! networks! based! on! previously! published!
biological! interactions.! Published! theoretical! geneWprotein! networks! using! the!
bioinformatics! software! (www.ingenuity.com),! are! increasingly! common! (Volinia! et! al.!
2010;! Philippidou! et! al.! 2010).! Statistical! significance! permits! confidence! that! the!
predicted!linkage!is!a!real!one.!The!genes!and!network!can!also!be!fine!tuned!to!display!
those! processes! that! carry! most! pathological! relevance.! Although! not! directly!




Put!at! its!most! fundamental! level,! loss!of!components!of!microRNA!synthesis! leads! to!
death.!Dicer! deficient! organisms! die! at! early! stage! of! embryogenesis! (Bernstein! et! al.!






















In! the! context! of! this! thesis! I! have! made! special! reference! to! microRNA! involved! in!
inflammatory!signalling!networks.!The! inflammatory!cascade!requires! tight! regulation!
and!microRNA!have!emerged!as!important!regulators.!There!is!a!close!link!between!loss!
of! regulation! and! autoimmunity! and! cancers.! They! achieve! this! by! targeting! those!
fundamental!molecules! involved! in! these! pathways.! These!may! include! the! TLRs! and!







microRNAW155! are! up! regulated! following! TLR! signalling! (reviewed! by! (O'Neill! et! al.!
2011).! McCoy! et! al! demonstrated! that! TLR! signalling! also! leads! to! microRNA! downW
regulation!(W155!and!ILW10!via!SHIPW1!(McCoy!et!al.!2010).!The!role!of!microRNAW146!and!
IRAK1/TRAF6!is!further!discussed!below!but!is!an!example!of!a!microRNA!targeting!key!
components! of! the!MyD88! dependent! pathway! distal! to! the! TLR! leading! to! eventual!
nFkB!activation.!Stanczyck!et!al!observed!that!microRNAW155!and!W146a! increase!upon!
stimulation!by!TLR! ligands.!They!propose! that! cellular!debris,! in!addition! to! cytokines,!
could!perform!this!role!within!the!joint!(Stanczyk!et!al.!2008).!
In!the!same!way,!microRNAW155!can!target!and!regulate!TLR!signalling;!Ceppi!et!al!show!























Measurement! in! blood! is! accessible,!minimally! invasive! and! acceptable!on! the!whole.!
Synovial! sampling! is!more! invasive!and!potentially!harmful.!Polymerase!chain! reaction!
(PCR)! testing! is! both! sensitive! and! rapid.! However! the! use! of! different! extraction!









endosome!derived)! or!microvesicles! (larger)! packaged! in! lipid! bilayers.! It! is! presumed!
that! uptake! into! target! cells! occurs! and! that! this! may! be! a! mechanism! of! ‘cell!
communication’.! Measuring! microRNA! must! account! for! this! and! that! the! secreted!
profile!is!reflective!of!the!‘active’!intracellular!profile.!
!
In! Oncology! the! question! of! whether! circulating! microRNAs! reflect! the! cancer! or! a!
additional!condition!present!has!been!extensively!addressed!and!reviewed!by!a!number!
of!authors!(Wittmann!&!Jäck!2010;!Heneghan!et!al.!2010;!Cortez!&!Calin!2009;!Ng!et!al.!
2009;! K.!Wang! et! al.! 2009;! R.!Wang! et! al.! 2011).! This! has! led! to! the! potential! use! of!
microRNA!as!validated!prognostic!tools!(markers!of!recurrence!or!effective!treatment).!
As! illustration,!Wang!et! al! found! a! close! correlation!between! the!microRNA!profile! in!
serum!versus! that!of! breast! cancer!pathological! samples! (F.!Wang!et! al.! 2010a).! They!
also! concluded! that! tumour! grading! and! clinical! features! correlated! with! microRNA!
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below.! Several! studies! suggest! the!peripheral! blood! signature! is! similar! to! that!of! the!
articular!compartment.!However,!many!of!the!studies!do!not!allow!for!individual!patient!
related! differences! (demographics,! disease! duration! etc)! and! influence! of! current!
treatment.!Control!groups!have!included!osteoarthritis!in!which!similar!microRNA!have!





the! process! remains! expensive.! Assessment! by! qPCR! or! microarrays! allows!





as! differentiation! and! apoptosis! led! to! the! discovery! of! distinct! microRNA! profiles!
between! tumour! types! versus! normal! tissue.! In! addition! to! DNA! methylation! and!
histone! modifications,! abnormal! microRNA! expression! is! characteristic! and! often!
distinctive! between! tumour! types.! Furthermore! microRNA! contribute! to! the!
transformation! from! early! preWmalignant! to! the! malignant! phenotype! promoting! the!
tumour! line!persistence! and! their! observation! (Santarpia! et! al.! 2010).! ! Their! action! in!




There! are! a! number! of! detailed! reviews! of! this! everWexpanding! field! with! detailed!
reference! to! individual! microRNA,! their! targets! and! associated! cancer! type! (Wiemer!
2007;! RodríguezWParedes! &! Esteller! 2011;! Esteller! 2008).! A! relevant! example! is! the!
association! of! microRNAW155! with! many! haematological! tumours.! The! finding! of!
microRNAW155!in!inflammation!by!Pedersen!et!al!(and&discussed&in&relation&to&RA&below)!
is! of! note! as! up! to! a! quarter! of!malignancies!may! be! related! to! inflammation! (Tili! &!
Michaille!2011;!Pedersen!et!al.!2009).!
!
Identification! of! such! microRNA! offers! great! clinical! application.! MicroRNA! are!
accessible!in!most!bodily!fluids;!Xie!et!al!studied!microRNAW21!in!sputum!with!improved!
specificity!and!sensitivity!over!cytology!(Xie!et!al.!2010).!!Potential!lies!in!diagnosis!(such!
as! expression! profiling! of! undifferentiated! tumours! in! distinguishing! origin! (Lu! et! al.!













intermediateWstep!processing!or! the!ultimate!microRNAWmRNA! interaction! (Ryan!et! al.!
2010).!One!relevant!example!is!a!variant!in!the!preWmicroRNAW146a!gene!and!increased!
prostate!cancer!risk!(Xu!et!al.!2009).!Chatzikyriakidou!et!al!have!examined!the!variants!
in! microRNAW146a! and! polymorphisms! in! it’s! target! IRAK1! and! susceptibility! to!
developing! RA! (Chatzikyriakidou,! Voulgari,! Georgiou! &! Drosos! 2010a).! ! Their! group!
identified!a!polymorphism!in!the!3’UTR!of!the!mRNA!encoding!IRAK1!(a!microRNAW146a!
target)!in!RA!patients!versus!controls.!They!propose!this!could!increase!susceptibility!to!
RA.! The! same! group! identified! the! same! finding! in! a! smaller! cohort! with! psoriatic!
arthritis! and! ankylosing! spondylitis! (Chatzikyriakidou,! Voulgari,! Georgiou! &! Drosos!
2010b).!
1.17.3.11!What!regulates!microRNA?!
The! identification! of! microRNA! not! only! requires! consideration! of! their! functional!
significance! but! also! consideration! of! their! own! regulation;! namely! what! are! the!





Schmeier! et! al! 2009! explored! those! transcription! factors! (TFs)! involved! in! controlling!
microRNA!and!the!differentiation!of!monocytes!to!macrophages!(Schmeier!et!al.!2009).!
By! identifying! those!microRNA!expressed!during!monocyte! stimulation! they! identified!
the! promoter! region! TF! binding! sites! and! both! computationally! (in! silico)! and!
experimentally!predicted!those!TF!involved!in!the!regulatory!process:W!several!novel!TFs!
were! identified! and! validated.! Fazi! et! al! identified! the! two! competing! transcription!
factors! involved! in! granulopoeisis.! Both! act! at! the! microRNAW223! promoter! gene! in!
opposing!fashions!to!influence!microRNAW223Wmediated!myeloid!differentiation!(Fazi!et!







In!RA,!Nakamachi!et!al! identified! reduced!microRNAW124a! in!RA!FLS! (Nakamachi!et!al.!
2009).! Lujambio! et! al! had! previously! identified! the! hypermethylated! status! of! the!
promoter! gene! for! microRNAW124a! in! colon! cancer! cell! lines! and! thus! the! observed!
reduced! levels!of! W124a! (Lujambio!et!al.!2007).!One!of! the!key!targets! for! W124a! is! the!
oncogene! CDK6! involved! in! cell! differentiation! (cyclin! D! kinase! 6)!which!may! thus! be!




to! OA! samples! in! RASF! unresponsive! to! further! TLR! stimuli.! In! this! way,! RASF! were!
resistant! to! apoptosis.! They! identified! the!microRNAW34a! promoter! to! be!methylated!
and! thus!microRNAW34a! downWregulated.! This! was! reversible! under! the! action! of! deW
methylating! treatments.! Similarly,! (Stanczyk! et! al.! 2011)! ! also! identified! elevated!
microRNAW203!in!RASF!unaffected!by!further!stimulation.!Treating!the!RASFs!with!a!deW
methylating!agent!reversed!this.!This!suggests!promoter!methylation!contributes!to!the!
persistently! activated! phenotype.! Furthermore! they! postulate! the! variable! levels! of!




The! first! study! of! microRNA! and! DNA! methylation! patterns! together! was! recently!
published!(la!Rica!et!al.!2013).!They!studied!RASF!versus!OA!synovial!samples!identifying!
altered!methylation! in! key! regulatory!genes!and!appropriate! changes! in!expression!of!
microRNA!that!may!explain!the!RASF!activated!phenotype.!Some!genes!were!regulated!
in!opposing!fashions!by!methylation/microRNA!actions.!Details!regarding!treatment!and!
disease! characteristics! were! not! known.! Reassuringly! they! identified! many! of! the!
microRNA! listed! below! in! addition! to! a! number! of! other! novel! targets.! Their! study!
reiterates!additional!levels!of!regulation.!
!
In!Oncology,! several! studies/reviews!have! identified!microRNA!as! tumour! suppressors!
and! the! methylation! status! of! their! promoters! being! important! (Saito! &! P.! A.! Jones!
2006;!Huang!et!al.!2010).!(Toyota!et!al.!2008)!identified!low!microRNA!34b/c!in!colonic!
tumour!cell!lines!(thus!acting!as!tumour!suppressors).!The!neighbouring!CpG!island!was!
found! to! be! hypomethylated.! Finally,! similar! interacting! epigenetic! processes! can! be!
found! in! the! related! rheumatic!disorder! SLE.! (Pan!et! al.! 2010)! identified!microRNAW21!




Pseudogenes! may! play! a! role! in! regulation! of! microRNA.! These! are! nonWcoding!





the! inflammatory! pathway.! However,! expression! is! cellWtype,! timeW! and! tissueW
dependent! meaning! unintended! side! effects! may! be! unpredictable! with! systemic!
delivery.!The!first!human!trials!have!been!carried!out!in!hepatitis!C!treatment!with!antiW
miRW122!with!successful!Phase!IIa!trials!and!a!number!of!others!in!Oncology!(Zhang!et!al.!
2010).! MicroRNA! regulate! important! repair! and! remodelling! processes! in! ischaemic!
heart! disease/infarction! and! the! early! phase! trials! underway! have! been! reviewed! by!




To! date! there! have! been! a! number! of! important! studies! published! which,! when!
considered! together,! suggest! epigenetic!modifications!underpin!RA!pathogenesis.! This!
field! has! evolved! rapidly! from! the! conception! of! this! study! and! the! use! of! high!
throughput!methods! and! predictive! bioinformatics! has! advanced! the! field.! Epigenetic!
modifications!are!consistently!demonstrated!not!only!in!the!development!of!RA!but!may!
also!explain!the!finding!of!persistent!inflammation!observed!in!RA!(Ammari!et!al.!2013).!
I!will! briefly! consider!DNA!methylation! and!histone!modifications!before! focussing!on!
microRNA.!!
1.18.1!DNA!methylation!!
Within! studies! of! DNA! methylation! in! RA,! the! synovial! fibroblast! remains! the! bestW
studied!cell!type.!!








proWinflammatory! molecules.! They! confirmed! global! genomic! demethylation! in! RA!
patients.! In! addition! the! levels! of! DnmtW1! were! reduced! in! RA! contributing! to! the!
persisting! demethylated! state.! This!may! be! a! part! of! the! contribution! to! the! chronic!
state!observed.!
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Nakano!et!al!2013!have!built!upon! this!observation!by!demonstrating! that! the!
differentially!methylated!loci!are!key!regulatory!loci!involved!in!RA!(Nakano!et!al.!2013).!
Similarly,! Gowers! et! al! examined! the! methylation! status! of! the! TNF! promoter! by!
examining! PBMCs! in! healthy! individuals.! With! age,! the! promoter! was! increasingly!
demethylated,! a! finding! that! may! relate! to! the! increasing! incidence! of! RA! with! age!




Nile! et! al! identified! a! single! demethylated! CpG! promoter! regulating! ILW6!
production! in! RA! PBMC’s.!Whether! this! represents! a! primary! susceptibility! finding! or!
mere! disease! characteristic! requires! further! examination.! Study! in! early! RA! or! even!
individuals!prior!to!symptom!onset!would!be!of!interest(Nile!et!al.!2008).!
Takami! et! al! examined! death! receptor! 3! (DR3)! gene! regulation! and! promoter!
methylation! status! in! RA! patients! and! OA! patient’s! synovial! samples! in! addition! to!
PBMCs.!Methylation!of!the!promoter!reduced!DR3!gene!expression!and!contributes!to!
the!observed!resistance!to!apoptosis!(Takami!et!al.!2006).!
Schwab! et! al! studied! BWcells! and! identified! that! the! CpG! island! related! to! the!
CD21!molecule!(present!on!mature!immunoglobulin!producing!BWcells)!is!demethylated!
in!both!peripheral!mononuclear!cells!(PBMC)!and!in!the!synovial!compartment!(Schwab!
&! Illges!2001).!CD21! is!necessary! for! recognition!of!C3d!as!part!of! immune!complexes!




plethora! of! different! types! of! tail! modifications! (and! more! than! one)! that! may! be!
present.! There! a! number! of! animal! model! experiments! confirming! the! important!
potential!of!HDAC!inhibitors.!
(Huber!et!al.!2007)!identified!differences!(reduced)!in!relative!histone!acetylase!
and! deacetylase! activity! in! RA! synovial! tissue! when! compared! to! OA.! RASFs! have! a!
hyperacetylated! genome,!owing! to! the! low!activity! levels! of! total! histone!deacetylase!
(HDAC)!enzymes,!possibly!resulting!from!reduced!levels!of!HDAC1!and!HDAC2.!LowWlevel!
HDAC! activity! might! therefore! contribute! to! the! activation! of! proWinflammatory!
transcription!factors.!
(Kawabata! et! al.! 2010)! investigated! nuclear! HDAC/HAT! expression! and!
cytoplasmic!TNFa!in!RA!synovial!tissue!versus!OA.!HDAC!activity!was!found!to!be!higher!









As! with! other! epigenetic! modifications,! acetylation! is! potentially! reversible.! Notably,!





necessary! to! review! the! evidence! to! date! that! shows!microRNA!are! the!most! studied!
and! reported!epigenetic!marks! in!RA.!Publications!have! increasingly! focussed!on! their!
biological! role! and! integration! in! inflammatory! networks.! I! have! reviewed! the! initial!




in! inflammation! and! tissue! destruction! and,! in! many! ways,! contrasting! actions.! Yet,!





the! BIC! gene! (chromosome! band21q21.3)! and! microRNAW155! is! regulated! both!
transcriptionally! and! post! transcriptionally.! It! has! a! fundamental! role! in! the! immune!
system!and!can!be!found!expressed!by!activated!immune!cells.!Both!proW!and!negative!
regulatory!roles!have!been! identified!which!are!cell! type/context!dependent! (Stanczyk!
et!al.!2008;!Spoerl!et!al.!2013).!!
!
MicroRNAW155! is! central! within! myeloid! physiology! from! germinal! centre! BWcell!
maturation!and!memory!cell! formation! to!myeloid!and!TWcell!differentiation! (Tili!et!al.!
2009;!Thai!et!al.!2007;!Vigorito!et!al.!2007).!The!observation!of!a!close! link!with!many!
haematological!malignancies! such! as! lymphoma! and! leukaemia! is! of! note.!MicroRNAW
155! levels! are! elevated! in! these! conditions.! Tili! et! al! propose! not! only! persistent!
production! of! microRNAW155! (perhaps! by! oncogenes)! but! also! a! failure! of! normal!





In! general,! inflammatory! ligands! increase! microRNAW155.! Tili! et! al! 2007! confirmed!
mIcroRNAW155!as!a!positive!regulator!of!inflammation!in!mice.!It!is!up!regulated!(under!
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nFkB! control)! in! response! to! LPS! and! may! enhance! the! TNFa! transcript! stability! and!
thereby!serum!TNFa.!It!is!in!this!way!a!key!part!in!the!regulation!of!the!innate!immune!
system! in! response! to! bacterial! infection.! Teng! et! al! and! Thai! et! al! also! demonstrate!
microRNAW155!is!induced!by!inflammatory!stimuli!(Teng!et!al.!2008;!Thai!et!al.!2007).!!
!
Initial! observational! studies! in! RA! confirm! a! constitutive! increase! in! both! PBMCs! and!
synovial!joints!in!RA!(Pauley!et!al.!2008;!Stanczyk!et!al.!2008).!RASFs,!upon!stimulation!




al.! 2011).! Importantly,! double! staining! for! microRNAW155! and! macrophages!




articular! compartment.! Importantly,! microRNAW155! deficient! mice! were! resistant! to!
collagenWinduced!arthritis.!
!
FLS! also! produce! elevated!microRNAW155! and! further! increases! with! exposure! to! the!
proWinflammatory! milieu.! This! observation! would! be! consistent! with! an! autocrine!
positive!feedback!loop!unWreliant!on!the!need!for!onWgoing!exposure!to!antigen.!
!
















Increased! Human! SHIPF1! SHIPF1! expression! reduced! by! microRNAF155! thus! increased!









Absence!of! Murine! n/a! MicroRNAF155! deficient! mice! do! not! develop! clinical! findings! of!




! PBMC! Increased! Human! ! Increased!F155!(and!other)!x1.8!fold!relative!to!healthy!controls!(see!














blood! and! synovial! fluid.! Few! details! about! RA! patient’s! disease!
characteristics.!
Synovial! fibroblasts! then! stimulated! with! TNFa! and! measured!




















F.! Wang! et! al.! 2010b).! In! general! it! is! up*regulated! in! many! of! the! cell! types! and!
compartments!studied! in!RA,! including!blood!and!joint,!by!proDinflammatory!signals.! It!
should! act! to!downDregulate!downstream! inflammatory!pathways,! one!example!being!
inhibition! of! apoptosis! (Curtale! et! al.! 2010),! but! fails! to! act! in! this! way.! Biologically!
validated!targets!are!key!players!within!the!inflammatory!cascade!including!TNFa,!ILD6,!





2008).! Their! group’s! findings! are! shown! Table! 1D15! and! built! upon! the! findings! of!
Taganov!et!al!who!had!identified!TRAF6!and!IRAK1!as!downstream!targets!of!microRNAD





to! examine! peripheral! blood! findings! (Pauley! et! al.! 2008).! They! examined! patients!
(n=16)!and!correlations!with!clinical!factors;!they!demonstrated!significant!differences!in!
microRNA! irrespective!of! treatment!or!not,!DMARD!or!biologic!use!and!no!correlation!
with! age.! Their! data! did! suggest! some! correlation!with! inflammatory!markers.! Finally!
they! noted! the! relative! levels! of! TRAF6! and! IRAK1! mRNA! and! protein! were! not!
decreased! versus! control.! This! suggests! an! unregulated! effect! and! explaining!
persistently!elevated!TNFa!via!elevated!microRNAD146a.!
!
Li! et! al! 2010!demonstrates! that!microRNAD146a!expression! is! correlated!with! TNFa! in!
blood! and! synovium! but! not! disease! activity.! (AbouDZeid! et! al.! 2011)! have! also!
demonstrated!elevated!microRNAD146a!in!peripheral!monocytes.!Furthermore,!they!did!
demonstrate!correlation!with!TNFa!and!were!able!to!demonstrate!some!correlation!with!
ESR! and! DASD28! in! 70! RA! patients.! Of! note! there! did! not! seem! to! be! a! difference! in!
microRNAD146A!levels!in!those!treated!with!TNFi!and!conventional!DMARDs.!
!





MicroRNAD146! is! also! not! limited! to! RA.! It! is! increased! in! OA! (Yamasaki! et! al.! 2009;!
Okuhara! et! al.! 2011)! along! with! D155,! D181a! and! D223! adding! further! complexity! to!
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interpretation! of! longstanding! arthritis! where! both! inflammatory! and! degenerative!
arthritis!often!coDexist.!
!
Therefore! elevated! microRNAD146a! is! consistently! demonstrated! in! RA! (and! other!
autoimmune! diseases)! and! in! the! pathogenesis! by! targeting! key!molecules.! The! close!
correlation!with!TNFa!but!not!other!cytokines!is!of!interest;!TNFi!act!through!TNFa!and!



















! PBMC! Increased! Human! TRAF6,!
IRAK1!
Examined!PBMC!in!RA.!Some!correlation!with!disease!activity!between!E146a!and!E







! RASF! Increased! Human! n/a! 5!RA!patients!vs!5!OA!vs!1!control.!Low!CRP!levels!but!long!disease!duration!(9E28!
years)!
E146a!upEregulated! in!RA! synovium!along!with!elevated!TNFa.! E146a!also!present!
on! normal! and! OA! tissue! but! much! lower! levels.! Expressed! mostly! in! CD68+!






Increased! Human! n/a! Subjects! varying! activity! (ESR! 8E74mm/hr,! disease! duration! 2E17years,! mixed!
treatments).! E146a!/b,! letE7a,! E26,! E150!and! E155! identified!by! initial!microarray.! E












TNFa! levels! (both! in! blood! and! synovial! fluid)! but! NOT! inflammatory! markers,!
cytokines!nor!clinical!markers!of!disease!activity.!E146a!target!FAF1!that!modulates!
T!cell!apoptosis.!!





















role! alongside! cytokines! and! transcription! factors! in! the! regulation! of! osteoclast!
differentiation! from!marrow!macrophages! (Sugatani!&!Hruska!2009).!As! an! important!
effector!cell!in!joint!erosion,!this!is!a!key!finding!in!RA.!In!RA,!microRNA,223!is!increased!
in! both! blood! and! synovial! compartments! yet! action! is! cell! type,dependent.! The!
important!publications!are!shown!in!Table!1,16!below.!
Additionally,!Murata!et!al!noted!a!difference!in!,223!vs!osteoarthritis!in!both!plasma!and!
synovial! fluid!but!no!correlation!with! clinical! factors!other! than!an! inverse! correlation!



















(Ichimura! et! al.! 2010).! It! acts! as! a! ‘tumour! suppressor’! under! the! influence! of! p53!
leading!to!cell!apoptosis.!In!RA,!(Niederer!et!al.!2011)!identified!the!down,regulation!of!
microRNA,34*! accounting! for! the! observed! resistance! to! apoptosis! in! synovial!






















Patients! at! arthroplasty! or! synovectomy! Disease! duration! 3G17! years! and!
mixed! treatments,! all! destructive! and! erosive! disease.G223! present! in! joint!
subGlining,!macrophages,!mononuclear!cells!and!CD4+!TGcells.!!









Increased! Human! n/a! Hypothesis;!TGlymphocytes!involved!in!early!stages!of!Ag!presentation.!
Either!on!no!treatment!or!steroid!<10mg!only!but!had!established!disease.!No!




















MicroRNA! 124a! significantly! reduced;! predicted! targets=CDKH2! (role! in! cell! cycle!
control)! &! MCPH1! (attracts! memory! THlymphocytes! and! NK! cells! and! role! in!
angiogenesis!via!VEGF);!increasing!respectively!
If!transfect!cells!with!precursor!microRNAH124a!then!cells!arrest!at!G1!phase!




















Some! variation! according! to! disease! stage! (more! variable! in! early! disease).! No!
correlation!with!treatment.!Disease!activity!not!examined!
!
Showed!methylation' status' of' the'upstream'promoter! region! important! and! this! in!















































binding! proteins! (Faraoni! et! al.! 2009).! Although! the! predicted! number! of! ‘in! silico’!
targets!is!far!greater,!some!validated!examples!are!shown.!
!
'''''''c5MAF! (repressed! ! by! microRNAH155,! dendritic! cell! maturation! and!
haematopoietic!maturation)!(Rodriguez!et!al.!2007)!!











target! by! a! number! of! authors! and!may! also! act! as! a! ‘tumour! suppressor!
gene’! in! this! way.! Androulidaki! 2009! demonstrated! LPS! stimulated!
microRNAH155! production! in! macrophages! is! suppressed! via! AktH1.!
MicroRNAH155! may! act! to! suppress! SOCS1! via! AktH1! (one! of! the! known!
negative! feedback! pathways! to! reduce! TNFa).! (Androulidaki! et! al.! 2009).!
Jiang! 2010! identified! high!microRNAH155! and! suppressed! SOCSH1! in! breast!
cancer.! In! turn! the! unregulated! production! of! inflammatory! cytokines!
contributes! to! cell! growth! (Jiang! et! al.! 2010).! Wu! et! al! concluded! that!
microRNAH155! modulates! TNFa! driven! osteogenic! differentiation! by!
targeting! SOCSH1! expression.! TNFa!may! increase!microRNAH155,!which,! via!
SOCSH1,!leads!to!osteoblast!differentiation!(J.!Wu!et!al.!2011).!!
SHIP1/C/EBPbeta' in! mice! are! both! targets! of! microRNAH155! and! act! as!
regulators!of!ILH6!signaling!(Costinean!et!al.!2009).!
SMAD2'microRNAH155! repressed! SMAD!2!protein! and! in! this!way! reduced!
TGFHB!action!(Louafi!et!al.!2010)!
TAB2! (TAK1!binding!protein!2,!a!signaling!molecule!downstream!of!TRAF6).!
Ceppi! showed! that! LPS! induced!microRNAH155! inhibits! TAB2! expression! (a!
part!of!TLR4!signaling)!and!thus!acted!as!an!inhibitory!regulator!in!monocyte!
derived!dendritic!cells!(Ceppi!et!al.!2009)!
FADD! (the! antiHinflammatory! and! proHapoptotic! molecule! FasHassociated!
death!domain!protein)!Involved!in!TLR!signaling.!
p53'Tumor!protein!53Hinduced!nuclear!protein!1!expression!is!repressed!by!
miRH155,! and! its! restoration! inhibits! pancreatic! tumor! development!
(Gironella!et!al.!2007)!
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1.18.3.7' MicroRNA' targeting' key' inflammatory' signalling' pathways' and' within'
regulatory'networks'
JAK/STAT!pathway!














• McCoy' et' al' propose' that' IL>10' down>regulates'microRNA>155.! The! binding! of!
LPS!produces!microRNA!155!leading!to!an!increase!in!SHIP1!(McCoy!et!al.!2010)!!
Furthermore! the! LPSHinduced! production! of! ILH10! inhibits! microRNA! 155! and!
thus!further!fineHtunes!the!response.!!
• MicroRNA' 146a' negatively' regulates' TLR' signalling.! Taganov! et! al! in! 2006!
demonstrated!following!TLR!receptor!activation!with!LPS,!nFkB! is!up!regulated.!
MicroRNAH146a! is! also! transcribed! in! parallel! creating! a! negative! feedback!
pathway!acting!through!IRAF1!and!TRAF6!(Taganov!et!al.!2006).!
• MicroRNA>187' regulates' IL>10'driven'anti>inflammatory' response.'Whereas! the!
TLR!are!the!important!mediators!of!inflammation,!ILH10!is!an!important!negative!
regulator.! Rossato! et! al! sought! to! identify! the!microRNA! involved! in! the! ILH10!
mediated! reduction! of! inflammation.! They! identified! microRNAH187! as! being!
elevated!and!a!corresponding!reduction!in!TNFa!and!ILH6!(Rossato!et!al.!2012)..!
ILH10!leads!to!a!fall! in!microHRNAH155!(in!keeping!with!McCoy!et!al)!and!a!rapid!




Within! these!publications!and! in!order! to!summarise,! the!observation!of!an! individual!
microRNA!such!as!H155!can!be!seen!in!common!between!cell!types!from!monocytes!and!








! ! ! ! 124;!Nakamachi!
! ! ! ! 155;!Stanyczk!
• Osteoclast! 155;!Stanyczk,!Bluml!
! ! ! 146;!Nakasa!
• Fibroblast! 346;!Alsaleh!
! ! ! 155;!Stanyczk!
! ! ! 146;!Nakasa,!Stanyczk!
! ! ! 203;!Stanyczk!












loops.! Modifications! in! key! effector! cells! may! also! provide! an! explanation! for! the!
persistent! state! of! activation!within! the! immune! system! (Ospelt! et! al.! 2011).!Notable!
observations!relevant!to!the!findings!and!methodology!of!this!study!therefore!include;!!
!
• That! the! link! between! both! microRNAH155! and! H146a! and! TNFa! is! strong! and!
potentially! pathological.! It! is! not! clear! if! this! observation! reflect! a! primary!
disturbance!of!microRNA!regulation!or!is!merely!a!marker!of!other!dysregulated!
immune/epigenetic!processes.!










• That! the! peripheral! blood! compartment! signature! is! similar! to! that! of! the!
articular! compartment.! Correlation! between! peripheral! blood! analysis! and!
disease!activity! is! inconsistentH!a! finding!that!may/not!be!of!use! in!overcoming!
the!inherent!weaknesses!in!the!DAS!composite!scoring!system.!















1.19.2' Challenges' in' RA' management' and' potential' application' of' examining'
epigenetic'modifications'
There! exist! shortfalls! in! the! current! treatment! of! RA! that! can! be! approached! by!
examining!the!disease!course!of!the!individual.!At!the!earliest!stages,!it!is!not!possible!to!
either!screen!for!or!identify!‘pre!RA’.!Intervention!prior!to!symptoms!would!be!the!ideal!
scenario! but! faces! ethical! and! practical! challenges.! Genetic! risk! loci! alone! do! not!
adequately! predict! risk! of! developing! RA! owing! to! the! unpredictable! influence! of!
environmental!risk.!!
Once! symptoms! have! become! present! and! persistent! then! treatment! choices! remain!
imperfect.! Although! treating! to! low! disease! activity! is! key! attempts! to! define! disease!
subsets! based! on! autoantibody! or! treatmentHresponse! profiling.! A! personalised! bioH








Research! in! the! field!of!epigenetics,!most!notably!microRNA,!suggests!a!potential! role!
for!these!processes!in!RA.!!
• Epigenetics! offers! an! appealing! mechanism! to! tie! together! the! principal!
established!risk!factors!of!genetic!predisposition!and!environmental!factors.!!
• In! addition,! through! their! appreciable! relative! contributions,! epigenetic!
modifications! could! offer! an! explanation! for! the! range! of! phenotypes,! disease!
severity!and!responses!to!therapy!seen!in!RA.!!
• Epigenetic!changes!could!explain!biologic!resistance!such!as!the!example!of!the!
persistently! activated! fibroblast.! Persistent! methylation! may! explain! this!
phenomenon!and!why!RA!persists.!!








That! networks! of! microRNA! mediate! the! observed! resistance! to! standard! available!
therapies! in! rheumatoid! arthritis! and! that! these! changes! are! accessible! in! peripheral!
leucocytes.!!
1.20.1'Primary'Aims''
The! primary! objective! is! to! firstly! define! the! phenotype! of! and! carry! out! a! detailed!
examination! of! patients! with! severe! RA! with! active! inflammatory! joint! disease!

















clinical! methods! including! study! design,! ethical! considerations! and! application,!
recruitment!and!assessments!performed!at!each!visit.!
!
A! careful! characterisation! of! the! 'resistant'! patient! phenotype! will! be! performed.!
Information! collected! will! include! disease! history! to! examine! onset,! previous! and!
current! therapy! including! reasons! for! drug! termination.! Employment! status! and!
demographics!including!postcode!were!collected.!Previous!joint!surgery!and!presence!of!
extraHarticular!features!were!examined.!
Measurement! of! coHmorbidities,! nonHRA! related! and! RAHrelated! were! collected.!















Ethical! approval! for! the! study,! and! subsequent! amendments,! was! obtained! from! the!
Local!Research!Ethics!Committee!(West!of!Scotland)!REC!Ref!Number!10/S0703/4!
(R&D!Ref:!GN09RH669)!in!Mach!2010!and!was!obtained!prior!to!the!study!commencing!















was! later!added!to!help!recruitment.!Patients!were! initially!opportunistically! identified!
from! records! of! those! regularly! attending! respective! Day! Units! for! infusions.! These!
patients! were! sent! Patient! Information! Sheets! (see! PIS! appendix)! prior! to! contact.!
Disease!activity!was!assessed!on!the!day!and!inclusion/exclusion!criteria!revisited!prior!
to! consent! being! provided.! Where! possible! and! time! allowing,! questionnaires! were!




The! second! and! third! clinical! visits!were! carried! out! at! three!months! and! six!months!
where! practically! possible.! Many! patients! endured! multiple! other! hospital! visits! and!
study! visits! were! often! earlier! or! later! to! accommodate! this! but! all! +/H! three! weeks.!
Furthermore,!drug!safety!monitoring! is!undertaken! in!primary!care!and!so!as! to!avoid!
duplication,! study! visits! were! arranged! on! occasion! to! coincide! with! such! time,! as!
venepuncture!would!have!been!otherwise!due.!!
In! order! to! minimise! errors! in! joint! assessments,! DB! had! attended! a! EULAR! joint!
assessment! workshop! and! thus! standardised! techniques! followed.! DB! carried! out! all!
clinical! assessments! other! than! patients! 416! to! 421! inclusive! (recruited! from! the!
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Glasgow!Royal! Infirmary! and! clinical! assessments!were! carried!out! by!Dr! Eva!Ruzicka,!




four! groups! were! carried! out! between! August! 2010! and! September! 2011.! Blood!




drawn.! Blood! sampling! for! epigenetic! analysis! and! clinical! assessments! were! always!
carried!out!on!the!same!day.!
Characteristics! of! each! study! and! control! group,! recruitment,! inclusion! and! exclusion!
















databases! (Gartnavel! General! Hospital! and! Stobhill! Hospital)! employed! in! Greater!
Glasgow! and! Clyde! centres.! Further! information! was! then! obtained! in! the! drug!
administration! areas! where! more! detailed! examination! of! biologics! prescription! files!
could! be! carried! out.! Additional! patients! were! opportunistically! identified! from!
colleagues! and! Biologic! follow! up! outpatient! clinics! (Glasgow! Royal! Infirmary! and!
Gartnavel!General!Hospital).!
!
Group'Characteristics5! Such! individuals!may!have!demonstrated!primary!or! secondary!
loss!of!efficacy!to!standard!synthetic!disease!modifying!medication!and!to!at! least!two!
!! 101!
biologic! therapies! (including! for! reasons! of! primary! failure! (lack! of! effect),! secondary!
failure!(loss!of!effect),!side!effect!and!‘other’!reasons).!This! includes!all!biologic!agents!
approved! for! use! in! the! Scotland! including! Etanercept,! Adalimumab,! Infliximab,!





DASH28! ESR! of! greater! than! or! equal! to! 3.2.! This! is! in! keeping! with! most! recent!
recommendations! that! a! DASH28! of! this! level! be! applied! when! starting! antiHTNFa!
therapy!than!the!2005!guidance!of!5.1!(Deighton!et!al.!2010;!Ledingham!et!al.!2005).!
Insofar!as!can!be!best!ascertained!from!clinical!records,!response!to!and/or!side!effects!
to! standard! disease! modifying! therapy! was! collected.! Response! to! previous! biologic!
therapy!was!collected.!A!primary!lack!of!response!is!defined!as!failing!to!achieve!a!DASH
28!reduction!of!1.2!or!residual!disease!activity!failing!to!suppress!to!less!than!or!equal!to!








inadequate! responder,! DMARDHIR).! In! such! patients,! current! treatment!
recommendations! are! that! biologic! therapy! would! be! the! next! therapeutic!
intervention96.!
!
Group' characteristics5'The!ORBIT! (Optimal!management!of! patients!with!Rheumatoid!
Arthritis! who! require! BiologIc! Therapy,! REC! Ref! 09/S0703/109)! study! is! an! onHgoing!
twelveHmonth!study!across!Scotland!and!North!England!randomising!treatment!to!either!
antiHTNFa! therapy!or!BHcell!depletion!with!Rituximab.!The!primary!outcome!compares!
efficacy! and! costHeffectiveness.! Inclusion! and! exclusion! criteria!were!met! (see! below)!
and! within! the! consent! for! this! study! was! permission! to! examine! peripheral! blood!





































Group' characteristics5! this! comparator! group! aims! to! mediate! the! effect! of! disease!
duration! upon! observed! findings.! A! good! response! to! treatment! with! two! or! fewer!
standard! DMARDs! should! be! demonstrated.! Thus! at! the! time! of! examination! low!
disease! activity! (as! demonstrated! by! a!DAS28! of! less! than! or! equal! to! 3.2)! should! be!
present.!
Disease!duration!of!greater! than! ten!years!was! chosen!pragmatically! for! two! reasons.!
Definitions!of! ‘longstanding’! RA!have!not! been! formally! defined.! ‘Early’! rheumatoid! is!
generally! accepted! as! disease! of! less! than! one! year! and! after! the! second! year!
!! 103!
‘established’!and!thus!persistent.!Symmons!et!al!chose!between!five!and!twenty!years!
as! inclusion! to! a! study! of! ‘established! RA’! in! 2006! whereas! by! 2012! this! period! was!
defined! as! ‘greater! than! six! months’! by! the! American! College! of! Rheumatology!
consensus! guidelines! (Symmons! et! al.! 2006;! Singh! et! al.! 2012).! In! this!way,! ten! years!
would! represent! ‘longstanding’!disease!with!a! stable!phenotype.! Secondly,! the! cohort!
disease!duration!would!approximate!the!main!study!group.!
Additional! clinical! data! collected! included! age,! gender,! and! medical! coHmorbidities!




Recruitment5healthy! controls! were! age! matched! where! possible.! Recruitment! using!
ageHmatched! relatives! was! used! where! possible! and! supplemented! by! the! use! of!
volunteers!based!at!the!three!local!recruiting!hospitals.!
!





hitherto! asymptomatic! epigenetic! modifications! has! yet! to! be! elucidated.! CCP!
antibodies!can!be!demonstrated!prior!to!symptomatic!joint!disease!(RantapaaHDahlqvist!
S!2003)!and!epigenetic!modifications!could!be!expected.!
Additional! clinical! data! collected! included! age,! gender,! and! medical! coHmorbidities!


























































drawn! in! this! fashion! supplemented!by!patient! recall! at! study! visit.! Patients! at!














HADS! <5mins! 3mins! Psychological! 0&6!months!



















































Patients! from! the!DMARD! resistant! group! (ORBIT! patients)! had! clinical! data! collected!
























Blood! sampling! was! undertaken! at! ORBIT! study! visits! as! per! protocol.! Additional!




evaluated! using! the! University! of! Edinburgh! free! to! access! online! calculator!




using! the!highHrisk! chart!and! the! suggested!x1.5!multiplier.!Perk!et!al! (eur!heart!2012!
guideline)!suggest! if! the!score!result! (risk)!>5%!then!those!patients! 'may'!benefit! from!
drug! treatment! if! any! other! target! value! is! not! met.! If! risk! >10%! then! treatment! is!
'frequently!required'.!Whilst!not!prescriptive,!this!serves!as!a!guide.!
2.3.2 Blood'Sampling'
See! Appendix! 3! for! details! of! sampling! and! transport.! This! collection! procedure! was!
carried!out!on!all!patients!recruited!to!this!study.!
Carstairs! deprivation! scores! were! calculated! using! the! charts! available!
(http://www.sphsu.mrc.ac.uk/publications/carstairsHscores.html)! based! on! data! from!
the!2001!census.!
2.4'Discussion'of'Study'Design'
The! frequencies!of!clinical!visits!are!defined! in!Table!2.7!below.!We!chose! to!examine!
the!biologic!and!DMARD!resistant!groups!across! three!visits! to!allow!a!cross! sectional!
analysis.! It! would! be! anticipated! that! within! the! ORBIT! group! there! would! be! good!
responders!and!nonHresponders!that!may!allow!an!analysis!of!the!effect!of!therapy!and!
any!observed!changes.!The!biologic!group!were!considered!likely!to!undergo!alterations!
to! therapy! during! the! course! of! the! study! as! guided! by! their! treating! physician.! This!
!! 108!
would! facilitate! some! correlation! between! disease! activity,! treatment! change! and!
epigenetic!findings.!
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CRP! testing!was! undertaken!using! a! highly! sensitive! CRP! (hsCRP)! assay! undertaken! at!
Greater! Glasgow! Biochemistry! Laboratories.! One! healthy! control! patient! (227)! was!








The! Siemens! Healthcare! Diagnostics! UK! NHLatexHRF! kit! was! used! to! quantify! RF.! ! The!
manufacturer’s!guidance,!reagents!and!method!were!followed.!The!nephelometer!used!
to!quantify!the!antigenHantibody!complex!was!the!Dada!Behring!model!BNII.!!
The! Latex! testing! principle! is! as! follows;! when! serum! containing! RF! is! mixed! with!
polystyrene! beads! coated! in! human! immunoglobulin! and! sheep! antiHhuman! IgG! then!
aggregation! (agglutination)! occurs.! This! scatters! a! beam! of! light! passed! through! the!
sample! and! the! intensity! is! proportional! to! the! concentration! of! RF.! This! is! then!
compared!against!a!reference!of!known!concentration.!
The! reference! range! suggested! by! the!manufacturer! and! on! the! basis! of! local! agreed!
cutHoffs! at! the! Gartnavel! Immunology! Laboratory! were! determined! as! follows;!




carried! out! on! a! Zenit! processor! model! SP+.! The! technique! used! was! an!
immunofluorescence!assay!and!HEPH2!slides.!The!principle!is!as!follows;!patient!serum!is!
incubated!with!mitotic!human!epithelial!cells!(HepH2!cells)!and!if!ANA’s!are!present!then!
binding! will! occur! forming! antigenHantibody! complex.! To! this! fluorescent! antibody! is!
bound!which! is! visible! by!microscopy.! The!degree!of! and!pattern!of! binding! form! the!
basis!of!the!result.!In!terms!of!reported!binding!avidity!then!1/40!and!1/80!is!considered!
very!weak,! 1/160! and! 1/320!weak! positive,! 1/640! and! 1/1280!moderate! positive! and!








mix! proportions! undisclosed).! The! manufacturer! details! a! sensitivity! of! 87.8%! and!









Descriptive! (univariable)! analysis! was! performed! including! calculation! of! mean! (and!








study! was! designed! for! the! reasons! stated! (lack! of! published! body! of! evidence).!
Statistical!significance!was!assumed!where!pHvalue!was! less! than!0.05!(ie! less! than!5%!





DB,! using! SPSS! statistical! package! for! Windows! version! 19,! performed! all! statistical!
analysis.!Analysis!of!descriptive!clinical!variable!was!presented!using!median!values!as!
the! clinical! values!were! skewed.! Log! transformation! of!microRNA! relative! values!was!
undertaken.!Mann!Whitney!U!test!was!used!to!compare!differences!between!the!clinical!
variables! and! the! groupings.! Spearman’s! correlation! coefficient! was! used! to! test!












used! with! the! Bonferroni! correction! method! to! allow! for! multiple! comparisons! for!
parametric!data!or!Kruskal!Wallis!testing!with!pairwise!comparisons!for!non!parametric!
results.!!
For! cross! sectional! analysis! the! null! hypothesis! was! considered! that! there! was! no!
difference!between!the!four!study!groups.!








applied! as! representing! ‘possible! depression! or! anxiety’! used! so! as! to! represent! a!




between! groups.! In! order! to! relate! variables! and! seek! any! relationship/causality,!
bivariate!correlations!were!made!between!clinical!variables,! fatigue!and!disability!with!
HADS! anxiety/depression! scores! and! Spearman’s! correlation! coefficient! used.! For! the!
Brief! COPE! questionnaire! where! each! item! has! two! questions,! internal! consistency!
coefficients!(ICC)!were!calculated!using!Cronbach’s!alpha!between!dimension!items.!
Multivariable! analysis! was! performed! to! assess! the! independent! contributions! of!
selected!clinical,!patient!related!outcome!variables!and!illness!perception!in!evaluating!
mood! and! fatigue! as! dependent! continuous! variables.!Only! those! significant! bivariate!






Within! this! chapter! I!will! set! out! the!main! clinical! findings! of! this! study.! The! primary!
focus! is! the! main! biologic! resistant! study! group! upon! whom! the! most! detailed! data!
collection!was!performed.!The!aim!of!examining!disease!characteristics!such!as!patient!
demographics,! disease! history! and!markers! of! severity! in! addition! to! current! disease!
activity!will!place!the!molecular!findings!in!context.!!
!
Quantification! of! the! burden! of! medical! coHmorbidities! and! patient! related! outcome!
measures! is! captured!by! the!questionnaires!administered!herein!and!aims! to!quantify!







Finally,! discussion!of! the! importance!of! considering! the! external! influences! on! clinical!







' Baseline! Three!months! Six!months!
Biologic!resistant! 50! 49! 48!
DMARD!resistant! 26! 21! 24!
DMARD!good!
responder! 21! X! X!














Baseline'visit! ! !50! clinical! assessments! were! completed! and! 48! sets! of!
questionnaires!returned.!!
!




Third'Study'Visit' 47! clinical! assessments! were! carried! out! (six! months)! and! 4!
patients!did!not! return!questionnaires.! The! same!patient! from! the!2nd! study! visit!was!













































































Significant! disease! duration! was! recorded! of! over! seventeen! years.! Additionally,! 58%!


































need! a! third! biologic! therapy! reflects! how!difficult! treatment! remains! for! this! cohort.!
The! majority! of! those! that! display! a! loss! of! effect! with! their! first! drug! need! more!





The! nature! of! the! condition! and! potential! for! drug! toxicity! requires! frequent! drug!

















not! treated!with!a!biologic!agent.! The!most! common! therapy!was!Rituximab! (twentyH

























Adalimumab! ! 22! 17! 4! 0! 0!
Etanercept! 4! 19! 15! 4! 1! 0!
Infliximab! ! 5! 4! 7! 1! 0!
Rituximab! 24! 0! 14! 14! 1! 1!
Abatacept! 2! 1!(Trial)! 0! 0! 1! 2!
Tocilizumab! 8! 0! 0! 4! 3! 1!
Campath! ! 1!(Trial)! 0! 0! 0! 0!
Anakinra! ! 1!(Trial)! 0! 1! 0! 0!




For! the!majority! of! the! cohort,! first! biologic! therapy!was! targeting! TNFa! followed! by!















In! keeping! with! the! presence! of! disease! activity,! changes! were! made! to! therapy!
between!visits.! !By! study!visit! two! thirteen!patients!had! treatment!escalation.!By!visit!
three!an!additional! fifteen!patients! required! treatment!escalation,! three!of!which!had!
also! had! changes! between! baseline! and! visit! three.! Overall! 50%! (25/50)! patients! had!
therapy! escalation! during! the! study! period.! Table! 3H32! and! 3H38! demonstrates! that!
meaningful! improvements! in! DAS28! were! achieved! whereas! the! HAQ! remains! less!
responsive.
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! Baseline! ! 6months! !
Patient!study!No.! DAS28ESR! SDAI! CDAI! HAQ! DAS28ESR! SDAI! CDAI! HAQ!
101! 6.53! 70.60! 120.60! 1.875! 4.87! 29.90! 101.30! 1.750!
106! 6.50! 91.20! 95.80! 2.625! 6.38! 40.60! 96.50! 2.500!
107! 6.92! 52.60! 125.00! 3.000! 5.77! 30.90! 108.30! 2.500!
109! 4.12! 131.30! 51.40! 3.000! 2.69! 10.10! 59.20! 3.000!
111! 4.98! 28.30! 46.70! 2.250! 3.77! 12.70! 38.00! 2.250!
114! 5.28! 47.70! 69.40! 2.000! 4.49! 27.40! 75.70! 2.125!
119! 3.62! 18.80! 20.30! 1.875! 2.04! 3.30! 3.20! 1.000!
122! 7.05! 62.90! 134.00! ! 2.22! 11.60! 11.60! 0.750!
123! 3.75! 19.10! 15.40! 2.500! 4.15! ! 28.70! 2.375!
124! 6.07! 111.10! 58.10! 2.875! 4.27! 95.00! 8.60! !
125! 6.31! 35.50! 117.40! 2.500! 3.37! ! 23.10! 2.625!
127! 5.48! 33.60! 85.30! 2.375! 3.88! 13.80! 50.50! !
128! 6.01! 45.50! 72.10! 1.875! 3.58! 11.70! 34.60! 2.125!
129! 6.85! 99.60! 112.10! 2.375! 5.88! 43.20! 81.70! 2.125!
131! 3.34! 21.80! 21.80! 0.875! 2.35! 9.30! 15.30! 1.125!
132! 4.28! 65.70! 25.00! 2.000! 2.10! 4.10! 7.40! 2.250!
134! 4.85! 37.00! 82.90! 1.625! 4.68! 33.20! 79.40! 2.000!
137! 5.61! 46.30! 104.80! 2.375! ! ! ! !
138! 4.69! 40.60! 97.80! ! 4.02! 25.30! 76.40! 2.250!
141! 5.59! 55.30! 53.70! 1.750! 5.72! 36.70! 72.30! 1.750!
144! 3.67! 15.60! 32.20! 1.375! 2.27! 13.20! 17.70! 1.625!
145! 5.27! 25.50! 82.00! 1.875! 6.15! 34.10! 125.60! 1.875!
146! 4.95! 82.20! 56.50! 2.250! 3.43! ! 32.90! 2.375!
148! 6.09! 64.30! 83.20! 2.000! 7.14! 105.90! 117.30! 2.000!
149! 5.26! 60.20! 53.90! 1.375! 3.00! 19.90! 22.30! !






In! contrast,! three! and! four! patients! respectively! had! treatment! reductions! between!

















The! 2010! EULAR/ACR! guidelines! to! classify! RA! (Aletaha! et! al.! 2010)! would! suggest!
alternative!cut?off!values!for!positive!status!as!<20!as!negative,!21?59!as!weak!positive!
and!>60!as!strong!positive.!The!group!acknowledge!the!difficulties!of!non?standardised!
methods! to!assay!CCP!and!assume!similar!predictive!weighting!of!RF!and!CCP! in! their!
scoring! algorithm.! They! also! highlight! the! heterogeneity! of! RA,!with! probable! disease!
subtypes,! and! the! use! of! this! distinction! for! analysis! purposes.! Their! criteria! could! be!
































Of! the! fifteen!patients!who!were!RF!negative,! nine!of! these!were!CCP!positive! (weak!
positive! or! positive).! The! presence! of! either! autoantibody! confers! a! poorer! prognosis!
and,!as!expected,!this!group!often!exhibit!either!or!both.!As!expected,!40/50!(80%)!was!
positive! at! significant! titres! for! either! or! both! antibodies.! However,! these! numbers!
suggest! it! is! not! a! prerequisite.! The! double?negative! cohort! display! similar! baseline!














! ! ! !
DAS28! 3.97! 5.70! P=0.017★$
ESR!(mm/hr)! 6! 32! P=0.002★★$
CRP!(mg/dl)! 5.8! 14! P=0.078!
TJC! 8! 8! P=0.566!











HAQ! 1.94! 2.25! P=0.136!





36%! (18/50)! of! patients! had! a! positive! ANA! titre! of! levels! of! 1/160! or! higher.! This!
observation!is!in!keeping!with!expected!values!observed!in!RA!populations.!!
3.3.6$Disease$Activity$









N! Valid! 50! 46! 47!
Missing! 0! 4! 3!
Mean! 5.31! 4.54! 4.17!
Median! 5.36! 4.36! 4.09!
Minimum! 3.12! 2.60! 1.40!
Maximum! 7.15! 7.86! 7.30!
Table$3737$DAS28$ESR$score$of$biologic$resistant$study$group$at$all$study$visits$
!
Using! both! composite! disease! activity! measures! and! examining! the! component!




























45.35! 70.75! 24! 11!
& Max!
Min!
7.15! 131.30! 134.0! 95! 116!










& Max! 7.86! 180.90! 126.40! 86! 132!
& Min! 2.60! 8.40! 8.70! 4! 0.2!
Six&months&








7.30! 114.0! 125.60! 122! 90!














































! ! ! ! ! !
EMS!(mins)!







! ! ! ! ! !
SJC!







! ! ! ! ! !
TJC!







! ! ! ! ! !
Pain!







! ! ! ! ! !
!
Patient!Global!



















! ! ! ! ! !

























n=46! Problems! 98%! 85%! 96%! 98%! 54%!
! No!
problems! 2%! 16%! 4%! 2%! 46%!




Problems! 95%! 88%! 95%! 93%! 42%!
! No!




















A!paired! tQtest!was!applied! (p=0.030).!The!whole!group!median!pain! scores! (collected!

























































As! shown,! the! most! important! influences! are! early! morning! stiffness,! patient! global!
assessment!of!disease!and!pain!with!some!correlation!with!disease!activity!at!baseline!



























visit.! Patients! scored! substantially! worse! on! physical! measures.!Mean! PCS! score! was!
26.4!(SD!7.97)!and!mean!MCS!42.94!(SD!14.99).!The!physical!functioning!mean!score!of!
21.44!and!role!physical!of!25.59!are!most!notably!low.!General!health!and!vitality!scores!




In! view! of! the! strong! influence! of!mood! and! other! assessments! (further! discussed! in!
3.3.6.3),!correlation!between!the!components!of!the!SFQ36!and!responses!to!the!HADS!
questionnaire! were! examined.! Significant! correlations! were! seen! in! some! individual!
physical! domains! although! correlation! with! the! summary! physical! score! was! not!
demonstrated.! Social! functioning! and! emotional! role! showed! strong! statistical!
correlation!with!anxiety.!Mental!summary!scores!correlated!with!prevailing!mood!again!
suggesting! consistency! of! response.! Indeed,! 55%! merit! screening! for! depression! and!















































In! order! to! examine! the! factors! that! may! relate! be! important! in! fatigue,! bivariate!
































































































SJC! 9! 11! 12! %%0.021★%
TJC! 8! 8! 8! 0.220!
Pain!(mm)! 19! 44.5! 59! %%%0.004★★%
Patient!Global! 18! 53! 60.5! %%%0.002★★%
DAS28!ESR! 3.86! 5.60! 5.55! %0.016★%
! ! ! ! !
Function!and!QoL!(median)! !
HAQ! 1.88! 2.25! 2.38! 0.050★!
SFQ36!vitality!! 45.85! 30.24! 25.55! <0.0001★★%
SFQ36!physical!
functioning! 27.57! 21.26! 17.05! 0.047
★%
! ! ! ! !
Mood!(median!value)! !
HADSQD!score! 3! 7! 9.5! 0.086!
HADSQA!score! 4! 7! 9.5! 0.17!
! ! ! ! !
Inflammatory!Markers!(median)!
ESR!(mm/hr)!! 17! 30! 23.5! 0.563!
CRP!(mg/dl)! 7.8! 16.5! 7.5! 0.256!














61.6!(7.2)! 60.8!(10.5)! 52.5!(9.3)! 0.077!
Disease!Duration!
(Mean!+SD)!
247!(104)! 238!(116)! 184!(59)! 0.284!
Table%3:48%Selected%clinical%factors%associated%with%severity%of%fatigue%at%baseline%in%biologic%resistant%RA%
!
Correlation! was! observed! between! severity! of! fatigue! and! the! DASQ28! ESR! (and! it’s!
components)! and! with! disability.! There! was! no! correlation! with! Haemoglobin! values,!
inflammatory!markers!or!age.!Although!not!achieving!statistical!significance,!age!in!the!















Clinical! TJC% :0.321*% 0.028!
! SJC% :0.405**% 0.005!
! Pain% :0.533**% <0.0001!
! EMS% :0.351*% 0.017!
! Patient%Global% :0.543**% <0.0001!
! Age! 0.257! 0.081!
! Disease!duration! 0.234! 0.113!
Disease!Activity! DAS:28%ESR% :0.398**% 0.006!
Biochemical! ESR! 0.003! 0.985!
! CRP! 0.034! 0.827!
! Haemoglobin! 0.105! 0.481!
PROMs! HAQ% :0.311*% 0.037!
! HADS:A% :0.435**% 0.002!
! HADS:D% :0.513**% <0.0001!












with! severe! disease! experience! but! also! the! complex! interaction! between! physical,!
biochemical!and!psychological!factors!involved!that!constitute!severe!disease.!
3.3.7.6.1%Disease%Activity%%
As! expected,! even! achieving!moderate! disease! activity! levels! is! difficult! in! this! group!
with! longstanding! disease.! The! treating! physician! made! changes! to! therapy! in! an!
!! 143!
unstructured! fashion! in! half! of! the! study! group.! Meaningful! improvements! in!
inflammatory!disease!were!observed.!
!
Analysing! the! component! values!of! the!DAS!provides! insight! into! those!elements! that!
remain!responsive!to!treatment!changes.!Early!morning!stiffness!improved!(reflective!of!
inflammation)! and! improvements! observed! in! both! tender! joint! counts,! swollen! joint!
counts! and! inflammatory! markers! are! in! keeping! with! reduced! inflammation.!




Physical! function! may! be! considered! by! examining! the! HAQ,! PCS! of! the! SF36! and!
mobility!category!of!EQ5D.!Quality!of! life!may!be!assessed!by!the!SF36.!Assessing!and!
quantifying!the!burden!of!health!related!quality!of!life!outcomes!(HRQoL)!measures!are!
important! not! only! in! assessing! treatment! efficacy! but! also! for! healthcare! budget!
planners.!
!
In! view! of! the! lack! of! a! comparison! control! group! to! establish! differences,! I! have!
examined! selected! published! results! of! other! authors! to! put! results! in! context.! The!





















duration% 18.6yrs% 0.92yrs% %<3yrs% %<2years% 6.1yrs% 6.2yrs% 12.9yrs%
PF! 21.44! 27.72! 52.5! 33.95! 41.8! 32.9! 47.3!
RP! 25.59! 30.04! 32.4! 16.11! 29.8! 14.2! 27.0!
BP! 32.63! 30.98! 43.9! 33.98! 30.1! 30.8! 41.0!
GH! 32.96! 37.10! 47.5! 45.41! 44.0! 34.3! 42.0!
MH! 43.76! 38.64! 70.2! 60.53! 50.3! 38.1! 68.1!
RE! 31.00! 32.63! 56.9! 42.33! 38.2! 49.3! 52.0!
SF! 32.9! 29.34! 69.4! 51.32! 46.9! 31.4! 63.7!
VT! 34.35! 37.02! 42.0! 32.93! 41.9! 52.9! 39.4!
PCS! 24.55! 30.9! ! 31.42! 32.5! 31.1! !









not! the! sole! determinant! of! impaired! QoL.! Overall,! the! MCS! score! is! better! in! this!
biologic! resistant!cohort!yet!PCS!substantially! lower!compared!with!cohorts!of!shorter!
duration.! A! process! of! acceptance! and! adaptation! could! be! proposed! in! this! group!
despite!significant!disability.!
!
When! considered! together,! two! important! observations! can! be! made.! Firstly,!
longstanding!RAQrelated!disability!remains!relatively!refractory!to!modest!improvements!
in! inflammatory! disease.! This! suggests! that! a! considerable! component! of! disability! is!
unresponsive!and!may!be!related!to!existing! joint!damage!and!muscle!deconditioning.!!!!
This! phenomenon! may! be! a! ‘ceiling! effect’! of! disability! achieved! in! these! patients!















Results! shown! in!Table!3Q51!are!mixed!but! there!are! individuals!who!can! still! achieve!




















Firstly,! levels! of! fatigue! are! comparable! if! not! higher! than! similar! RA! cohorts! (see!
Chapter!1).!Fatigue!in!RA!is!also!multifactorial:Q!sleep!disorders,!prescription!medication,!
pain!and!medical!comorbidity! (thyroid!dysfunction,! renal!and!cardiac! failure)!may!also!
influence!severity.!Fatigue!must!also!be!considered!in!context!of!social!stressors!such!as!
employment,! young! family! and! availability! of! support.! Future! assessment! of! these!
variables!would!compliment!those!factors!assessed!above.!
!
Secondly,! many! clinical! variables! correlate! with! fatigue,! the! strongest! of! which! are!
depression!and!disability.!Pain!also!correlated!with!fatigue!and!is!potentially!treatable!if!
the! nature! of! the! symptom! is! carefully! considered.! In! this! cohort! there! is! a! lack! of!
correlation! with! laboratory! markers! of! inflammation! yet! association! with! composite!
disease! activity! scores.! This! may! be! explained! by! the! relative! influence! of! clinical!




Fatigue! thus! reflects! in! higher! DAS28! scores! and! lower! physical! and! emotional!
functioning.! In! addition,! fatigue! is! correlated! mood! (depression)! and! disability! but!
direction! of! causality! is! not! established.! A! complaint! of! high! fatigue! should! prompt!

































! ! ! ! !
DAS28! 4.98!(2.27)! 5.32!(1.58)! 5.81!(1.46)! 0.102!
EMS! 60!(80)! 60!(101)! 90!(90)! 0.170!
SJC! 9!(2)! 10!(6)! 11!(4)! 0.393!
TJC! 8!(3)! 8!(8)! 10!(12)! 0.316!
Global! 29!(26)! 49!(39)! 64!(30)! 0.053!
Pain% 28%(33)% 40%(26)% 60%(31)% 0.008%
ESR! 25!(25)! 32!(26)! 21!(28)! 0.485!
CRP! 7.8!(15.3)! 10.0!(23.2)! 19!(52.5)! 0.229!
! ! ! ! !
FACIT% 28%(14)% 21%(15)% 18%(13)% 0.024%
HAQ! 1.625!(0.875)! 2.250!(0.563)! 2.000!(0.656)! 0.090!
HADS:A% 4%(4)% 5%(9)% 8%(6)% 0.039%
HADS:D% 3%(4)% 6%(8)% 9%(3)% 0.040%
PCS! 27.6!(9.3)! 23.4!(8.4)! 25.1!(5.9)! 0.105!
MCS% 56.4%(22.9)% 42.7%(16.0)% 36.4%(10.4)% 0.043%
! ! ! ! %
Weight!(kg)! 68!(25)! 71!(17.3)! 80!(27.4)! 0.495!
BMI! 24!(13)! 27!(6)! 28.5!(11)! 0.535!
WHR! 1.08!(0.22)! 1.03!(0.08)! 1.04!(0.14)! 0.740!
! ! ! ! !
Joints!replaced!(n=)! 3!(4)! 2!(3)! 0.5!(2)! 0.182!
Joint!surgeries!(n=)! 1!(2)! 1!(3)! 0!(3)! 0.383!
Number!of!previous!
biologic!therapies! 2!(2)! 3!(1)! 3!(1)! 0.586!
Number%of%previous%
DMARDs% 6%(4)% 6%(4)% 4%(3)% 0.015%




Table! 3Q52! confirms! that! deprivation! may! influence! a! number! of! assessments! and!
outcomes! in! keeping! with! previous! observations.! Reported! pain! scores! increase! with!
worsening! deprivation.! Similar! findings! are! suggested! with! higher! anxiety! and!






























The! ATP! III! guideline! suggests! those! ‘major’! risk! factors! of! most! importance! may! be!
smoking,!hypertension!(systolic!BP!>130mmHg!or!diastolic!BP!>85mmHg!OR!preQexisting!












Clinically! evident! vascular! disease! was! however! noted! infrequently! in! this! cohort.! At!
baseline! visit! two! patients! had! confirmed! ischaemic! heart! disease! and! previous!
!! 148!
myocardial! events.! 52%! (26/50)! reported! a! family! history! of! cardiovascular! disease! at!
any!age.!!









! Normal!range! Mean!value! Range!(minQmax)!
Total!Cholesterol!(mmol/L)! <5.00! 5.10! 2.80Q8.60!
Triglycerides!(mmol/L)! <2.30! 1.35! 0.50Q2.84!
HDL!(mmol/L)! >1.00! 1.43! 0.79Q2.48!
Ratio!total!Cholesterol/HDL! <4.0! 3.70! 2.10Q6.00!



























Interpretation!of! the!BHS!guideline! required!both! systolic!and!diastolic!BP!above! their!
target! thresholds.! However,! isolated! systolic! hypertension! was! common! within! the!
group! and! using! the! EULAR! guideline! as! reference! over! a! third! of! the! group! was!
hypertensive.! BP! was! only! measured! on! one! occasion! but! only! one! patient! had!
modification!of!their!antiQhypertensive!regime!made!during!follow!up.!
Of! the! thirty! patients! on! a! regular! NSAID,! fourteen! have! a! prior! diagnosis! of!
hypertension! requiring! monitoring.! This! group! had! a! mean! blood! pressure! of!
131/74mmHg.!
No!correlation!between!systolic!blood!pressure!and!either! inflammatory!markers! (ESR!









using! combined! thresholds! from! the! ATP! III,! SIGN! guidance! and!WHO! guideline.! The!
presence!of!three!or!more!features!is!suggested.!Neither!serum!glucose!nor!evaluation!


































































Significant! numbers! of! patients! displayed! values! outwith! individual! target! ranges! and!
three! patients! met! the! criteria! for! MetS! before! formal! glucose! or! microalbuminuria!























14%! (5/37! had! an! abnormal! ECG.! Of! these! four! had! ischaemic! ECG! changes,! one!




50%! (4/8)! took! a! regular!NSAID.! The!NSAIDs! prescribed!were!mixed;!most! commonly!
used! was! etodolac! 600mg! (13/30),! diclofenac! (5/30),! naproxen! (3/30)! etoricoxib,!
































Number! with! either! BP! >140mmHg! and/or! total! Chol! >/=4.5=! all!
4.! !Therefore!all& four!would!merit! statin!and!BP! lowering! therapy.!At! the!
time!of!assessment,!one!was!treated!with!a!statin!and!three!would!merit!





















of! vascular! events! occurred.! Significant! numbers! with! CV! risk! parameters! observed!
outwith! suggested! target! values! might! explain! this.! It! may! be! postulated! that! this!
population!have!yet!to!display!much!of!their!CV!morbidity.!
!
Targeted! lifestyle! and! drug! treatment! is! necessary! for! those! with! increased! risk.! The!
SCORE!calculator!highlights!a!small!number!of!individuals!with!multiple!risk!factors!that!
would!merit!targeted!intensified!intervention.!Isolated!systolic!hypertension!(ISH)!was!a!
common! finding.! ISH! is! related! to! arterial! stiffness,! a! finding! found! in! RA! (and! may!
improve! with! TNFi! therapy)! (Angel! et! al.! 2012)! may! explain! this! observation.! The!
prescription!of!a!regular!NSAID!requires!regular!review!owing!to!possible!increased!CV!
events!(Peters!et!al.!2010).!Withdrawal!of!NSAID!is!usually!well!tolerated!(McKellar!et!al.!
2011).! The! Rose! questionnaire! is! a! useful! screening! tool! but! may! be! limited! in! such!




necessitated! inflammatory!disease!activity!and,!as!previously!outlined,! this!may! lower!
the!already!adverse!lipid!profile.!We!have!not!undertaken!a!formal!estimate!of!glucose!
tolerance! and! taken! with! the! high! rate! of! central! obesity! in! this! cohort,! glucose!
intolerance! could! be! anticipated.! Finally,! the! presence!of! obesity! is! a! contributory! CV!
risk!factor!that!is!not!accounted!for!by!all!CV!risk!calculators.!
!
Several! positive! suggestions! can! be! made! from! these! findings.! Current! CV! risk!
estimators! are! imperfect;! the! ideal! future! RA! risk! calculator! would! include! both! an!
inflammatory!biomarker!but!also!one! that! is!expressed!as!a! function!of! time! (eg! time!
spent! inflamed!and!degree!of! inflammation).!Secondly,!estimation!of!CV! risk!does!not!
include! use! of! NSAIDs! (which! were! used! regularly! in! this! cohort)! and! thus! a!



























N! Valid! 46! 46! 43! 43!
Missing! 4! 4! 7! 7!
Mean! 7.2! 7.4! 7.4! 7.1!
Median! 6.5! 7.5! 7.0! 6.0!
Minimum! 0! 1! 0! 1!




A! score! of! between! 8! and! 10!may! represent! a! ‘possible’! clinical! state! and! a! score! of!















































10^12%!a!probable!clinical! state.!Both!states!would!merit! further!evaluation.!Of! those!
scoring!≥11,!at!both!baseline!and!six!months!two!patients!had!depression!as!a!diagnosis!
previously! made.! One! patient,! with! prior! depression,! scored! >8.! One! of! the! twelve!
patients! scoring! ≥11! started! antidepressant! therapy! between! assessments.! HADS!
anxiety!and!depression!scores!were!consistent!over!follow!up.!
!
Depression! and! anxiety! are! known! to! co^exist! despite! treatment! strategies! differing.!
Fourteen!and!fifteen!patients!respectively!scored!sufficiently!to!merit!further!evaluation!























































































































































































There! is! no! correlation! between! laboratory! variables/markers! of! inflammation! and!
mood.!
3.3.9.3.5&Discussion7mood&disturbance&&



















No! relationship! between! inflammation! and! depression! was! observed! but!mood! does!
alter! the! subjective! components! of! the! DAS28.! This! is! further! explored! in! Chapter! 6.!









In! addition! to! scoring! highly! on!measures! of! fatigue! and!mood! (perceived! as! severe),!






Eight!patients!had!this!active!diagnosis.! It! is!of!note! then!that! thirty!patients! regularly!
took! NSAIDs.! Data! was! not! collected! on! use! of! gastric! protection! with! proton! pump!
inhibitors!or!H2!antagonists.!
3.3.9.4.2&Anaemia&

































Recruitment! to! the! ORBIT! study! was! made! on! the! basis! of! being! either! RF! or! CCP!
positive.! If! documented! status!was! clear! in! the! case!notes! then! this!was!not! retested!
and!for!this!reason!titre!not!available.!In!some!cases!autoantibody!status!had!not!been!
checked!for!over!five!years!and!was!a!historical!assumption.!In!this!way!complete!data!is!






Negative! 2! Positive! 11!
Equivocal! 1! Negative! 0!
Positive! 11! Unknown! 15!





Median!previous! number!of!DMARDs!was! 3! (range!2^6).! At! the! time!of! study! entry! a!
wide! range! of! therapy! was! in! place! from! none,! combination! therapy! with!
Methotrexate+Sulphasalazine+Hydroxychloroquine! and! variations! therein,!
monotherapy!with!Gold,!Penicillamine!and!Leflunomide.!










(min5max)! Median! Range! Median! Range!
TJC! 14! 2^28! 5.5! 0^23! 5.5! 0^22!
SJC! 10! 0^25! 4! 0^20! 2! 0^14!
Pain! 63.5! 1^100! n/a! n/a! 24.5! 8^80!
Patient!Global! 67! 14^100! n/a! n/a! 29! 0^81!
DAS!28!ESR! 6.04! 4.05^8.41! 4.13! 1.97^7.02! 3.89! 1.02^6.86!
DAS!28!CRP! 5.72! 3.89^7.95! ! ! ! !
CDAI! 94.5! 17.6^154! n/a! n/a! 58! N=13!















































According! to! protocol,! biologic! therapy! was! administered! as! per! Table! 3^70.! Joint!



































2! 31%! Mood!disturbance! 12%!
3! 15%! Dyspepsia! 31%!





calculation! and! one! patient! that!was! originally! included!was! later! excluded! (although!
disease!control!had!been!excellent!for!a!number!of!years,!disease!had!become!active!in!















































































Twenty^seven! patients! were! recruited.! Two! patients! were! later! excluded! after!
assessments;! one! asymptomatic! patient! tested! strongly!CCP!positive.! The! second!was!



















































84! 77! 74! 84!











Previous!DMARD!(range)! 6!(2J9)*! 3!(2J6)! 2!(1J4)! n/a!
BMI!(mean)! 28! 28! 28! 27!
RF!+!(%!positive)! 48%! 42%! 42%! 0!
CCP!+!(%!positive)! 88%! 42%*! 74%! 0!
! ! ! ! !
TJC!! 8! 14*! 0*! !
SJC!! 10! 10! 1*! !
DAS28!CRP! 5.17! 5.72! 2.81*! n/a!
DAS28!ESR! 5.36! 6.04! 3.15*! n/a!
SDAI!! 45.4! 100.7*! 40.6! n/a!
CDAI!! 70.8! 94.5! 29.0! n/a!
ESR!! 24! 25! 13! 8*!
























disease! duration!would! be! shorter.! Disease! duration!was! found! to! be! shorter!




the! biologic! therapy! resistant! group! although! not! achieving! statistical!
significance! (p<0.05).! This! is! driven! mainly! by! clinical! assessments! including!







this! reflects! the! absence! of! testing! in! small! numbers;! inclusion! to! the! ORBIT!
study! was! the! presence! of! either! antibody! and! serological! retesting! was! not!
undertaken.!
• The!DMARD! resistant! group!has! a!wider! range!of! clinical! variable! (tender! and!
swollen! joint! counts).! This! could!be!explained!by! the! study!assessments!being!
performed! by! different! research! staff! at! each! study! centre! and! introducing!
inconsistency.! It! cannot! be! determined! if! there! was! more! chronic!
pain/depression/fibromyalgia! driving! on! high! tender! joint! counts! or! more!
destructive!radiological!damage.!!
!













When! considering! those! elements! that! comprise! ‘severe’! RA! then! disease! duration,!
autoantibody!status,!deprivation,!disease!activity,!quality!of!life!measures!and!disability!
need! considered.! In! addition! to! meriting! separate! case! finding! and! treatment,! the!
presence! of! substantial! medical! comorbidity! influences! the! assessment! of! those!
measures!of!severity.!!
!
Employing! patient! reported! outcome! measures! in! the! form! of! questionnaires! is!
becoming! increasingly! common! but! remains! challenging!within! the! time! limited! clinic!
environment.!However,! this! study!would! suggest! they!add!an!additional!dimension! to!
disease! assessment.! Disability! and! quality! of! life! are! not! easy! to! assess! in! a! short!
















Several! findings! were! notable! in! terms! of! clinical! differences! between! the! groups! at!
baseline.! Longer! disease! duration! and! greater! smoking! history,!with! relatively! greater!
number! of! DMARDs,! was! observed! in! the! biologic! resistant! group.! Both! groups! had!








The!background! to!microRNA!and! their! studies! in!RA!has!been!extensively!outlined! in!
Chapter! 1.! MicroRNA! are! stable! and! accessible! but! have! demonstrated! inconsistent!
associations! with! clinical! measures! of! disease! activity.! There! are! several! specific!
published!examples!that!set!the!context!for!this!chapter.!!
!
(Murata! et! al.! 2010)! examined! the! plasma! and! synovial! fluid! profiles! of! RA! and! OA!
samples! (specifically! microRNAE16,! E32,! E146a,! E155,! and! E223! and! E39! only).! They!
studied!a!heterogeneous!RA!cohort! (n=30)! in! terms!of!disease!duration! (mean!10yrs),!
age! (mean! 60yrs)! and! treatment! (proportionally! higher! use! of! oral! steroid! than! a! UK!
population).!!Plasma!and!synovial!fluid!microRNA!profiles!differed!but!it!was!of!interest!
there! was! no! correlation! between! synovial! fluid! microRNA! and! clinical! variables.!
Synovial!tissue!and!synovial!fluid!had!comparable!profiles!suggesting!the!microRNA!are!
secreted!locally!and!may!explain!the!disconnection!between!peripheral!blood!microRNA!
profiles! and! clinical! variables.! Plasma! microRNAs! did! not! correlate! with! CRP! or! ESR.!
MicroRNAE16,! E146a,! E155,! and! E223! inversely! correlated! with! TJC! and! microRNAE16!
inversely!correlated!with!DAS28.!
!





of! their! patients! had!high! disease! activity! as! judged!by! a!DAS28! >4.1.!No!previous! or!
current!biologic!therapy!was!in!use.!MicroRNAE!24,!E26a!and!125aE5p!were!confirmed!as!






and! established! RA! (mean! disease! duration! 9.28yrs! and! 19/26! treated! with! biologic!
therapies.! Both! microRNAE223! and! E146a! were! reduced! in! early! disease! versus!
established!and!microRNAE16!showed!some!correlation!with!treatment!response!but!no!
association! with! disease! activity! in! established! disease.! The! authors! suggest! these!




microRNA! of! interest! have! been! identified! from! microarrays! and! studied! using! the!






Those! microRNA! referred! to! in! Chapter! 1,! and! having! been! examined! in! depth!
elsewhere,! were! not! further! studied! between! groups.! As! part! of! the! microarray!
performed! to! seek! a! biologic! resistant! microRNA! signal,! primers! for! those! microRNA!
referred!in!Tables!1E14!to!1E17!were!used!however.!
!





There! are! two! broad! aims! to! this! chapter.! Firstly,! the! study! of! specific! candidate!
microRNA!profiles!from!within!the!research!group!and!secondly!to!seek!novel!candidate!




Two! broad! techniques! were! employed! to! profile! microRNA! but! there! are! many!
variations!on!this!theme!to!extract!and!quantify!microRNA!(RAYMOND!2005;!Schmittgen!
et!al.!2004;!Kroh!et!al.!2010).!This!can!also!be!considered!a!weakness!in!view!of!the!lack!
of! standardized! methodology.! ‘Microarray! detection’! which! is! sensitive,! specific! and!
high!throughput!but!can!be!prohibitively!costly!and!results!may!be!skewed!by!batchEtoE
batch!variability.!!Kits!with!multiple!known!microRNA!sequences!can!be!preEloaded!and!








There!are!challenges!with!microRNA!measurement.!These! include! the!choice!of! tissue!
and! blood! (tissue! lysis! and! disruption! requirement),! precursor! and! mature! forms,!








blood! is! drawn,! is! unknown! (Kroh! et! al.! 2010).! This! was! transported! at! room!
temperature! to! the! Glasgow! Biomedical! Research! Centre! where! Lynn! Crawford,!
Laboratory! Technician,! carried! out! analyses.! The! GBRC! laboratory! has! built! local!
expertise! in! examining! microRNA! in! an! accurate! and! reliable! fashion.! This! local!
knowledge! fashioned!Appendix!3! to!be!created.! LC! carried!out!all!processing! to!avoid!
introducing! error! and! following! Appendix! 3! outline! strictly.! In! general,! one! to! two!
patient!samples!only!were!analyzed!in!any!single!day.!
4.3.2'Cell'separation'
Blood!was! separated! into!CD14!and!CD4!cell! populations!as! illustrated! in!Appendix!3.!!
The! addition! of! HistopaqueE1077! (Sigma! Aldrich,! polysucrose! and! sodium! diatrizoate!
adjusted! to! a! density! of! 1.077! ±! 0.001! g/ml)! created! an! aqueous! and! organic! phase!
layers!after!centrifugation.!Mononuclear!cells! remain! in! the!upper!aqueous!phase!and!
aggregates! of! red! cells! and! granulocytes! are! most! dense! gathering! at! the! base.! The!
mononuclear! cell! layer! was! drawn! off! by! pipette.! Bead/column!magnetic! technology!
(CD14! labeling! and! beads! Miltenyi! Biotec,! AutoMACS! cell! separator)! sorted! the! cells!











Later,! extraction! of! total! RNA! (including! microRNA)! was! carried! out.! Total! RNA! was!
extracted!using!the!miRNeasy!mini!kit!(Qiagen,!Cat!no!217004,!“quick!start!protocol”!Jan!
2011).! The! principle! uses! QIAzol! lysis! reagent! to! both! inhibit! RNAEases! and! remove!
DNA/organic!proteins!having!lysed!cells.!Chloroform!permits!the!RNA!to!separate!to!an!












tail! allowing! reverse! transcription! and! the! addition! of! a! universal! tag! (common! tail!
sequence).! Subsequently! qPCR! was! performed! with! the! miScript! SYBR! green! PCR! kit!
(Qiagen,!Cat!no!218073)! that! contains!DNA!polymerase,!SYBR!green,!Universal!primer!



















Proposed! detailed! analysis! was! undertaken! by! Expression! Analysis! USA.! Staggered!
shipments! were! made! in! December! 2011! and! February! 2012.! The! second! shipment!
included!ORBIT!Paxgene!samples!(a!separate!application!was!made!to!the!PEAC!biobank!
for!matched!PaxGene! tubes,! see!Appendix!8).!Baseline!analysis!only!of!microRNA!and!
mRNA! were! undertaken! before! samples! were! returned! (proposed! arrangement! with!
Roche!pharmaceuticals!terminated).!
4.3.7'Specific'instances'of'modifications'to'above'protocol'
Research! staff!accessed! the! stored!RNA!samples! in! the!Biomedical!Research! facility! in!
order! to! generate! the! data! analysed! and! produced! below.! As! such,! different!
methodology!may!have!been!applied!and!patient! samples! analysed!which! is!outlined.!
Final! selection! of! those! patients! who! have! data! presented!was! determined! following!
qPCR!quality!review.!
4.3.7.1'MicroRNA)34a'






Marina! Freita! at! the! Glasgow! Biomedical! Research! Centre,! University! of! Glasgow,!
undertook!analysis.!She!also!used!the!Applied!Biosystems!kit!for!TaqMan.!Results!were!











As! previously! stated,! this! was! performed! by! Expression! Analysis,! USA.! Total! RNA,!
including!microRNA!fraction!was!isolated!as!described!with!the!miRNesy!kit!according!to!
manufacturer! instruction! (Qiagen).! The! integrity! of! RNA! was! ensured! by! analysis! of!
ribosomal! 18S! and! 28S! RNA! intensity! using! an! Agilent! 2100! bioanalyser! (Agilent!
Technologies).! Total! RNA! was! then! polyadenylated! and! labeled! with! BiotinE3DNA!
molecules!with! FlashTag™!Biotin!HSR!RNA! Labeling! Kit! (Affymetrix).! Labeled!RNA!was!
hybridized! to! GeneChip
!
miRNA! 3.0! Array! (Affymetrix).! Signal! was! developed! by!
incubation! of! GeneChip! with! streptavidinEPE.! Background! correction! and! quintile!







Expression! levels! of! the! four! differentially! expressed! microRNAs! identified! by! the!
Expression! Analysis!microarray!were! validated! by! quantitative! real! time! RTEPCR! using!
the!methods!referred!to!previously! (Qiagen!kits/SYBR!green).!RNU6E2!was!used!as!the!
endogenous! control! to! normalize! the! data.! Rene! Oliveira! (RD)! at! the! Glasgow!
































































































































































N=30! N=25! N=22! N=18!
SJC! 11! 0! 10! 1.5!
TJC! 8! 0! 14! 0.5!
ESR!mm/hr! 23.5! 7! 26.5! 13!
CRP!mg/dl! 10.0! 1.3! 10.0! 7.3!
DAS28EESR! 5.44! n/a! 6.11! 3.15!























(p=0.177).! All! variables! were! highly! statistically! different! (p=<0.0001)! between! the!
biologic! resistant! group! and!DMARD! good! responder! group! other! than! ESR! (p=0.183)!
and! CRP! (p=0.274).! A! similar! observation! between! the! DMARD! resistant! and! DMARD!





















































was! examined! alone.! Correlation! between! microRNAE34a! copy! number! and! SJC!

















N=30! N=23! N=17! N=18!
SJC! 11! 0! 10! 1.5!
TJC! 10! 0! 14! 0.50!
ESR!mm/hr! 23.5! 5.0! 29! 13!
CRP!mg/dl! 11! 1.4! 10.5! 7.3!
DAS28EESR! 5.81! n/a! 6.30! 3.15!







































































joint! count.! This! effect! was! lost! when! the! biologic! resistant! group!were! examined! in!















n=24! n=16! n=11! n=15!
SJC! 11! 0! 10! 2!
TJC! 10! 0! 17! 0!
ESR!mm/hr! 23.5! 8! 32! 20!
CRP!mg/dl! 12.5! 1.8! 22.5! 12.0!
DAS28EESR! 5.81! n/a! 6.98! 3.15!






















































with! comparably! active! DMARD! resistant! patients! (p=0.011)! and! DMARD! good!
responders! (p=0.001)! with! low! clinical! disease! activity.! Values! are! similar! to! those! of!
healthy!controls. Higher!levels!of!miRE125a!in!PB!CD14+!cells!in!both!DMARD!responsive!
and! DMARDs! resistant! groups,! as! compared! to! other! groups! (healthy! and! biologic!

















































In! a! similar! fashion! to! microRNAE27b,! microRNAE125a! correlated! with! tender! and!
swollen! joint! counts! but! this! effect! was! lost! when! the! biologic! resistant! group! were!











and! a! DMARD! good! responder! group! mitigated! the! effect! of! disease! duration.!





27b' and' )125a' and' clinical' findings,' inflammatory' markers' and' composite'
disease'activity'scores'other'than'swollen' joint'counts.'This'suggests' that' the'


















































































Group'comparison' MicroRNA' Fold'change' P'value' FDR'
DMARD!GR!v!HV! 146a! +1.58! 0.025! 0.12!
21! +1.65! <0.001! 0.003!
629! +1.56! 0.02! 0.09!
!
DMARD!IR!v!HV! 1281! +1.88! 0.001! 0.001!
324E5p! E1.56! <0.001! 0.009!
!
Biologic!IR!v!HV! 1281! +1.72! <0.001! <0.001!
19b! E1.60! <0.001! <0.001!
3141! +1.62! <0.001! <0.001!
4270! +1.50! <0.001! <0.001!
4298! +1.51! <0.001! <0.001!
574E5p! +1.97! <0.001! <0.001!
!
DMARD! IR! v! DMARD!
GR!
1281! +1.59! 0.017! 0.055!
149! +1.58! <0.001! 0.001!
27b! E1.77! <0.001! <0.001!
30b! E1.58! <0.001! 0.004!
324E3p! E1.52! <0.001! <0.001!
324E5p! E1.64! <0.001! 0.002!
378! E1.50! <0.001! 0.002!
532E3p! E1.51! <0.001! <0.001!
!
Biologic! IR! v! DMARD!
GR!
1228! +1.68! <0.001! <0.001!
1275! +1.75! <0.001! <0.001!
1469! +1.55! <0.001! <0.001!
146a! E1.66! <0.001! 0.005!
149! +1.63! <0.001! <0.001!
15a! E1.51! <0.001! <0.001!
1908! +1.55! <0.001! <0.001!
199aE3p! E1.54! <0.001! <0.001!
27b! E1.53! <0.001! <0.001!
29a! E1.70! <0.001! <0.001!
30b! E1.76! <0.001! <0.001!
3178! +1.73! 0.003! 0.007!
423E5p! +1.64! <0.001! <0.001!
574E5p! +1.59! <0.001! <0.001!
660! E1.54! <0.001! <0.001!
663! +1.53! 0.0014! 0.003!
!
DMARD!IR!v!Biologic!IR! 1275! E1.55! <0.001! <0.001!
3178! E2.09! <0.001! <0.001!
423E5p! E1.57! <0.001! <0.001!





returned! as! differentially! expressed! between! the! biologic' resistant' and' DMARD'
resistant!groups!in!the!four!study!groups.!RD!analysed!CD14+!cells!in!selected!baseline!











N=46! N=14! N=12! N=18!
SJC! 10! 0! 11! 1.5!
TJC! 8! 0! 14! 0.5!
ESR!mm/hr! 22! 1.2! 18! 13!
CRP!mg/dl! 9.9! 4.5! 6! 7.3!
DAS28EESR! 5.36! n/a! 5.69! 3.15!
DAS28ECRP! 5.13! n/a! 5.15! 2.81!
! ! ! ! !
Age!(yrs)! 60.5! 50! 57! 60.5!
Disease!duration!
(months)!
204! n/a! 116!! 216.5!
Double!antibody!
negative!
17%! n/a! 0%! 6%!
Male! 15%! 7%! 17%! 39%!






The! biologic! resistant! group! had! comparable! clinical! variables,! smoking! status,! age,!
gender!and! immune! status.!Disease!duration!was! slightly! lower!at!204!v!213!months.!
Healthy!controls!in!the!qPCR!group!were!more!likely!to!be!female!(93%!female!vs!84%)!
and! higher! smoking! rates! (36%! vs! 20%).! The! DMARD! good! responder! group! in! the!
validation! group! were! very! similar! in! all! respects! to! the! main! study! group! (disease!
duration!shorter!216.5!months!vs!222!months).!
The!DMARD!resistant!group!varied!more!notably!however!(n=12!vs!n=26).!There!were!
fewer! males! (17%! in! the! validation! group! vs! 23%! in! the! main! study! group)! and!
proportionally! more! smokers! (50%! vs! 38%).! With! respect! to! clinical! variables,!
differences! in!median! values!were! present! but! not! statistically! different! (where! qPCR!
!! 209!










Figure' 4)48'Relative' expression' levels' of'microRNA)423'between' study' groups' at' baseline' study' visit'
(where!*=p<0.05!and!**=p<0.01)!
!



























Significant! differences! were! confirmed! between! the! biologic! resistant! group! and! the!
Healthy! controls! (p=0.039),! DMARD! resistant! (p=0.040)! and! DMARD! good! responders!
(p=0.050).!
!
The! microarray! results! (Figure! 4.50)! identified! a! panel! of! four! microRNA! that! were!
differentially! expressed! in! the! biologic! resistant! group! compared! to! the! DMARD!
resistant! group! that! we! sought! to! confirm! with! qPCR.!We! were! not! able! to! confirm!
microRNAE574!as!being!differentially!expressed!neither!between!biologic!resistant!and!
healthy!controls!nor!between!biologic!resistant!and!DMARD!good!responders.!However,!
qPCR! confirmed! differential! expression! of! three! other! microRNA! from! that! panel.!
MicroRNAE1275!was!confirmed!as!differentially!expressed!between!biologic!and!DMARD!
resistant! patients,! but! not! biologic! resistant! and! DMARD! good! responder.!MicroRNAE
423!also!differed! from! the!healthy! control! group!and!DMARD! resistant! group.! Finally,!
microRNAE3178!showed!differential!expression!in!the!biologic!resistant!group!compared!

















































! Baseline! Three!months! Six!months!
Biologic!











A! highly! significant! reduction! in! both! microRNAE423! and! E1275! was! observed! in! the!
biologic! resistant! study! group! by! six!months.! In! order! to! further! explore! this,! clinical!
variables! were! examined! and! change! to! treatment! examined.! ! Figures! 4E62! to! 4E65!




Of! those! patients! examined,! between! baseline! and! threeEmonth! visit,! 11/33! had! an!
increase! in! their! treatment! (such! as! DMARD! change,! steroid! by! intramuscular! or!
articular!route).!6/11!started!a!new!biologic!therapy!between!visits.!Between!the!three!
and! six! month! visit,! twelve! had! treatment! increases,! of! which! two! started! biologic!
therapy! (one! new! and! one! reEstart! after! a! suspension).! Therefore! appropriate!



























































are! shown! in! Figures! 4E70! and! 4E71.! Additionally,! microRNAE423! and! E574! correlated!
with!MCPE1!(r=E0.313,!p=0.043!and!r=E0.321,!p=0.032!respectively).!



















Previous! studies! have! used! heterogeneous! groups! of! patients! in! an! already! highly!
heterogeneous!condition! treated!with!a! range!of! treatments.! It!was! first! important! to!
define! specific! cohorts! on! the! basis! of! clinical! factors! in! order! to! identify! a! specific!
microRNA!profile!unique!to!a!biologic!resistant!cohort!but!to!also!remain!applicable! in!
daily! clinical! practice.! For! this! reason! we! chose! to! examine! the! microRNA! profile! of!
CD14+! cells. We! chose! CD14+! cells! as! they! contribute! to! systemic! production! of! proE
inflammatory! mediators! and,! most! importantly,! they! are! the! precursors! of! synovial!
macrophage,!which!are!the!pivotal!source!of!TNFa,!ILE6!and!ILE1b.!
4.5.1'Candidate'microRNA'
The! microRNA! studied! in! this! chapter! have! been! identified! in! previous! microarrays!































with! the!most! severe! disease:! upEregulation! or! downEregulation,! respectively! in! both!
groups,! biologic! and!DMARD! resistant!patients! compared! to!other! groups.!MicroRNAE
125a! showed! an! interesting! pattern! of! expression:! despite! comparable! inflammation!

































of! the! four! candidate! microRNA! from! the! microarray! screen! have! been! identified! in!
relation! to! RA! to! the! best! of! my! knowledge.! ! There! are! a! small! number! of! previous!
publications! referring! to! microRNAE423.! (Lin! et! al.! 2011)! identified! microRNAE423! as!
promoting!cell!growth!and!cell!cycle!progression!in!hepatocellular!carcinoma.!(Tijsen!et!
al.! 2010;! Goren! et! al.! 2012)! have! independently! identified! microRNAE423! as! upE
regulated! in!patients!with!heart! failure.! (Katsushima!et!al.! 2012)! identified!microRNAE



























valid! comparisons.! In! a! similar! way! to! the! observations! of! the! candidate! microRNA,!
there!were! differences! between! groups! that! persisted! despite! similar! clinical! findings!
and! measures! of! inflammatory! disease.! The! microRNA! differentially! expressed! have!
minimal! correlation! with! clinical! variables.! Despite! comparable! active! inflammation,!
microRNAE423,!E1275!and!E3178!were!upEregulated!in!biologic!resistant!CD14+!cells.! In!
particular,!miRE3178!seems!to!be!a!good!candidate!biomarker!of!resistance!to!biologic!




strongest! between! microRNAE423! and! E1275.! The! same! microRNA! were! observed! to!
correlate! with! ESR.! This! may! suggest! coEtranscription.! Correlation! was! observed!
between!microRNA!and! several! cytokines.! The!correlation!with!MMP!and!RANKL! is!of!
interest! raising! a! pathological! link! with! joint! damage! and! erosions.! There! was! also!
correlation!between!microRNAE423!and!E574!with!MCPE1.!Liou!et!al!identified!MCPE1!as!
a! useful! marker! of! disease! activity! in! heir! population! when! combined! with! clinical!
factors!(Liou!et!al.!2013).!Further!examination!of!these!links!is!desirable.!
Over! the! follow! up,! there! was! a! significant! reduction! in! DAS28! reflecting! treatment!
escalation.! There! was! a! concurrent! fall! in! both!microRNAE423! and! E1275! but! neither!
correlated!with!the!DAS28.!
!
Disease! duration! between! the! biologic! resistant! and! DMARD! resistant! group! differs.!
MicroRNA! profiles! change! with! both! age! and! disease! stage! (Filková! et! al.! 2013).!
However,! it! would! seem! unlikely! that! substantially! different! processes! are! at! play! in!
similar!cohorts!with!such!wellEestablished!disease.!Observed!differences!could!represent!
a!treatment!effect!(concurrent!DMARD,!steroid!use,!intermittent!infusions!of!Rituximab)!
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!
It! is! not! clear! if! this! profile! defines! treatment! resistance!mediated! by! an! unidentified!
pathophysiological!process.!The!next!step!would!be!microRNA:target!pathway!analysis.!!
Further!key!follow!up!work!would! include!seeking!these!microRNA!in!an!early!arthritis!
cohort! (blood! and! synovial! cell! lines)! and! the! requirement! to! validate! and! replicate!
these!findings!in!independent!cohorts.!
!
In! conclusion,! a! microarray! of! biologic! resistant! and! DMARD! resistant! patients! with!
similar! clinical! characteristics! has! identified! three! microRNA! not! previously! identified!
that! are! both! differentially! expressed! between! treatmentEresponse! groups! but! also!
associate! with! changes! in! disease! activity.! Further! investigation! of! their! utility! as! a!










that! they!may! not! reflect! true! biological! pathway! activity.! There! therefore! remains! a!
complementary!role!for!clinical,!PROMs!and!proteomic!studies.!
!
In! order! to! perform! this! an! exploratory! cytokine! panel! was! chosen! and! multiplex!
methodology!used.!The!aims!included!
!
• Establishing! the! cytokine! profile! of! the! biologic! resistant! group! and! comparing!
this!with!the!profile!of!the!control!groups!(cross!sectional!analysis)!
• Examine! the! biologic! and! DMARD! resistant! group! at! three! time! points! to!
examine!the!stability!with!time!of!the!serum!cytokine!profile!and!correlate!this!
with! the!observed! improvements! in!disease!activity!observed! in!Chapter! three!
(longitudinal!analysis)!













The! network! of! cell! involved! in! the! immune! response! requires! intense! coordination,!
which! is! mediated! by! cytokines.! InterEcellular! communication! is! facilitated! by! small!
soluble! or! membrane! bound! molecules! with! pleiotropic! roles.! ! At! the! cellular! level,!
receptor! binding! triggers! downstream! intraEcellular! signalling! leading! to! a! cellular!
response! through! gene! transcription.! There! must! be! a! balance! of! pro! and! antiE
inflammatory!activity.! It! is! this!balance! that! is!dysregulated! in!autoimmune!conditions!
(Chizzolini!et!al.!2009).!The!wide!heterogeneity!of!the!RA!phenotype!is!also!underpinned!




synovial! membrane! in! addition! to! adjacent! bone! marrow! and! recruited! circulating!
immune! cells.! The! major! proEinflammatory! cytokines! reflect! those! local! processes!
namely! general! inflammation,! tissue! destruction,! bone! damage! and! turnover,! fibrosis!
and!vascular!(angiogenesis).!Examples!include!TNF,!ILE6!and!ILE1,!which!have!gone!on!to!







that!exist!both! soluble!and!membrane!bound.! ILE6! is! secreted!by!monocytes,! T! and!B!











surface! TNF! receptor! (TNFR),!which! exists! in! two! forms.! Soluble! TNFa! acts! on! TNFR1,!
and! is! responsible! for! the! majority! of! the! observed! TNFa! effects,! where! membrane!
bound! TNFa! is! thought! to! act! on! TNFR2.! Binding! is! thought! to! act! through! p38/JNK!
kinases!leading!to!nFkB!transcription.!Excessive!and!unchecked!production!occurs!in!RA,!
which! leads! to! further! proEinflammatory! actions! including! fibroblast! activation! and!
further! cytokine! release,! TEcell! activation! and! antibody! production! by! BEcells,!
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ILE1!was! the! one! of! the! first! cytokines! to! be! identified! and! then! named.! ! It! is!mainly!
produced!by!monocytes!and!is!the!classic!mediator!of!the!febrile!response!in!infection.!
It! belongs! to! the! ILE1! superfamily! of! related!molecules,! the!most! significant! being! ILE







by! ILE12! and! 15! and! inhibited! by! ILE10! and! TGFB! (Liew! et! al.! 2003).! It! promotes!
angiogenesis! through! VEGF! expression,! increases! chemokine! secretion,! inhibits!
chondrocytes! and!may! facilitate! cartilage! damage! (Gracie! et! al.! 1999).! It! also! acts! to!






some! correlation! with! DAS28.! ILE15! is! a! pleiotropic! cytokine–! for! example! it! acts!
synergistically! with! those! cytokines! above! and! acts! to! facilitate! B! cell! differentiation,!
stimulate! neutrophils,! activate! synovial! fibroblasts! and! monocyte/macrophage!




Granulocyte! macrophage! colony! stimulating! factor! (GMECSF)Eproduced! by! synovial!












ILE1Beta! ILE15! ILE6R!alpha,!gp130! IFN!gamma!
IlE2! ILE17! ILE4! ILE10! (mainly! antiE
inflammatory!
ILE6! ILE18! ILE13! ILE33!
ILE12! ILE23! ILE25! TGFEBeta!
TNF!alpha! ILE1Beta! ! !




There!are!numerous!publications!pertaining! to! cytokine!evaluations! in!RA!at!different!
stages!of!disease!and! in! response! to! therapy.! In! ‘preEarthritis’,! (Kokkonen!et!al.! 2010)!
examined!the!cytokine!profile!of!individuals!who!went!on!to!develop!RA.!This!has!been!
replicated!by!Deane!et!al!and!shortly!after!symptoms!develop!where!the!cytokine!profile!
associates! with! autoantibody! status! (and! thus! disease! ‘subsets’)! (Deane! et! al.! 2010;!






baseline!to!predict! response!has!been! less!clear! (Wagner!et!al.!2013;!Emery!&!Dörner!
2011).!(Lequerré!et!al.!2007)!sought!a!predictive!cytokine!signal!of!Infliximab!response.!
They!could!not!identify!a!signal!in!the!clinical,!bone!marker!or!autoantibody!profiles.!In!
contrast,! den!Broeder! et! al! suggest!COMP!and! ICAME1! levels! as! a!marker!of! cartilage!
turnover!may!predict!Adalimumab!response!when!measured!at!baseline!(Broeder!et!al.!





More! recently,! (Liou! et! al.! 2013)! identified! MCPE1! as! a! promising! biomarker.!
There!was! close! correlation!with! elements! of! the! DAS28! in! addition! to! inflammatory!
markers.!A! ‘DAS28EMCPE1’! correlated!with! the!DAS28ECRP!and!performed!better! than!
ESR! or! CRP! alone! in! their! cohort! of! mixed! new! RA! cases! and! those! regularly!
treated/followed!up!(also!one!of!the!study!weaknesses).!
!
One! of! the! major! difficulties! in! studying! cytokine! profiles! is! both! the! marked! interE
individual!heterogeneity!observed!and! that! the! true!cytokine! signal! resides!within! the!
synovial! compartment.! In! one! of! the! earliest! studies! that! aimed! to! characterise! the!
!! 237!
synovial! improvements! with! TNFa! treatment! (Ulfgren! et! al.! 2001)! demonstrated!
cytokine! changes! in! synovial! biopsies! after! Infliximab! (n=8).! ! The! same! author! group!
demonstrated!the!reduction!in!effector!MMPs!after!Etanercept!treatment!(Catrina!et!al.!












(Hirata! et! al.! 2013)! examined! the! BeSt! early! arthritis! cohort! and! correlated! a!




















As! described! in! Chapter! 2,! 50! biologic! resistant! (biologic! IR! (inadequate! responders)!
were!profiled!at!baseline,!three!and!six!months.!25!DMARD!IR!patients!were!examined!





broad!and! relevant! selection!of! candidate!cytokines! to!give!a! representative!overview!




The! kit! employs! bead! technology! whereby! beads! conjugated! with! protein! specific!
antibody! binds! the! cytokine! of! interest.! This! complex! in! turn! binds! a!
antibody:fluorescent!molecule.! The! Luminex®! 100! system! quantifies! this! fluorescence!
and!thus!derives!concentration!of!the!cytokine!of!interest.!
!
All! assays!were!performed! in! duplicate! using! the!manufacturers! standard!protocol! by!






Quantification! (concentrations)! was! performed! with! reference! to! standard!
manufacturer! values! supplied!with! kits! and!entered! in! the! Luminex!with!each!analyte!
type! having! a! different! standard! range.!Mean! value! of! outputs!was! used.!Where! one!
value!was!out!of!range!or!extrapolated,!the!value!from!the!other!run!was!used.!Out!of!
range! values! were! treated! as! follows;! if! both! replicates! were! below! the! minimum!









EGF! Epidermal!growth!factor! Role! in! growth! and! cellular! differentiation! thus! in! synovial! cell!
proliferation.!May!be!future!therapeutic!target!(Killock!2012)!
Pro!
Eotaxin!(CCL11)! ! Role! in! eosinophils! and! some! evidence! may! be! related! to! erosions!!
(Syversen!et!al.!2008)!and!susceptibility!(Chae!et!al.!2005)!
Pro!
FGFMbasic! Basic!fibroblast!growth!factor! Produced!locally!in!the!synovium!leading!to!autocrine!stimulation! Pro!
GMCSF! Granulocyte! colony! stimulating!
factor!





Produced! by! synovial! macrophages.! Stimulate! T! cell! activation! and!
TNFa,!ILM1!
pro!
HGF! Hepatocyte!growth!factor! With!OPG!may! limit! osteoblast! differentiation.!Usually! elevated! and!
this!predicts!erosions.!Also!pro!angiogenic!
anti!
IFN!alpha! Interferon!alpha! Generally! produced! in! response! to! viral! infections! and! useful!
immunosuppressive/anticancer!therapy.!
pro!
IFN!gamma! Interferon!gamma! Produced! as! part! of! the! innate! immune! response;! CD4! cells!
differentiate!into!Th1!cells.!Suppresses!osteoclast!formation!
pro!
ILM1ra! Interleukin! Decoy!receptor!for!ILM1!and!thus!antiMinflammatory.! anti!
ILM1!Beta! InterleukinM1!beta! Synergistic!with!TNFa! pro!
ILM2! Interleukin!2! Produced!by!activated!T!cells!and!further!stimulates!T!and!B!cells! pro!
ILM2r! Interleukin!2!receptor! ILM2! is!a!growth!factor!for!T!cells;!the!soluble!form!of!the!receptor! is!
measured.!Correlation!with!disease!activity!has!been!described!
pro!




ILM6! Interleukin!6! Widespread!pro!inflammatory!actions! pro!
ILM7! Interleukin!7! Increased! in! RA! in! joint! but! variable! in! serum;! stimulates!
monocytes/macrophages!(Churchman!&!Ponchel!2008)!!
pro!
ILM8!(CXCL8)! Interleukin!8! Action! to! recruit! neutrophils.! Previously! shown! to! be! higher! in!
synovial!fluid!than!blood!(De!Gendt!et!al.!1996)!!
pro!
ILM10! Interleukin!10! Counter! to! inflammatory! process,! found! elevated! but! not! effective!
enough!to!abrogate!inflammation.!!
anti!
ILM12! Interleukin!12! TMcell!development.!Elevated!in!RA!(Morita!et!al.!1998).!Drives!a!Th1! pro!
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response!as!is!seen!in!RA!
ILM13! Interleukin!13! Increased! in!many!autoimmune!disorders!but!may!have! suppressive!
role!(Isomäki!et!al.!1996).!
Anti!
ILM15! Interleukin!15! From!macrophages!induces!TNFa!and!activates!neutrophils.!See!text! Pro!
ILM17! Interleukin!17! Lead!to!ILM6!production!and!role!in!osteoclast!action.!See!text! Pro!
IPM10!(CXCL!10)! Interferon! gamma! inducible!
protein!





Elevated! in! RA,! chemotactic! for! leucocytes! and! some! relation! to!
DAS28!(Liou!et!al.!2013)!
Pro!











RANTES!(CCL!5)! Chemokine!ligand!5! Chemo!attractant;!fibroblasts!produce!upon!TNFa!and!ILM1!stimulation! Pro!










ILM23! Interleukin!23! Role! in! ThM17! cell! activation! and! differentiation! and! correlates! with!
clinical!variables!(Rong!et!al.!2012)!
Pro!
MMP!3! Matrix!metalloproteinase!3! Important!effector!molecule!destroying!tissue!matrix! Pro!
MMP!12! Matrix!metalloproteinase!12!
MMP!13! Matrix!metalloproteinase!13!

























































































































































































Of! those! cytokines! tested,! the! majority! demonstrated! significant! differences! from!
healthy!control!samples!as!expected.!!
!
Measured! cytokines! between! the! biologic! resistant! and!DMARD! resistant! group!were!
statistically!different!only!in!those!pro!inflammatory!cytokines!ILP6,!ILP21!and!ILP23!and!








the! growth! factors,! negatively! regulating! cytokines,! chemokines,! neither! MMPs! nor!
OPG/RANKL!achieved!statistically!significant!differences.!Only!ILP6!measured!was!found!
to! be! statistically! higher! in! the! biologic! resistant! group! than! the! DMARD! good!
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potentially! reflect! those! treatment! changes! and! change! in! disease! activity! observed,!
only! those! analytes! demonstrating! significant! differences! between! study! visits! are!




































































! 0P3!months! 3P6!months! 0P3!months! 3P6!months!
! ! ! ! !
ILP1!Beta! 0.239! 0.383! 0.239! 0.383!
GPCSF! 0.040! 0.621! 0.317! 0.039!
EGF! 0.106! 0.462! 0.352! 0.171!
ILP10! 0.633! 0.816! 0.226! 0.568!
HGF! 0.471! 0.004! 0.418! 0.008★★$
FGFPbasic! 0.702! 0.613! 0.585! 0.182!
IFN!alpha! 0.322! 0.757! 0.582! 0.140!
ILP6! 0.673! 0.486! 0.225! 0.793!
IlP12! 0.407! 0.680! 0.296! 0.370!
RANTES$ 0.292! <0.0001★$ 0.145! 0.196!
EOTAXIN$ 0.353! <0.0001★$ 0.019! 0.167!
ILP13! 0.339! 0.809! 0.649! 0.054!
ILP15! 0.191! 0.719! 0.901! 0.384!
ILP17! 0.405! 0.852! 0.012! 0.329!
MIP1!alpha! 0.004! 0.457! 0.767! 0.336!
GMPCSF! 0.063! 0.257! 0.666! 0.215!
MIPP1!beta! 0.051! 0.778! 0.958! 0.316!
MCPP1! 0.687! 0.018! 0.119! 0.017!
ILP5! 0.112! 0.313! 0.876! 0.010!
IFN!gamma! 0.161! 0.147! 0.577! 0.213!
TNFa! 0.979! 0.589! 0.523! 0.017!
ILP1ra! 0.728! 0.004! 0.839! 0.371!
ILP7! 0.443! 0.503! 0.779! 0.141!
IPP10! 0.186! 0.057! 0.560! 0.008!
ILP2r! 0.993! 0.003! 0.578! 0.229!
MIG$ 0.281! 0.325! 0.196! <0.0001★$
ILP4! 0.275! 0.470! 0.457! 0.086!
ILP8! 0.470! 0.195! 0.849! 0.090!
MMPP3! 0.837! 0.268! 0.921! 0.831!
MMPP12! 0.079! 0.619! 0.437! 0.863!
MMPP13! 0.404! 0.595! 0.956! 0.731!
CXCL!11! 0.722! 0.070! 0.022! 0.338!
OPG$ 0.565! 0.025! 0.001★$ 0.007!
RANKL! 0.829! 0.834! 0.341! 0.827!
ILP21! 0.600! 0.465! 0.057! 0.142!
ILP23! 0.477! 0.491! 0.325! 0.939!
ILP2! 0.286! 0.215! 0.789! 0.999!















fatigue! (FACIT! fatigued!or!not).! In! the! same!way,!when!corrected! for!multiple! testing,!


















! Median! IQR! Median! IQR! !
ESR! 32! 23! 6! 13! 0.002$
CRP! 14! 24.8! 5.8! 10.6! 0.078!
ILP6! 56.34! 117.16! 40.94! 203.58! 0.306!
ILP15! 489.26! 1215.15! 63.88! 726.37! 0.001$
ILP23! 2596.97! 11887.37! 24.4! 415.03! 0.001$
IFNa! 1128.80! 1802.14! 252.31! 111.10! 0.001$
ILP7! 103.08! 299.10! 41.48! 216.23! 0.139!
MIG! 65.74! 92.11! 53.04! 49.37! 0.049$
GPCSF! 58.4! 118.6! 23.95! 11.11! 0.028$
MCPP1! 1102.68! 915.65! 674.52! 318.93! 0.022$





























Pearson!Correlation! P.158! .073! .236!
Sig.!(2Ptailed)! .289! .629! .115!
ILP10!Biologic!
IR!
Pearson!Correlation! .045! .151! .159!
Sig.!(2Ptailed)! .762! .317! .293!
FGFPbasic!
Biologic!IR!
Pearson!Correlation! P.096! .133! .244!
Sig.!(2Ptailed)! .519! .378! .102!
IFNa! Biologic!
IR!
Pearson!Correlation! P.173! .062! .270!
Sig.!(2Ptailed)! .245! .681! .070!
ILP6! Biologic!
IR!
Pearson!Correlation! P.021! P.054! .113!
Sig.!(2Ptailed)! .889! .722! .454!
ILP15!Biologic!
IR!
Pearson!Correlation! P.172! .020! .221!
Sig.!(2Ptailed)! .248! .894! .139!
MCPP1!
Biologic!IR!
Pearson!Correlation! P.155! P.001! .220!
Sig.!(2Ptailed)! .303! .996! .147!
TNFa!
Biologic!IR!
Pearson!Correlation! P.068! .007! .124!
Sig.!(2Ptailed)! .650! .961! .412!
ILP7! Biologic!
IR!
Pearson!Correlation! P.089! .031! .147!
Sig.!(2Ptailed)! .551! .838! .329!
MIG! Biologic!
IR!
Pearson!Correlation! P.032! .005! .108!
Sig.!(2Ptailed)! .832! .972! .474!
ILP23!Biologic!
IR!
Pearson!Correlation! P.148! .012! .138!
Sig.!(2Ptailed)! .327! .937! .366!








The! results! of! this! analysis! firstly! confirm! the! wide! range! of! results! observed! in! the!
serum!cytokine!profile!of!those!with!RA!irrespective!of!phenotype.!The!profile!identified!
in!this!cohort!represents!longstanding!yet!active!RA!as!judged!by!the!DAS28.!(Hirata!et!
al.!2013)! refer! to! their!use!of!a!multiPanalyte!panel!and!suggest! that!no!single!marker!





control! patients! but!were! closer! in!many!ways! to! the!DMARD! good! responder! group!
than! the! DMARD! resistant! group.! Indeed! only! a! small! number! of! cytokines! tested!
demonstrated! significant! differences! between! healthy! controls! and! DMARD! good!
responders.! The! DMARD! resistant! group! did! however! display! higher! composite! DAS!




• Why! are! the! biologic! resistant! and! DMARD! good! responder! profile! not! more!
dissimilar?!








In! contrast! with! this! hypothesis! are! the! improvements! noted! in! subjective! disease!
activity,! ESR/CRP! after! treatment! regimen! changes! and! reduction! seen! in! many!
cytokines.!The!observations!from!examination!of!the! longitudinal!analysis!suggest!that!





















the! DAS28! or! that! blood! and! synovial! compartments! (reflected! as! tender! or! swollen!
joints)!do!not!relate.!
!
Differences! in! cytokine! profiles! according! to! clinical! ‘categories’! were! also! sought.! It!
could! be! hypothesised! that! differences! may! be! apparent! according! to! treatment!
category! as! specific! cytokines!were! targeted.! In! the! small! numbers! in! each! treatment!
category! this! could! not! be! demonstrated.! ! Both! smoking! and! the! presence! of!














ILP6! in! serum! and! fatigue! suggests! other! factors!may! drive! on! fatigue! at! this! disease!
stage!as!hypothesised! in!Chapter!3.! It! is!presumed!that!circulating!cytokines!cross! the!
bloodPbrain! barrier! and! in! this! way! influence! central! fatigue! and! mood.! We! did! not!




not! be! reflective! of! central! processes! such! as! mood! and! fatigue! but! is! reflective! of!


















two! validated! questionnaires! that! would! capture! various! dimensions! of! coping! and!
illness! perception! to! allow! conclusions! about! the! biologic! resistant! study! group! to! be!
drawn.!
!




that! the! range! of! disability! and! function! observed! may! be! explained.! Finally,! the!






To! conclude,! the! implications! of! addressing! coping,! illness! perception! and!mood,! are!





There! are! factors! other! than! inflammatory! disease! activity! that! may! influence! the!
subjective! disease! process! in! RA.! ! For! example,! both! pain! and! prevailing! mood! may!
influence!a!number!of!disease!dimensions,!in!particular!the!subjective!components!of!he!
DSA28! scoring! system.! Both! function! and! severity! are! a! composite! of!many! different!
contributory! factors! from! the!physical! to! the!psychological.! Perception!of! the! severity!
and! implications! for! the! individual! of! RA! symptoms! vary! widely! and! also! subject! to!
external!influence.!Coping!is!thus!both!shaped!and!tested!by!these!factors.!However!not!
all! coping! is! considered! positive! and! it! is! on! this! basis! that! both! coping! and! illness!
perception!merit!evaluation.!
6.2.1$The$influence$of$pain$in$Rheumatoid$arthritis$
Studies! in! RA! suggest! that! the! experience! of! pain! is! a! regular! one! with! over! three!
quarters! experiencing!moderate! to! severe!pain! in! the! last! two!months.!As!one!would!
expect! this! is! associated! with! more! severe! disease! (Taylor! et! al.! 2010)! ! yet! despite!
‘severity’,!pain!remains!responsive!to!biologic!therapies.!Pain!may!be!experienced!as!a!
result!of!articular!damage,!biomechanical!pain!(feet!particularly),!inflammatory!disease!







and! 47%! ‘possible’! anxiety! disorder! as! described! in! Chapter! 3.! 28%! had! ! ‘probable’!
depression! and! 23%! ‘probable’! anxiety! disorder.! A! number! of! studies! in! RA! have!





Mood! disturbance! can! also! be! found! at! all! stages! of! disease! duration.! In! an! early!
arthritis! cohort,! (Covic! et! al.! 2012)! identified! 18.9%! ‘possible! depression’,! 9.4%!
‘probable’! and! 16.7%!with! ‘possible! anxiety’! and! 18.6%! ‘probable’.! (elPMiedany! &! elP
Rasheed!2002)!studied!an!Egyptian,!predominately!female!cohort!with!average!disease!




(Isik! et! al.! 2006).! Their! use! of! the! Hamilton! depression! and! anxiety! scale! introduces!
different! cutPoff! values!and!definition!of!both!diagnoses,!which!may!account! for! their!
notably!high!(70.8%)!prevalence!of!either!or!both!disorder.!Finally!Hider!et!al!examined!
RA! patients!with! a! disease! duration! of! 13.6! years! and! identified! 47.5%! prevalence! of!
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depression! in! a! cohort!with! active!disease! commencing! TNFi! therapy! (Hider,! Tanveer,!
Brownfield,!Mattey!&!Packham!2009a).!
!
There! are! a! number! of! proposed! reasons! from! the! bioPpsychosocial! to! the!
pathophysiological!accounting!for!this!finding!of!increased!prevalence!of!mood!disorder!







activation! causing! relative! glucocorticoid! insensitivity! (Yang! Liu! et! al.! 2012;! E! Leonard!
2010;!Jehn!et!al.!2010).!As!is!demonstrated!in!Chapter!3,!the!prevalence!of!depression!is!
increased!in!RA!but!not!directly!related!to!burden!of!inflammatory!disease.!In!this!way,!
patients! with! many! chronic! illnesses! such! as! diabetes! and! stroke,! and! not! just!
inflammatory! conditions,! have! increased! incidence! of! mood! disturbance.! Biologically!
this!may!be!plausible!as! chronic! stressors,! including! low!mood,!drive!elevated!cortisol!
and!it’s!suppressive!effect!in!the!immune!system.!!
!
Identifying! mood! disturbance! is! important,! as! there! are! significant! implications! from!
drug!compliance!to!perception!of!benefits!and!side!effects!of!therapy.!Low!mood!is!also!
related!to!job!productivity!and!absence!in!a!situation!where!this!may!also!be!affected!by!
reduced! function! and! disability.! Pain! intensity! perceived! is! also! elevated! with!
subsequent! additional! avoidance! behaviour! and! reduction! in! physical! activity! (R.! R.!
Edwards! et! al.! 2011;! van! Lankveld! et! al.! 2000).! The! implication! of! this! burden! of!
morbidity!is!also!important!in!healthcare!cost!planning.!
!
Effective! RA! treatment! to! remission! is! associated! with! reduction! in! anxiety! and!
depression! (Kekow! et! al.! 2011).! However,! being! depressed! or! anxious! at! baseline!




2010).!Mean!mental! health! scores! (SF36)! improved! from!39.4! to! 56! and!MCS!36.1! to!
42.3! in! a! cohort!with!mean! disease! duration! of! 8.8years.! Similar! improvements!were!
seen!in!earlier!disease!course!and!in!the!PsA!group.!Mathias!et!al!found!similar!but!less!
pronounced! improvements! could!be! seen!after! six!months! treatment!with!Etanercept!
(Mathias! et! al.! 2000).!Morris! et! al! found! higher! correlation! between! those! that!were!
depressed! and! pain! scores,! swollen! joint! scores! and! higher! disability! (A.!Morris! et! al.!
2011).!Mattey!et!al!found!higher!TNFa!therapy!discontinuation!over!a!36Pmonth!period!
in!those!depressed,!anxious,!smokers!and!those!with!a!higher!baseline!DAS28!(Mattey!
et! al.! 2010).! The! strongest! association! however! was! with! the! total! HADS! score.!






















yet! nonetheless! elevating! the! DAS! score.! This! may! have! some! bearing! in! composite!
scores!failing!to!exclude!an!additional!fibromyalgic!component!of!RA.!!
6.2.3.5$Pain$








5.2.! The! factors! that! have! accounted! for! such! high! parameters! require! consideration.!
These!may! be! low!mood,! accounting! for! higher! pain! perceived! and! thus! tender! joint!
count.!Other!types!of!pain!such!as!neuropathic!pain!or!degenerative!pain!may!exist! in!




In! summary,!mood!disturbance! is! common!and! important! and! there! are! a!number!of!







(Leventhal! et! al.! 1984).! In! order! to! form! a! cognitive! representation! of! a! disease,! and!
thus!adapt,!five!domains!of!the!illness!must!be!addressed.!These!are!
!





• Control! (cure);! the! degree! or! not! to! which! the! treatments! and! measure! the!
individual!takes!can!influence!the!experience!of!the!illness.!
!
Coping! is! the!means!by!which! a! subjective!perceived! threat!or! stressor! is! diminished.!
Behaviours!to!reduce!perceived!threat!are!based!upon!these!representations!and!then!




individual.! The! challenge! is! lifePlong! and! coping! behaviours! must! start! early.!
Additionally,!RA!as!a!disease!fulfils!those!criteria!associated!with!less!favourable!illness!
representation!such!as!lack!of!personal!control,!perceived!longPterm!condition!and!often!
poor! outcome.! Yet! functioning! and! psychological! outcomes! vary! widely.! Prior!
experience,!perhaps!in!another!major!illness,!may!shape!this!early!as!does!personality,!
but!as!the!challenges!of!RA!vary!often!weekPtoPweek!and!over!a!lifetime,!specific!coping!




after! knee! arthroplasty! was! directly! related! to! patient’s! beliefs! in! addition! to!
preoperative! function! and! mood! (Orbell! et! al.! 1998).! Rozema! et! al! examined! illness!
representations! in! breast! cancer! patients! and! both! physical! and! mental! health! were!
affected!by!health!beliefs!around!their!illness!(Rozema!et!al.!2009).!Outcome!in!RA!has!
also!been!shown!to!be!affected!by!illness!representation!(Carlisle!et!al.!2005).!Sharpe!et!
al! studied! RA! patients! with! disease! of! less! than! two! years! duration.! The! increasing!








Disease! activity! was! based! upon! subjective! physician! assessment! of! disease! activity!










activity!and! the!SFP36!and!HAQ!to!measure!quality!of! life!and!disability.! Illness!beliefs!
were! not! associated! with! disease! activity! at! the! time! of! assessment! but! degree! of!
personal! and! treatment! control! related! to! disability.! In! this! way,! assessment! of!
inflammation!and!illness!perception!is!important.!
!
Scharloo! et! al!measured! functioning,! coping! and! illness! perception! in! patients!
with!chronic!lung!disease,!psoriasis!and!RA.!In!RA!patients!with!a!mean!of!12yrs!disease!




less! disability! than! the!main! resistant! RA! group! in! this! cohort! (mean!HAQ!only! 0.54).!
They! set! out! to! determine! the! main! predictors! of! pain! and! depression;! these! were!
disability!(the!biggest),!helplessness!and!passive!coping!(Covic!2003).!!
!
Morris! et! al! examined! a! large! cohort! of! over! a! thousand! RA! patients!






Their! Turkish! diabetic! population! displayed! similar! influences! of! anxiety! and! socioP






• To! establish! the! role! of! perceived! disease! status! (illness! perception)! and!
relationship!to!disease!activity,!mood,!pain!and!function!!
• To!examine! the!hypothesis! that! the!coping!strategies!used!would! relate! to! the!
concurrent!severe!functioning,!fatigue!and!clinical!factors!identified!in!Chapter!3.!


















Examines! 14! dimensions! with! 2! items! (questions).! Each! item! answered! on! a! 1P4!













emotional! representations,! and! a! causal! question,! scored! on! a! 0P10! Likert! scale!
(where!zero=no!effect!and!10=extremely!










































































































Severe! disease! reflects! in! high! disability! scores! yet! also! the! presence! of! ongoing!









variable,!n=30! Median$ Range!(maxPmin)! IQR!
TJC! 4$ 0P19! 11!
SJC! 4$ 0P18! 5!
Pain! 3.9$ 0.2P9.8! 48!
Patient!Global! 39$ 2P96! 58!
ESR! 14$ 2P106! 23!
CRP! 4.25$ 0.3P79! 8.3!
DASP28!ESR! 4.22$ 2.04P7.14! 2.62!
DASP28!CRP!
(n=26)! 4.37$ 1.94P6.86! 2.83!
HAQ! 2.000$ 1.000P3.000! 0.531!
FACITPF! 25$ 3P48! 19!






















DAS28! 4.23! 4.80$ 3.71*$ 5.06$ 3.41*$
TJC! 4! 9.5! 3! 8! 3!
SJC! 4! 4.5! 3.5! 5! 3!
CRP! 4.3! 3.6! 6.6! 4.1! 5.3!
ESR! 14! 21.5! 12! 23! 12!
Pain! 39.5! 51.5! 21! 62$ 19**$
Patient!
Global! 39.0! 59.5$ 31.5*$ 73.0$ 25.0**$
HAQ! 2.00! 2.13! 1.88! 2.31$ 1.88*$
Fatigue!





Significant!differences! can!be! seen! in!many!of! the!clinical! variables! (numerically!more!
although!not!achieving!significance!owing! to! the!small! sample!size).!The!effect!on! the!
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DAS28! score! is! large! nonetheless;! the! ESR! contributes! to! this! observation! with! no!
supportive!CRP!differences.!There!were!also!large!differences!in!fatigue!levels!and!some!
numerical! differences! in! disability.! To! further! test! this,! HAQ! categorical! grouping!
(disabled!and!very!disabled!where!the!latter!HAQ!greater!than!2.000)!was!examined.!No!
differences!in!in!those!clinical!variables!shown!in!Table!6P98!above!were!seen!to!reach!





















































The! effect! of! mood! and! preferential! use! of! favourable! or! less! favourable! coping!
strategies! was! examined! and! results! shown! in! Table! 6P102.! Adaptive! strategies! were!
favoured!more!often!than!maladaptive!strategies;!there!was!no!influence!if!depressed,!
anxious!or!very!disabled.!!The!same,!although!less!pronounced,!observation!was!made!


























Depressed! 3.33! 0.189! 1.05! 0.677! 3.87! 0.324! 3.01! 0.143!Non!depressed! 3.75! 1.12! 4.10! 3.54!








0.553!Not!anxious! 3.45! 1.05! 3.73! 3.28!









Less!disabled! 3.72! 1.20! 4.21! 3.43!























(consistent!with! long! disease! duration)! but! lowest! scoring! in! the! domain! of! ‘personal!
control’.! Scoring! in! the! ‘treatment! control’! group! could! be! considered! higher! than!
expected!when!the!number!of!prior! treatments! is!considered.!The!range!of! responses!
observed! within! the! group! confirms! wide! variability! within! the! individual’s! illness!























Consequences! 8!(2)! 8.5!(2)! 8!(2)! 8!(2)! 8!(2)! 8!(2)!
Timeline! 8.5!(2)! 10!(0)! 3!(6)! 10!(0)! 10!(0)! 10!(0)!
Personal!
control! 3!(5)! 3!(6)! 3!(6)! 3!(5)! 2!(7)! 4!(3)!
Treatment!
control! 8.5!(4)! 5!(3)! 8!(4)! 5!(2)! 5!(4)! 8!(4)!
Identity! 8!(4)! 8!(3)! 8!(2)! 8!(3)! 8!(2)! 8!(3)!
Emotional!
concern! 5!(4)! 10!(2)! 5!(4)! 9!(3)! 8!(4)! 7.5!(6)!
Illness!
comprehension! 8.5!(3)! 9!(2)! 8!(3)! 9!(2)! 9!(2)! 9!(3)!
Emotional!





Table! 66104! shows! the! effect! of! mood! and! IPQ! response! scoring.! As! expected,! both!
emotional! concern! and! effect! were! affected! by! mood! but! timeline! and! treatment!
control! median! scores! were! influenced! by! mood! state! and! functioning.! In! order! to!
further!examine!the!influence!of!prevalent!mood!on!illness!perception,!correlation!with!
clinical!factors!and!the!B6IPQ!items!were!sought!(Table!66105).!!
There! was! no! correlation! between! the! five! Brief! COPE! strategies! of! Table! 6694! and!








Clinical% TJC! 0.313! 0.276! 40.476*%
% SJC! 0.419*% 0.386*% 40.465*%
% Pain! 0.506**% 0.579**% 40.579**%
% Patient!Global! 0.621**% 0.675**% 40.647**%
% Age! 0.064! 60.193! 0.028!
% Disease!duration! 60.245! 40.389*% 0.259!
% ! ! % %
Disease%
Activity% DAS628!ESR! 0.456*% 0.498**% 40.656**%
% ! ! ! !
Biochemical% ESR! 0.071! 0.181! 60.124!
% CRP! 60.050! 60.007! 60.287!
% ! ! ! !
Questionnaires% HAQ! 0.347! 0.413*% 60.283!
% FACIT6F! 40.648**% 40.603**% n/a!
% HADS6A! n/a! n/a! 40.603**%
% HADS6D! n/a! n/a! 40.648**%
% ! ! ! !
B4IPQ%domains% Consequences! 0.436*% 0.467**% 60.196!
% Timeline! 60.313! 60.237! 0.226!
! Personal!control! 60.231! 60.269! 0.408*%
! Treatment!control! 40.601**% 40.600**% 0.587**%
! Identity! 0.197! 0.149! 60.131!
! Concern! 0.527**% 0.626**% 40.160%
! Understanding! 60.023! 60.003! 60.016!
! Emotional!response! 0.652**% 0.733**% 40.539**%






This! exploratory! bivariate! analysis! identified! that! a! number! of! clinical! variables! were!
significantly!associated!with!depression!and!anxiety!and!fatigue!in!this!smaller!cohort!(as!
demonstrated! in! the! main! resistant! RA! group! in! Chapter! 3).! Several! of! the! items! of!
illness! perception! correlated! with! mood,! namely! consequences! (“how! much! does! it!
affect! your! life”,! treatment! control! (a! negative! influence),! concern! and! emotional!
response.!
Regression! analysis! was! then! performed,! using! those! statistically! significant! bivariate!
associations,! to! examine! which! illness! perception! variables! both! independently! and!
overall!explained!the!most!variance! in!mood!and! fatigue.!As!a!composite!of! the!other!
clinical!variables,!the!DAS28!ESR!was!entered!only!and!this!variable!was!entered!at!Step!




The! fatigue! ‘enter!method’!model! had! a! high! R2! overall.! Overall! effect! of!mood!was!





Fatigue!Model! Variable! Overall!R2! Change!R2! Beta!
1! DAS28!ESR! 0.379! 0.379! 40.507*%
2! HADS6A! 0.438! 0.059! 0.134!


























1% 6Depression! 0.407! 60.655!(<0.0001)!








For!anxiety,! the!overall!model!R2!was!0.638!and! the!contribution!of! illness!perception!
variables! to! anxiety! was! 26.1%.! In! the! forward! stepwise!model,! DAS28! and! disability!
were!significant!independent!variables!relating!to!anxiety!outcome.!!
!
Anxiety!Model! Variable! Overall!R2! Change!R2! Beta!
1! DAS28!ESR! 0.230! 0.230! 0.480*%
2! HAQ! 0.312! 0.082! 0.302*%
3! FACIT! 0.370! 0.058! 0.208!
4! Treatment!Control! 0.396! 0.026! 60.005!
5! Concern! 0.484! 0.081! 60.281!








1% 6Emotional!response! 0.416! 0.645!(<0.0001)!


























In! the! final! depression! model,! fatigue! accounted! for! nearly! 25%! of! the! variance! of!








1! DAS28!ESR! 0.182! 0.182! 0.119!
2! FACIT! 0.430! 0.248! 40.381*%
3! Treatment!control! 0.437! 0.007! 60.005!









1% 6Fatigue! 0.429! 60.655!(<0.0001)!














To! test! the!hypothesis! that! social!deprivation!may! influence!choice!of! coping! strategy!
















strategy! 0.206! Consequences! 0.930!
Emotional!
based!strategy! 0.774! Timeline! 0.441!
Dysfunctional!
Strategy! 0.871! Personal!control! 0.486!
Adaptive!
Strategy! 0.538! Treatment!control! 0.435!
Maladaptive!
Strategy! 0.871! Identity! 0.957!
! ! Concern! 0.798!











Inclusion! to! the! main! study! cohort! was! the! presence! of! both! DMARD! and! biologic!
resistant! disease! and! active! inflammatory! disease! as! determined! by! the! DAS28! ESR.!
Significant!disease!duration!and!substantial!co6morbidity!was!noted.!It!is!evident!from!a!




The!prevalence!of!depression!and/or!anxiety! in! this! cohort! is!over!40%!and! therefore!
should!be! actively! sought! in! similar! groups.! The!HADS!questionnaire! takes!only! a! few!
minutes! to! complete! and! is! thus! ideal! in! the! out! patient! setting.! Anxious! and/or!
depressed! patients! exhibit! a! higher! DAS28! as! a! result! of! higher! pain! scores,! patient!


















would! affect! self! reported! coping! strategies.! This!was! not! observed! and! the! favoured!
use! of! ‘positive’! strategies! such! as! adaptive! or! problem! based! approaches! was! seen!
irrespective!of!mood.!This!would!suggest!a!disconnect!between!mood!(often!variable!in!




The! IPQ! questionnaire! quantifies! the! patient’s! experience! and! understanding! of! their!
disease.! RA! patients! with! long! disease! duration! experience! little! control! over! their!
disease!although!have!high!levels!of!understanding,!perhaps!reflecting!good!education.!





Prevalent! mood! and! higher! levels! of! fatigue! influence! reported! domains! of! illness!
perception! and! correlation! was! observed! between! clinical,! PROMs! and! illness!
perception! responses.! The! presence! of! mood! disorder! correlates! with! perceived!
concern! about! their! condition,! perceived! treatment! control! and! consequences! of! RA!
(how! much! they! see! their! condition! as! affecting! them),! an! observation! reflected! in!
higher! patient! global! assessments.! There! were! some! differences! between! the!





• Reported! fatigue! should! also! prompt! evaluation! of! depression! scoring! and!
careful!examination!and!consideration!of!the!DAS28.!
• A! report! of! anxiety! would! have! similar! implications! for! the! DAS28! but!
consideration!of!disability!and!any!aid!that!could!be!provided.!
• Finally,! those! reporting! depression! are! likely! to! report! high! fatigue! levels.!
Consideration! of! the! central! and! peripheral! causes! of! fatigue! should! be!
performed!in!addition!to!treatment!of!mood.!!
6.4%Limitations%
Examination! of! this! small! cohort! raises! a! number! of! discussion! points! and!
acknowledgement!of! limitations.!Replication!with!a! larger!cohort!would!of!course!add!
power!to!any!findings.!The!influence!of!any!acute!social!stressors!such!as!bereavement!
at! the! time! of! completion! of! questionnaire! cannot! be! excluded.! In! a! similar!way,! the!
presence!of!social!assistance!such!as!family!support!was!not!assessed.!Social!support!is!








The! identification! of! these! findings! is! not! only! an! opportunity! to! carefully! consider!
disease! assessment! but! to! consider! best! treatment! options.! For! example,! mood!
disturbance!may!be!the!sole!factor!blunting!response!to!biologic!therapy!as! illustrated!
above.!It!is!also!of!interest!that!although!the!clinical!features!of!depression!and!anxiety!
differ,! the! effect! on! clinical! variables! is! similar.! This!would! suggest! that! screening! for!
either! or! both! is! sufficient.! Therefore,! an! assessment!prior! to! treatment!may! help! in!
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managing! expectation! of! treatment! response! and! allow! an! assessment! of! mood! to!
direct!additional!appropriate!treatment.!In!the!same!way,!prospectively!studying!coping!
would! be! of! interest! to! identify! those! traits! demonstrated! at! baseline! that! influence!
disease!outcome.!In!late!disease!such!as!this!cohort!display,!and!despite!favoured!use!of!
more! positive! coping! strategies,! coping! seems! less! important! showing! little! or! no!
correlation!with!clinical!factors,!mood!or!illness!perception.!
Finally,!the!use!of!the!DAS286CRP!may!help!to!minimise!one!of!the!variables!weakening!




This! sub6study! defines! a! group! of! patients! with! concurrent! mood! disturbance! who!
display! elevated! components! of! the! DAS28! score.! The! effect! is! to! blunt! reported!





the! DAS28! assessment,! and! illness! perception! thereof,! but! does! not!
determine!coping.!
!







Chapter!3!presents! the!heterogeneous! ‘phenotype’!of! the!main!study!cohort.! I!
have!demonstrated!the!substantial!burden!of!disease!in!terms!of!prior!treatments,!joint!
surgery! and! employment! status.! The! related! comorbidity! this! cohort! displays! is!
significant.! Within! the! findings! of! significant! numbers! that! merit! screening! for!
depression,! anxiety! or!merit!more! aggressive! CV! risk! factor!modification! there! is! the!
opportunity! to! target! these! areas.! The! information! gained! from! PROMs! enriches! the!
assessment! process.! Fatigue,! disability! and! impairment! of! quality! of! life! are! all!
recognised! features! in! longstanding! RA! but! rarely! quantified! in! daily! practice.!
Unfortunately,! these! domains! are! relatively! unresponsive! to! treatments! in! published!





in! conventional!markers!of! inflammation! (not! statistically! significant),! and!appropriate!




and! an! exploratory!microarray! of! the! defined! study! groups.! The! candidate!microRNA!
showed! some! correlation! with! swollen! joint! counts! and! distinct! profiles! were! seen!
between! study! groups! suggesting! integrity! of! the! groups! determined! by! clinical!
differences.!Three!novel!microRNA,!microRNA6423,! 63178!and!61275!were!validated!as!
being! relatively! upregulated! in! the! biologic! resistant! group! compared! with! the! other!
control! groups.! MicroRNA6423! and! 61275! were! studied! at! three! and! six! months! and!
showed! comparable! reductions! as! was! observed! with! the! DAS28! score.! Strong!
correlation! between! microRNA! suggests! co6transcription.! Correlation! with! RANKL,!
MMP612! and! MCP61! was! observed.! These! microRNA! may! represent! biomarkers! of!
disease!activity!in!biologic!resistant!RA.!
!
Chapter! 5! examined! the! serum! cytokine! profile! in! cross6section! and!
longitudinally.! Examination! of! cytokines! at! baseline! confirmed! significant! differences!
between!study!groups:6!findings!of!the!inflamed!clinical!phenotype!were!confirmed.!The!
DMARD! good! responder! and! DMARD! resistant! group! profiles! appeared! distinct! but!
differences! from! the! biologic! resistant! group!were! less! clear! (a! function! of! degree! of!
inflammation?).!A!number!of!cytokines!followed!an!observed!pattern!of!reduction!that!
was! reflected! in! the! DAS28! however.! Correlation! with! the! DAS28! was! not! seen! with!




Chapter! 6! examined! a! subset! of! the! main! biologic! resistant! study! group! to!
examine!coping!and!illness!perception.!This!sub6group!displayed!comparably!high!rates!
of!mood!disturbance!with! resultant! increases! in! clinical! variables! such!as!pain,! tender!
joint! counts! and! global! assessments! that! drove! the! DAS28.! Coping! strategies! were!
generally!favourable!but!not! influenced!by!prevalent!mood!unlike! illness!perception! in!
which!the!opposite!was!observed.!Both!mood!and!fatigue!influenced!current!perception!





excluded.! The! clinical! data! is! observational! and! in! trying! to! draw! conclusions! about!
mood,! fatigue! and! associations,! firm! conclusions! would! be! undoubtedly! affected! by!
smaller! numbers.! The! Bonferroni! correction!method! is! used! to! reduce! the! chance! of!
type!1!statistical!errors!but!may!increase!the!likelihood!of!a!type!II!error!(false!negative).!
In! the! regression! calculations,! particularly! in! Chapter! 6,! larger! numbers! are! always!
desirable! so! results! should!be! interpreted!with! caution.! For! this! reason!both! types!of!
regression! were! performed.! ! Furthermore,! in! the! clinical! group,! selection! bias! and!
reporter!bias!(patients!more!likely!to!respond?)!may!be!present.!The!number!of!PROM!
questionnaires! (evaluated! in! Chapter! 3)! returned! at! subsequent! visits! fell! slightly.! In!







by! creating! study! groups! that! are! phenotypically! similar! and! in! this! way! clinically!
applicable.! However,! the! effect! of! individual! treatments! and! their! changes! is! not!
possible! to! calculate.! There! were! a! number! of! treatment! variations! between! study!
assessments! from! intra6articular! and! intramuscular! steroid,! DMARD! changes! and!
biologic! therapy! changes.! In! particular! the! effect! of! intermittent! B6cell! depletion!with!
Rituximab!is!particularly!difficult!to!estimate.!Statins!are!prescribed!primarily!to!reduce!





diabetes.! In! view! of! the! significant! number! of! comorbidities! recorded! in! the! biologic!
resistant!cohort,!an!effect!on!the!peripheral!microRNA!profile!cannot!be!excluded.!The!
effect!of!concurrent!OA!should!also!be!considered! in!any!profiling!of! longstanding!RA.!





















have! already! been! highlighted! including! the! weaknesses! of! the! DAS28! score,! the!
challenge! of! achieving! low! disease! activity! in! longstanding! disease! (yet! apparent!
responsiveness! of! inflammation)! and! importance! of! considering!mood!disorder! in! the!
case!of!a!lack!of!response!to!treatment.!Several!specific!examples!stand!out!such!as!the!




The! challenge! remains! that! we! are! unable! to! reliably! predict! outcome.! Table! 162!
outlines! the! range! and! combination! of! factors! that! have! been! shown! to! influence!
outcome.!Added!to!this!are!epigenetic!factors.!The!results!of!the!biologic!resistant!group!
confirm!the!wide!heterogeneity!even!within!a!phenotypically!similar!group!and!suggest!
resistance! to! treatment! is! a! function! of! many! variables.! In! disease! of! significant!
duration,! effective! treatment! should! include! a! comprehensive! holistic! approach! to!






7.1.4%What% is% the% link% between% inflammation,%mood,% epigenetics% and% cardiovascular%
disease?%
As!demonstrated!in!this!cohort!of!patients,!there!is!substantial!co6morbidity!and!I!have!




The! link! between! atherosclerosis! and! RA! has! been! observed! epidemiologically! and!
referred!to!in!Chapter!1.!Pathophysiologically,!atherosclerosis!is!a!chronic!inflammatory!
process.! It! is! therefore! of! no! surprise! to! find! publications! referring! to! microRNA!
mediating! this! process.! Nazari6Jahantigh! et! al! examined! microRNA6155! within!
atherosclerotic!plaques!(Nazari6Jahantigh!et!al.!2012).!They!found!microRNA6155!highly!
expressed! in! both! atherosclerotic! plaque! and! the!macrophages!within.!MicroRNA6155!














found! raised! inflammatory!markers! (IL66! and!CRP)!higher! in! the!depressed! individuals!
(Uddin! et! al.! 2011).! They! identified! unique! DNA! methylation! patterns! in! those! with!
depression! but! no! correlation! with! CRP.! The! same! authors! demonstrated! epigenetic!
changes!in!peripheral!blood!after!psychological!stressors!(post!traumatic!stress!disorder!





!Bjerkeset! et! al! examined! CRP! in! over! 9000! subjects.! They! identified! an! association!
between! increased! CRP! with! increased! risk! of! myocardial! infarction! (Bjerkeset! et! al.!
2011).! Empana! et! al! also! found! those! that! were! depressed! had! raised! inflammatory!
markers! in!a!prospective!study!of!otherwise!healthy!middle!aged!males.!They!went!on!
to!identify!an!association!with!ischaemic!heart!disease!(Empana!et!al.!2005).!Miller!et!al!
review! the! links! between! these! observations! in! their! review.! They! propose! that!
depression! induces! a! mild! inflammatory! response! and! encourages! CV! risk! behaviour!
such!as!smoking!and!inactivity.!The!hypothalamic6pituitary!axis!activation!may!increase!
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In% summary,% RA% patients% display% a% combination% of%many% of% these% features% perhaps%
explaining%the%clustering%of%adverse%risk%and% increased%morbidity.%Molecular% links%tie%





disturbance! to! the! identification!of!biomarkers! that!predict! subclinical!atherosclerosis.!
Aggressive! treatment! of!modifiable! CV! risk! factors! is! needed.! Prospective! studies! can!









Figures! 76123! and! 76124! graphically! represent! the! factors! that! ‘define’! this! biologic!
resistant! cohort.! Resistance! to! treatment! is! multifactorial.! Subjective! response! is!
affected!by! illness!perception,!mood!and! fatigue.!Deprivation!may! interact!with! these!
variables.! Epigenetic! factors! have! been! identified! in! this! cohort! suggesting! biological!
mechanisms!may!characterise!the!inflammatory!response!and/or!mediate!the!resistance!
to!treatments.!!!
On! the! other! hand! severity! could! be! defined! by! number! of! joint! surgeries! and!

















There! is! a! wealth! of! clinical! and! biological! information! that! can! be! gathered! at! each!
patient!encounter! in!RA.!The!PROMs!and!the! time!to!complete!and!score! them!raises!
the! question! of! how! best! to! incorporate! their! use! in! daily! practice.! In! disease! of!
longstanding!duration,! study!of! this! cohort!puts! forward!a! case! for! the!assessment!of!
such!dimensions!but!only!to!understand!which!domains!require!focussed!interventions.!
Determining! which! dimensions! are! of! most! value! to! patients! and! which! dimensions!
could!be!used!to!best!determine!disease!status!will!be!of!value.!
!
The! clinical! application! of! the! identification! of! the! ‘resistant!microRNA’! is! dependent!
upon!similar!observations!being!made!in!cohorts!with!earlier!disease.!As!illustration,!the!
question!of!RA!becoming!milder!has!been!raised!by!previous!authors!and!as!patients!are!
referred! and! treated! earlier,! overall! outlook! for! the! disease! has! improved! (Wolfe! &!
Pincus! 2001;!Welsing! et! al.! 2005;! Alcorn! et! al.! 2009).!Without! doubt! however! there!
remain! individuals! with! severe! and! aggressive! disease.! ! Such! aggressive! disease!will!
often! become! clear! in! the! first! few! years! but! should! a! unique! microRNA! profile! of!
resistant!disease!be!present!in!early!disease,!there!is!the!potential!to!seek!this!resistant!
microRNA!signature!with!clinical!assessments!and!genotyping!to!target!most!aggressive!
therapy.!Profiling! the! resistant!microRNA! in!a!cohort!of!early!RA!patients!would!be!of!
value.!








The! effect! of! DNA! methylation! and! other! epigenetic! modifications! have! not! been!
examined!within!this!thesis.!In!view!of!the!regulatory!effect!of!DNA!methylation!status!
and! microRNA! profile! referred! to! in! Chapter! 1,! the! relation! to! observed! microRNA!
profile!would!be!of!enormous! interest! in! this!population.!A!systematic!examination!of!



































































































To! examine! the! prevalence! of!
psychological! morbidity! in! the!
group.!
Total! score! 0621! (>8! suggesting!







Examines! how! the! individual!
manages!day6to6day!activities.!
Responses!tally!a!score!translated!to!






Examines! 8! domains! (4! physical,! 4!
mental).!Uses!a!norm!based!scoring!
system.! Assumes! population!
mean=50,! <45! then! health! status!











Applies! 5! short! responses! and! a!
visual!analogue!score!06100.!
Outcome! variables! are! the! change!




Rose%angina%questionnaire% Direct! questioning! regarding!























• PaxGene) RNA®) (PreAnalytiX)) tube) (tourniquet) released) prior) to) PaxGene)tube))followed)by)8X10)inversions))
















































20! ml! of! patient/control! blood! should! be! collected! into! lithium! heparin!
containing! tubes! (4! green! cap! tubes).! Blood! samples! should! be! kept! in! room!







PBMC’s! will! be! extracted! using! RPMI! wash! and! Histopaque! creating! a! layer! on! the!
diluted!blood.!This!is!centrifuged!at!2100!rpm!for!15!minutes!and!the!opaque!interface!





PBMC! are! re6suspended! in!MACS! buffer! and! CD14+! beads! (Miltenyi! Biotec,! 13060506







incubate! the! samples! in! RNAlater! solution! overnight! at! 40C! to! allow! thorough!








6pallet! 0.2x106! cells! in! RNase/DNase! free! eppendorf! tube! by! spinning! down! at!
2500!rpm,!5!min,!40C;!




















THE ROLE OF EPIGENETICS IN RESISTANT RHEUMATOID ARTHRITIS 
PROTOCOL FINAL VERSION JUNE 2011 
 
FULL TITLE An Observational, Multiple-Centre Study to 
investigate the Clinical, Pathological, 
Immunological and Epigenetic Characteristics of 
patients with biologic therapy-resistant Rheumatoid 
Arthritis 
SPONSOR Greater Glasgow and Clyde Health Board 
 
INDICATION Rheumatoid Arthritis 
HYPOTHESIS Patients! with! therapy6resistant! RA! show! greater!
plasticity!in!gene!expression!regulation!in!response!
to! inflammation! and! treatment! with! current!
standard6of6care! therapies! as! evidenced! by!
differences! in! the! pattern! and! extent! of! DNA!
methylation,! post6translational! modifications! of!
histone! structure! and!micro! RNA! expression.! Such!




• To describe the clinical and epigenetic characteristics of 
rheumatoid arthritis (RA) patients who have ‘biologic 
therapy-resistant’ disease  
• To explore how any epigenetic profile identified is related 
to the presence of RA, the disease duration, or disease 
severity (or a combination thereof), by comparing them 
to control groups detailed below: 
 
Secondary: 
• To characterize the peripheral blood plasma / serum 
biomarker signature and examine its’ stability over time 
within this RA patient population  
 
STUDY DESIGN This is a multi-centre, observational study in RA patients 
(n=50) previously treated with conventional DMARDs and at 
least two previous biologic therapies.  Patients will be admitted 
to the study regardless of reason for prior drug continuation 
and will therefore include toxicity and efficacy failures. This 
will ensure that a broad patient population is captured for 
subsequent analysis.   
 
Enrolled patients will undergo three (3) assessments on Day 1 
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(baseline), and at approximately Weeks 12 and 24 (see table 
1), including: 
• Clinical and laboratory disease activity assessment 
• Biomarker blood sampling 
• Assessment of co-morbidity and presence thereof 
 
 
CONTROL PATIENTS There will be three comparator groups recruited: 
1. Normal subjects – all patients recruited to the 
‘therapy-resistant’ group will be asked to bring a 
close friend of the same gender and similar age.  
2. DMARD-resistant RA patients – up to 50 patients 
with moderate/severe RA who meet the BSR 
eligibility criteria for starting anti-TNF therapy 
3. DMARD-sensitive RA patients – 25 patients with 
longstanding RA (meeting the ACR 1987 definition) 
who have responded to conventional therapy (see 
below) 
 
NUMBER OF SUBJECTS Up to 200 RA patients (50 biologic therapy resistant RA 
patients, 25 DMARD sensitive RA patients and up to 50 
DMARD resistant RA patients)  
25 normal controls will be enrolled in total. 
LENGTH OF STUDY  Up to 28 weeks from screening through to the end of the 
observational period for biologic therapy resistant group and 
group 2 above: 
• Screening: Up to 4 weeks prior to baseline visit 






Patients will continue to receive standard of care altered 
according to the judgement of the treating physician.  
INCLUSION CRITERIA Biologic therapy-resistant RA 
1. Diagnosed with RA by the 1987 American Rheumatism 
Association (ARA) criteria for the classification of RA  
2. Active RA at screening as defined by:  
• Disease activity score (DAS28) ≥ 3.2 
3. Multiple treatment failure as indicated by: 
• Prior receipt and failure of conventional DMARD 
treatment. 
• Previously received at least two (2) biologic therapies 
for rheumatoid arthritis, such as, but not necessarily 
limited to, etanercept, adalimumab, infliximab, 
rituximab, abatacept, anakinra and /or tocilizumab.  
 
Normal controls 
• participant should not display any features of active 
arthritis, inflammatory or degenerative, or any current 
symptomatic joint injury 
 
 
DMARD Therapy-resistant RA 
1. Diagnosed with RA by the 1987 American Rheumatism 
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Association (ARA) criteria for the classification of RA  
2. Active RA at screening as defined by:  
• Disease activity score (DAS28) ≥ 3.2 
3. No previous biologic therapy, but with active disease 
despite the use of at least two conventional DMARDs 
 
DMARD Sensitive RA Group 
1. Diagnosed with RA by the 1987 American Rheumatism 
Association (ARA) criteria for the classification of RA  
2. Disease duration of  >10 years 
3. Demonstrate a good response to 2 or fewer conventional 
DMARD 
4. DAS <3.2 reflecting low disease activity 
 
Inclusion criteria related to all participants 
1. Able and willing to give written informed consent and 
comply with the requirements of the study protocol 
2. Age 18 and older to 75 yrs 
EXCLUSION CRITERIA  Active cancer or acute/chronic infection 
Surgery within one month prior to screening. 
 
ASSESSMENTS PERFORMED:  















Data will be collected on age, gender, ethnicity, employment, 
years of formal education, marital status, smoking status 




All patients will have a full detailed clinical history and 
clinical examination that will collect data on: 
 
1) Rheumatoid arthritis (articular): 
• age of symptom onset; disease duration (diagnosis made) 
• ESR at disease onset 
• ACR core set (Swollen joint count [SJ], Tender joint count 
[TJ], Health Assessment Questionnaire [HAQ], Patient's 
pain score [PS], Patient's Global Assessment [P Global], 
Physicians Global Assessment  (Inv Global), ESR and 
hsCRP 
• Disease activity scores (DAS, DAS28, CDAI and SDAI) 
• Total Sharp Score on plain hand & feet radiographs 
 
2) Rheumatoid arthritis (extra-articular) 
• history, signs or diagnosis of: 
- nodulosis 
- pulmonary fibrosis 
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- sicca syndrome 
- cutaneous vasculitis including nail-fold vasculitis 
- pleuro-pericarditis 
- scleritis or corneal melt 
 
Additionally, all patients will have data collected on: 
 





4) Cardiovascular profile 
• clinical history and examination and blood pressure 
• BMI and waist:hip ratio 
• lipid profile 
• Rose questionnaire and ECG 
 
5) Psychological profile 
• Hospital Anxiety & Depression (HAD) questionnaire 
 
6) Bone profile 
• history of fracture 
• bone densitometry (if DEXA performed within previous 2 
years) 
• vitamin D, (PTH assays if appropriate) 
 
7) Drug therapy 
• current therapy 
• history of previous DMARD/biologic therapy; start/stop 
dates with reason for stopping 
• exposure to oral/IA/IM steroid 
• postmenopausal HRT use and duration 
 
8) Co-morbidity 
• History of other auto-immune disease (including diabetes 
and thyroid disease), cardiovascular, cerebrovascular, 









On the days and times specified in ‘Table 1’, the following 
tests will be included, but not limited to, all patients in the 
Biologic-therapy Resistant group, DMARD sensitive group, 
DMARD resistant group and healthy control groups. 
 



















































• Acute Phase Panel: hsCRP  
 
• Auto-antibodies: Rheumatoid Factor (RF), anti-cyclic 
citrullinated peptide (CCP) antibodies, anti-nuclear 
antibodies (ANA), immunoglobulins and their isotypes, 
reflex ENA testing as appropriate. Processing will be 
undertaken at the Immunology Department at Gartnavel 
General Hospital, 1053 Great Western Road, Glasgow, 
G12 0YN 
 
• Bone Metabolism Panel: may include CTX-I, CTX-II, 
MMP-3, TIMP-1, DKK-1, OC, COMP, PDP, DPD, NTX-
I, BAP, PIINP, Helix-2, Vitamin D, PTH. Analysis of 
bone markers will be undertaken by Roche. Samples will 
not be stored for longer than five years and remain within 
the Rheumatoid Arthritis Inflammation Discovery group. 
 
• Core Inflammatory Cytokines:  may include IL-1, TNF, 
sTNFR1, sTNFR2, IL-6, sIL-6R, sgp130, BAFF, APRIL, 
sBCMA, sBAFF-R, sTACI, IL-12p40, IFNg , TGFb  (to 
be extended pending multiplex methodology to include 
other  novel disease relevant markers ) 
 
 
Samples to assess exploratory biomarkers will be collected 
on the days and times specified in ‘Table 1’. These samples 
will be used only for research purposes to identify dynamic 
biomarkers that help characterize the molecular and patho-
physiological mechanisms of the disease process - such as, but 
not limited to, TNFα, IL-1β and IL-6. These samples will be 
stored for up to 5 years after database closure, and include: 
 
• DNA for pharmaco-genomic analysis / drug resistance-
toxicity / epigenetic modifications 
• Serum/plasma and mRNA for the analysis of disease-
related analytes (whole genome profiling) 
• Whole blood for cell subset purification and subsequent 
protein/mRNA processing 
 
Further exploratory analysis during or after 5 years will only 
be undertaken after consent has been obtained. 
 
Processing and analysis of samples will be undertaken at the 
Glasgow Biomedical Research Facility unless stated above. 
 
Healthy controls will undergo demographic assessment as 
outlined above and limited clinical examination. 
Blood sampling will be collected at single baseline visit only 













DMARD Sensitive Group 
 
Blood Sampling at following visits (weeks); separate consent 
obtained through linked ethics application 
• Acute phase panel; 0, 12, 26 
• Bone Metabolism panel; 0, 12, 26 
• Core Inflammatory cytokines; 0, 12, 26 
• Autoantibody and Immunology profiling; 0 
• Epigenetic sampling; 0, 12, 26 
 
DMARD-sensitive controls will undergo demographic 
assessment as outlined above and limited clinical examination. 
Blood sampling will be collected at single baseline visit only 
and reflects those samples listed above. 
 
 
PROCEDURES:A detailed schedule of assessments and procedures is tabulated below (Table 1). 
 
Informed Consent: 
It is the responsibility of the investigator, or a person designated by the investigator (if acceptable by 
local regulations), to obtain written informed consent from each subject participating in this study, after 
adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study.  The 
informed consent must be obtained prior to initiating screening procedures. Participants will be given 
written and verbal information about the study, and will have a minimum of 48 hours to consider the 
information before deciding whether or not to participate 
 
 
Study Procedures and Assessments 
 
Subjects will be enrolled based on the inclusion/exclusion criteria detailed above in accordance with 
prevailing standard operating procedures. Only those subjects who fulfil all entry criteria and none of the 
exclusion criteria will be enrolled into the study. 
 
At Visit 1 (day 1) 
• Full clinical history, drug history and examination (as above) 
• ECG 
• RA disease activity assessment (DAS, DAS28, CDAI, SDAI, ACR core set)  
• Questionnaires – Rose, HAQ, HAD, SF36v2, EQ5-D, FACIT-fatigue 
• Blood for Antibodies (RF, anti-CCP, Immunoglobulins and isotypes), Acute Phase Panel, Bone 
Metabolism Panel and Core Inflammatory Cytokines. 
• Epigenetic blood collection.  
 
At visit 2 (12 weeks) 
• Clinical and drug history 
• RA disease activity assessment (DAS28) 
• Sampling for Acute Phase Panel, Bone Metabolism Panel & Core Inflammatory Cytokines 
• Epigenetic blood Collection 
 
At visit 3 (24 weeks, end of study) 
The study will end at Visit 3.  
• Full clinical history, drug history and examination  
• RA disease activity assessment (DAS, DAS28, CDAI, SDAI, ACR core set) 
• Questionnaires –  HAQ,  HAD, SF36v2, EQ5-D, FACIT-fatigue 
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• Blood for  Acute Phase Panel, Bone Metabolism Panel & Core Inflammatory Cytokines. 
• Epigenetic blood collections.  
 
Patients may visit the outpatient clinic on additional occasions during the course of this study or before 
Visit 2 for other treatments or assessments, as dictated by standard of care.  No specific procedures are 
mandated by this study protocol for those visits. 
 
STATISTICAL ANALYSES  
Disease Activity/Safety Composite disease activity scores (e.g. EULAR Disease Activity Score 
[DAS]) will be calculated. Summaries will also be prepared. As appropriate, 
listings, summary tables and graphs (subject plot and/or mean plots) will be 
provided for clinical assessments 
Other Descriptive statistics will be performed including calculation of mean, 
median, standard deviation for assessment of population gene expression 
levels.  Analysis of variance techniques may be used in an exploratory 
context to assess relationships between selected variables.  These data may 
additionally be used as a reference control dataset for future analyses of 
clinical, synovial, and biomarker parameters in this RA population. 
 
SAMPLE SIZE JUSTIFICATION: 











101 19/08/2010 23/11/2010 05/04/2011
102 20/08/2010 16/11/2010 25/03/2011
103 25/08/2010 30/11/2010 15/03/2011
104 26/08/2010 26/11/2010 14/04/2011
105 14/09/2010 11/01/2011 26/04/2011
106 16/09/2010 06/01/2011 02/06/2011
107 23/09/2010 22/12/2010 16/03/2011
108 28/09/2010 12/01/2011 11/05/2011
109 30/09/2010 11/01/2011 12/04/2011
110 01/10/2010 21/12/2010 18/03/2011
111 01/10/2010 10/02/2011 16/06/2011
112 05/10/2010 26/01/2011 20/05/2011
113 07/10/2010 02/02/2011 04/05/2011
114 08/10/2010 20/01/2011 14/04/2011
115 12/10/2010 31/03/2011 09/06/2011
116 15/10/2010 06/01/2011 27/04/2011
117 18/10/2010 07/01/2011 01/04/2011
118 21/10/2010 11/02/2011 01/07/2011
119 27/10/2010 16/02/2011 15/04/2011
120 04/11/2010 19/01/2011 13/04/2011
121 09/11/2010 10/02/2011 15/06/2011
122 11/11/2010 28/07/2011 declined2visit
123 15/11/2010 06/04/2011 18/07/2011 venepuncture2not2possible
124 16/11/2010 24/05/2011 26/07/2011
125 23/11/2010 24/02/2011 22/07/2011
126 03/12/2010 16/02/2011 13/06/2011
127 09/12/2010 23/02/2011 08/07/2011
128 13/12/2010 01/06/2011 28/07/2011
129 14/12/2010 10/03/2011 29/06/2011
130 17/12/2010 24/02/2011 31/05/2011
131 21/12/2010 24/03/2011 15/07/2011
132 21/12/2010 10/03/2011 11/07/2011
133 22/12/2010 15/03/2011 07/06/2011
134 10/01/2011 23/03/2011 14/07/2011
135 12/01/2011 28/04/2011
136 14/01/2011 28/04/2011 28/06/2011
137 18/01/2011 08/04/2011
138 18/01/2011 04/04/2011 14/07/2011
139 19/01/2011 13/04/2011 05/07/2011
140 19/01/2011 24/03/2011
141 20/01/2011 27/04/2011 18/07/2011
142 20/01/2011 01/06/2011 19/07/2011
143 21/01/2011 10/04/2011 07/06/2011
144 21/01/2011 03/05/2011 08/07/2011
145 21/01/2011 30/03/2011 18/07/2011
146 24/01/2011 29/03/2011 05/07/2011
147 25/01/2011 06/05/2011 07/07/2011
148 26/01/2011 04/05/2011 29/06/2011
149 27/01/2011 03/06/2011 21/07/2011







Name: Date:  
Clinicians are aware that emotions play an important part in most illnesses. If  your
clinician knows about these feelings he or she will be able to help you more.
This questionnaire is designed to help your clinician to know how you feel. Read each
item below and underline the reply which comes closest to how you have been feeling
in the past week. Ignore the numbers printed at the edge of  the questionnaire.
Don’t take too long over your replies, your immediate reaction to each item will
probably be more accurate than a long, thought-out response.
I feel tense or ‘wound up’
Most of  the time
A lot of  the time
From time to time, occasionally
Not at all
I still enjoy the things I used to enjoy
Definitely as much
Not quite so much
Only a little
Hardly at all
I get a sort of  frightened feeling as if
something awful is about to happen
Very definitely and quite badly
Yes, but not too badly
A little, but it doesn’t worry me
Not at all
I can laugh and see the funny side of  things
As much as I always could
Not quite so much now
Definitely not so much now
Not at all
Worrying thoughts go through my mind
A great deal of  the time







Most of  the time





I feel as if  I am slowed down




I get a sort of  frightened feeling like





I have lost interest in my appearance
Definitely
I don’t take as much care as I should
I may not take quite as much care
I take just as much care as ever






I look forward with enjoyment to things
As much as I ever did
Rather less than I used to
Definitely less than I used to
Hardly at all











Now check that you have answered all the questions
This form is printed in green. Any other colour is an unauthorized photocopy. TOTAL
HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994.
Record form items originally published in Acta Psychiatrica Scandinavica 67, 361–70, copyright © Munksgaard International
Publishers Ltd, Copenhagen, 1983.
This edition first published in 1994 by nferNelson Publishing Company Ltd,
414 Chiswick High Road, London W4 5TF
GL Assessment is part of  the Granada Group






























































































HI7! I!feel!fatigued!.........................................................................................!!0! 1! 2! 3! 4!
HI1
2!
I!feel!weak!all!over!.................................................................................!!0! 1! 2! 3! 4!
An1! I!feel!listless!(“washed!out”)!..................................................................!!0! 1! 2! 3! 4!
An2! I!feel!tired!...............................................................................................!!0! 1! 2! 3! 4!
An3! I!have!trouble!starting!things!because!I!am!tired!..................................!!0! 1! 2! 3! 4!
An4! I!have!trouble!finishing!things!because!I!am!tired!.................................!!0! 1! 2! 3! 4!
An5! I!have!energy!..........................................................................................!!0! 1! 2! 3! 4!
An7! I!am!able!to!do!my!usual!activities!.........................................................!!0! 1! 2! 3! 4!
An8! I!need!to!sleep!during!the!day!...............................................................!!0! 1! 2! 3! 4!
An1
2!
I!am!too!tired!to!eat!...............................................................................!!0! 1! 2! 3! 4!
An1
4!
I!need!help!doing!my!usual!activities!.....................................................!!0! 1! 2! 3! 4!
An1
5!































FATIGUE% % HI7! !!!!!! 4! 6! ________! ! =________!
SUBSCALE% % HI12! ! 4! 6! ________! ! =________!
!!!% % % An1! ! 4! 6! ________! ! =________!
An2! ! 4! 6! ________! ! =________!
An3! ! 4! 6! ________! ! =________!
An4! ! 4! 6! ________! ! =________!
An5! ! 0! +! ________! ! =________!
An7! ! 0! +! ________! ! =________!
An8! ! 4! 6! ________! ! =________!
An12! ! 4! 6! ________! ! =________!
An14! ! 4! 6! ________! ! =________!
An15! ! 4! 6! ________! ! =________!
An16! ! 4! 6! ________! ! =________!
%
))))))))))))))Sum)individual)item)scores:________!!!











HEALTH ASSESSMENT QUESTIONNAIRE (HAQ-DI)© 
 
 
Name: ____________________________________________  Date:  ____________________ 
 
 
Please place an “x” in the box which best describes your abilities OVER THE PAST WEEK: 
 
 WITHOUT ANY WITH SOME WITH MUCH UNABLE 
   DIFFICULTY DIFFICULTY DIFFICULTY   TO DO 
DRESSING & GROOMING 
 
Are you able to: 
 
  Dress yourself, including shoelaces and buttons?  
 




Are you able to: 
 
  Stand up from a straight chair?    
 




Are you able to: 
 
  Cut your own meat?    
 
  Lift a full cup or glass to your mouth?    
 




Are you able to: 
 
  Walk outdoors on flat ground?    
 
  Climb up five steps?    
 
 
Please check any AIDS OR DEVICES that you usually use for any of the above activities: 
 
      Devices used for Dressing Built up or special utensils Crutches 
      (button hook, zipper pull, etc.) 
  Cane  Wheelchair 
 
 Special or built up chair Walker   
 
Please check any categories for which you usually need HELP FROM ANOTHER PERSON: 
 
 Dressing and grooming Arising Eating Walking 
 
 











By placing a tick in one box in each group below, please indicate 
which statements best describe your own health state today.!
 
Mobility 
I have no problems in walking about ! 
I have some problems in walking about ! 
I am confined to bed ! 
 
Self-Care 
I have no problems with self-care ! 
I have some problems washing or dressing myself ! 
I am unable to wash or dress myself ! 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities ! 
I have some problems with performing my usual activities ! 
I am unable to perform my usual activities ! 
 
Pain/Discomfort 
I have no pain or discomfort ! 
I have moderate pain or discomfort ! 
I have extreme pain or discomfort ! 
 
Anxiety/Depression 
I am not anxious or depressed ! 
I am moderately anxious or depressed ! 
I am extremely anxious or depressed ! 
  
!!
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to 
whichever point on the scale indicates how good or 
bad your health state is today. 
 
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 
































































We are interested in how people respond when they confront difficult or stressful events in 
their lives. There are lots of ways to try to deal with stress. This questionnaire asks you to 
indicate what you generally do and feel, when you experience stressful events. Obviously, 
different events bring out somewhat different responses, but think about what you usually 





I have been 
doing this 
sometimes






I’ve been concentrating my efforts on doing something about the situation I am in. 0 1 2 3
I've been taking action to try to make the situation better. 0 1 2 3
I've been trying to come up with a strategy about what to do. 0 1 2 3
I've been thinking hard about what steps to take. 0 1 2 3
I've been trying to see it in a different light, to make it seem more positive. 0 1 2 3
I've been looking for something good in what is happening. 0 1 2 3
I've been accepting the reality of the fact that it has happened. 0 1 2 3
I've been learning to live with it. 0 1 2 3
I've been making jokes about it. 0 1 2 3
I've been making fun of the situation. 0 1 2 3
I've been trying to find comfort in my religion or spiritual beliefs. 0 1 2 3
I've been praying or meditating. 0 1 2 3
I've been getting emotional support from others. 0 1 2 3
I've been getting comfort and understanding from someone. 0 1 2 3
I've been trying to get advice or help from other people about what to do. 0 1 2 3
I've been getting help and advice from other people. 0 1 2 3
I've been turning to work or other activities to take my mind off things. 0 1 2 3
I've been doing something to think about it less, such as going to the movies, watching 
TV, reading, daydreaming, sleeping or shopping. 0 1 2 3
I've been saying to myself "this isn't real". 0 1 2 3
I've been refusing to believe that it has happened. 0 1 2 3
I've been saying things to let my unpleasant feelings escape. 0 1 2 3
I've been expressing my negative feelings. 0 1 2 3
I've been using alcohol or other drugs to make myself feel better. 0 1 2 3
I've been using alcohol or other drugs to help me get through it. 0 1 2 3
I've been giving up trying to deal with it. 0 1 2 3
I've been giving up the attempt to cope. 0 1 2 3
I've been criticizing myself. 0 1 2 3






Application to obtained samples from the PEAC Biobank 
Iain McInnes & Duncan Porter 
December 2011  
Request 
As part of a study investigating the role of epigenetic changes in conferring resistance to 
therapeutic intervention in patients with rheumatoid arthritis (RA), we request access to 
baseline PAXgene Blood RNA tubes from 26 patients recruited to the ORBIT study 
from Glasgow.   
Details of request 
Formal study title: An Observational, Multiple-Centre Study to investigate the Clinical, 
Pathological, Immunological and Epigenetic Characteristics of patients with biologic 
therapy-resistant Rheumatoid Arthritis (Sponsor: Greater Glasgow & Clyde Health 
Board). 
This study is testing the following hypothesis, namely that patients with therapy-resistant 
RA show greater plasticity in gene expression regulation in response to inflammation 
and treatment with current standard-of-care therapies as evidenced by differences in the 
pattern and extent of DNA methylation, post-translational modifications of histone 
structure and micro RNA expression. Such epigenetic changes will be evident in 
accessible circulating peripheral blood leukocyte subsets. 
The endpoints for this study are as follows: 
Primary: 
• To describe the clinical and epigenetic characteristics of RA patients who have 
‘biologic therapy-resistant’ disease  
• To explore how any epigenetic profile identified is related to the presence of RA, the 
disease duration, or disease severity (or a combination thereof), by comparing 
them to control groups detailed below 
 
Secondary: 
• To characterize the peripheral blood plasma / serum biomarker signature and 
examine its’ stability over time within this RA patient population  
 
This is a multi-centre, observational study in RA patients (n=50) previously treated with 
conventional DMARDs and at least two previous biologic therapies.  Patients will be 
admitted to the study regardless of reason for prior drug continuation and will therefore 
include toxicity and efficacy failures. This will ensure that a broad patient population is 
captured for subsequent analysis.   
 
Enrolled patients will undergo three (3) assessments on Day 1 (baseline), and at 
approximately Weeks 12 and 24 (see table 1), including: 
• Clinical and laboratory disease activity assessment 
• Biomarker blood sampling 
• Assessment of co-morbidity and presence thereof 
 
There will be three comparator groups recruited: 
4. Normal subjects – all patients recruited to the ‘therapy-resistant’ group will be 
asked to bring a close friend of the same gender and similar age.  
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5. DMARD-resistant RA patients – up to 50 patients with moderate/severe RA who 
meet the BSR eligibility criteria for starting anti-TNF therapy 
6. DMARD-sensitive RA patients – 25 patients with longstanding RA (meeting the 
ACR 1987 definition) who have responded to conventional therapy (see below) 
 
We have now successfully recruited the study group together with control groups 1 and 
3. The RA population entering the ORBIT study in Glasgow comprise control group 2 
above and as such we request access to the PAXgene Blood RNA tubes retrieved from 
26 patients thus far recruited from Glasgow into the ORBIT study.  From these tubes we 
will extract total RNA, including small RNAs. We wish to use one of the three PAXgene 
Blood RNA samples (2.5mls) stored from each patient at baseline to examine the 
microRNA and mRNA expression profile in matched samples. By this means we aim to 
minimise the use of the irreplaceable component of the sample resource. 
In parallel, we are conducting miR/mRNA and DNA methylation analysis of 
separated blood cell populations from all 4 groups. Thus, our study will reveal cell type 
unique epigenetic changes related to arthritis pathogenesis and treatment. Moreover, 
matched analysis of epigenetic modifications of whole blood will allow exploring the 
potential of these modifications as potential diagnostic/prognostic biomarkers. 
 
Statistical considerations 
This is a descriptive study – no prior data are available to inform the sample size and on 
this basis our numbers can only be based on pragmatic considerations. Studies of 
similar size have been successful in unravelling biomarker signatures in cancer cohorts 
e.g. in lung cancer. 
 
Supporting statement 
We currently have little notion as to why some RA patients do well on initial DMARD 
therapy and remain essentially stable over a prolonged period of time, whereas others 
exhibit an aggressive disease course marked by intolerance or poor response to a 
variety of therapeutics.  Specific drug related factors are likely to operate e.g. by 
biologics inducing neutralizing antibodies, as may genetically defined pathway specific 
elements e.g. concerning the biology of the target or of the metabolism or other 
pharmacology of a given agent. It is also possible that acquired epigenetic changes 
within the patient will influence the capacity of RA patients to respond to any agent per 
se. This study examines this latter possibility using a variety of clinical phenotypes and in 
particular will test the idea that epigenetic changes underlie at least in part the biology of 
the clinically observed variance of therapeutic response.  As such the study addresses a 
question of critical clinical importance, with substantial individual patient benefit and 
health economic impact if promising data are obtained.  As such we further contend that 
it meets the core criteria set for access to samples within the PEAC biobank. 
 
!
!
! %
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